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Abstract 
Exposures to ionising radiation resulting from natural sources or medical 
diagnostics are generally very low. In contrast, exposures to therapeutic radiation, 
although, they are often partial exposures, represent much higher doses. Similar 
levels of exposure may also occur as a consequence of a radiological accident, where 
it would be necessary to quickly separate individuals requiring urgent medical 
attention from the “worried-well”. 
The well-established biodosimetry techniques based on cytogenetics, 
particularly scoring dicentric chromosomes, are accurate and sensitive, yet, they are 
unsuitable for mass screening due to limited capacity and the time required for 
providing dose estimates. Measuring gene expression changes following radiation 
exposure was suggested over a decade ago to be an alternative method for dose 
estimation, as it is a quick, sensitive and suitable technique for high throughput 
application. The qPCR protocol was extensively optimised for increased reproducibility 
and sensitivity in order to be suitable for biodosimetry purposes. Radiation-responsive 
transcripts were identified and characterised in terms of temporal- and dose-
responses. Finally, candidate transcripts were validated in human blood irradiated ex 
vivo and in vivo in blood samples obtained from cancer patients undergoing 
radiotherapy treatment.  
The data generated here serve as a proof of principle that qPCR-based gene 
expression assays can be used for radiation biodosimetry purposes to aid classical 
cytogenetics tools in an event of mass causality. 
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1.1. Ionising radiation 
Ionising radiation (IR) is a type of high energy radiation which is capable of 
ionising other particles, i.e. removing one or more electron from an atom. The quantity 
of absorbed radiation is expressed in the International System of Units (SI) by the unit 
called the gray (Gy) which corresponds to absorption of 1 J of energy per 1 kg of tissue. 
IR can be particulate in nature (such as α-particles, high energy electrons, protons, 
neutrons and heavy ions) or electromagnetic (X-rays and γ-rays). X-rays and γ-rays 
both have similar characteristic and physical properties but they differ in the process 
by which they are formed, i.e. X-rays are produced when electrons are accelerated 
using special device and stopped abruptly, that causes part of the electron’s kinetic 
energy to be released in a form of X-rays, whereas γ-rays are produced naturally by 
radioactive isotopes like Cobalt-60 (IAEA, 2010, Hall and Giaccia, 2011).  
All types of charged particulate radiation cause direct ionisation of molecules 
by physical interaction with the material through which they traverse and they directly 
produce chemical change and consequently the biological effect. Conversely, the 
mechanism of ionisation for electromagnetic radiation and neutrons is indirect – when 
they are absorbed, part of their energy is used to produce fast moving charged 
particles which are then capable of producing damage to target molecules. The 
different mechanisms of ionisation translate into different biological effectiveness – a 
dose of 1 Gy of α-particles causes more complex biological damage than the same 
dose of X-ray. This is a consequence of the linear energy transfer (LET) of the radiation 
which is the amount of energy deposited per unit distance along the track path in the 
traversed material. Charged particles deposit more energy per unit length along the 
track than X-rays or γ-rays, and therefore they have higher LET and cause larger 
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biological effects. Relative biological effectiveness (RBE) is used to compare biological 
effects caused by different types of radiation and it is expressed as ratio of a dose of a 
reference γ-ray radiation and a dose of a test radiation which is required to produce 
the same particular biological effect (for example kill 50 % of cells). The equivalent 
dose measured in the SI unit, Sievert (Sv) is used to compare doses of different types 
of radiation weighted for biological effectiveness and it is expressed by absorbed dose 
multiplied by radiation weighting factor. For X-rays and γ-rays 1 Gy is equal to 1 Sv, 
comparing to 2 Sv for protons and 20 Sv for α-particles. The effective dose is also 
expressed in Sv and it reflects the health risks from non-homogenous IR exposures. 
Each tissue has individual sensitivity to radiation and based on that organs have been 
assigned to three weighting factors. Effective dose is expressed as a sum of organ 
doses corrected for organ weighting factors and it bears the same health risks as if the 
same dose was delivered homogenously to the total body (ICRP, 2007, UNSCEAR, 
2008, IAEA, 2010, Hall and Giaccia, 2011)  .  
The sources of exposure to ionising radiation can be natural (natural earth crust 
background radiation, radon gas), medical (computed tomography (CT) scans, 
radiotherapy), occupational (nuclear plant workers, aircraft crew), accidental (nuclear 
incidents) or malicious acts (acts of terrorism) (IAEA, 2010) (Figure 1). The exposure 
from natural sources is unavoidable, the United Nations Scientific Committee on the 
Effects of Atomic Radiation (UNSCEAR) estimates that the worldwide average annual 
effective dose of natural radiation to the population is 2.4 mSv (UNSCEAR, 2008). The 
range of effective doses used in clinical diagnostic radiography is between 0.01 and 
100 mSv depending on the procedure (Mettler et al., 2008, Brenner, 2014). Nuclear 
accidents may lead to higher exposures, for example in Chernobyl accident, 134 
17 
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Figure 1. Sources and dose ranges of IR exposure  
Graph presents “orders of magnitude” dose ranges delivered by natural sources, 
diagnostic and therapeutic medicine and occupational exposures. Doses of IR are 
expressed as equivalent dose except for medical diagnostics which are presented as 
maximum organ doses (adapted from lowdose.energy.gov).  
DHS – Department of Homeland Security; DOE – U.S. Department of Energy; EPA – 
Environmental Protection Agency; G-I – gastrointestinal; LD50 – Lethal Dose to 50% 
(whole body dose that results in lethality to 50% of exposed individuals in 30-60 days); 
NRC – Nuclear Regulatory Commission; TIPS – Transjugular Intrahepatic Porto-systemic 
Shunt;  
*Note: Whole body acute prognoses assume no medical intervention 
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rescuers were exposed to doses between 0.8 and 16 Gy and suffered from acute 
radiation syndrome; 28 of those exposed to doses above 2.2Gy died from radiation 
sickness within 2 months from exposure (UNSCEAR, 2008). However, in the Fukushima 
incident, despite being the second largest nuclear accident after Chernobyl, which 
resulted in major release of radioactive material into the environment, doses received 
by general public were low or very low with no deaths or radiation sickness cases 
reported and no excess of cancer risk is expected (UNSCEAR, 2013). 
1.2. Effects of IR exposure on living organisms 
Biological effects of exposure to IR can be broken down into two categories – 
deterministic effects, where the severity of reaction increases with the dose of 
radiation above certain threshold and below this threshold no reaction is observed (e.g 
radiation syndrome), and stochastic effects, where the probability of reaction 
increases linearly with the dose with no threshold (e.g. cancer risk) (IAEA, 2010). 
Each tissue has a different tolerance to IR exposure; usually the highly 
proliferating tissues like bone marrow or small intestine are the most radiosensitive, 
whereas slowly proliferating tissues like kidneys or liver are considered to be more 
radioresistant and they can tolerate higher doses of radiation (Hall and Giaccia, 2011). 
There is also considerable inter-individual variation in sensitivity to IR and existence of 
hereditable radiosensitivity disorders caused by mutations in genes involved in sensing 
or repair of DNA damage like Ataxia-Telangiectasia (AT) (Savitsky et al., 1995), 
Nijmegen breakage syndrome (Varon et al., 1998, Carney et al., 1998), or Lig4 
syndrome (O'Driscoll et al., 2001) suggests that this variation has significant genetic 
component (Barnett et al., 2009). 
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In cancer patients undergoing radiotherapy the treatment plan is designed to 
spare healthy tissue by targeting and fractionation of radiation, however patients still 
often suffer from normal tissue reactions. Normal tissue reaction is caused by 
radiation-induced cell killing that impairs tissue functionality and it can manifest as 
acute or late response (IAEA, 2010). Acute tissue reactions are usually observed within 
weeks following IR exposure and occur mainly in renewing tissues; depending on the 
irradiated tissue it can present itself as erythema and/or ulceration in skin or vomiting 
following abdomen irradiation. Late tissue reactions occur more than three months 
following IR exposure and they are the limiting factor for total dose delivered during 
the course of radiotherapy. The nature of late response depends on the irradiated 
tissue but usually it is manifested as weakened organ function caused by tissue fibrosis 
(IAEA, 2010, Hall and Giaccia, 2011). 
In humans, exposure to a total body dose lower than 2 Gy will generally not 
produce any acute reaction whereas doses higher than 2 Gy will have early clinical 
manifestations (IAEA, 2010). Above a dose of 2 Gy, nausea and early vomiting is 
observed. For doses between 2 and 8 Gy individuals will suffer from haematopoietic 
syndrome caused by depletion of blood cell populations. Doses between 5 and 15 Gy 
will cause gastrointestinal syndrome, which is caused by damage of the mucosal lining 
of the intestine. Doses higher than 20 Gy result in a rapid death due to the neurological 
and vascular failure. The lethal total body dose for human is estimated between 4 and 
7 Gy depending on the level of supportive care (IAEA, 2010) (Figure 1). 
Long term effects of exposure to IR are both cancer and non-cancer. The life 
span study of a cohort of atomic bomb survivors from Hiroshima and Nagasaki 
provides the most comprehensive data regarding long term effects of radiation 
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exposure. There is a clear dose-dependent excess in cancer risk for atomic bomb 
survivors, the risk depends on sex and age at the exposure, moreover the excess risk 
for solid tumours seems to follow a linear non-threshold model. There is some 
nonlinearity in dose response for non-cancer effects including heart, respiratory and 
bladder diseases, where no effect could be seen for doses below 0.5 Gy (Preston et al., 
2003). It is known that IR causes mutations and the hereditary effects of IR exposure 
are of great concern. Although no hereditary effects of IR exposure were described in 
the human population so far, mouse experiments clearly show that such effects exist 
(Dubrova et al., 2000, Barber et al., 2002, Barber et al., 2006) and based on animal 
data the absolute risk of hereditary effects in humans is estimated to be between 0.3 
% to 0.5 % per Gy (UNSCEAR, 2013). 
1.3. DNA damage 
Any biological effect of IR exposure is primarily caused by damage to 
deoxyribonucleic acid (DNA) within the cell. The IR can damage the DNA molecule 
directly as generally happens for high LET radiations, or the damage can be a result of 
water radiolysis caused by low LET radiation, which in turn produces large amounts of 
free radicals capable of damaging DNA (Hall and Giaccia, 2011).  
The IR exposure causes a wide spectrum of DNA lesions including base damage, 
single and double strand breaks and protein-DNA crosslinks. It is estimated that a dose 
of 1 – 2 Gy would induce more than a thousand base lesions, around a thousand single 
strand breaks (SSB) and about forty double strand breaks (DSB) in the DNA of 
mammalian cell (IAEA, 2010). Base damage and SSBs do not usually cause cell killing as 
they are easily repaired by various mechanisms using the opposite strand as a 
template, on the contrary, DSBs are the most toxic lesions caused by IR exposure, as 
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they are complex to repair and can potentially lead to loss of genetic information, 
chromosome breakage and rearrangements potentially leading to carcinogenesis or 
cell killing (Caldecott, 2001, Jackson and Bartek, 2009).  
Eukaryotic cells have evolved two major DSB repair mechanisms: non-
homologous end joining (NHEJ) and homologous recombination (HR) repair 
(extensively reviewed in (Shibata and Jeggo, 2014). NHEJ simply ligates two ends of 
broken DNA without requiring any sequence homology and therefore it is considered 
as an error-prone pathway, whereas HR uses an identical DNA molecule (usually sister 
chromatid in mammals) as a template to repair DNA damage therefore it is considered 
to be an error-free mechanism (Kakarougkas and Jeggo, 2014). In mammalian cells, 
NHEJ is the first choice DSB repair pathway and it is active through the whole cell cycle, 
while the HR requirement for a homologous DNA molecule restricts it to the late S/G2 
phase (Mladenov and Iliakis, 2011). The complexity of DSB and its position in the 
chromatin are two major factors determining repair pathway utilised – complex DSB 
caused by high LET radiation or DSB localised in heterochromatin are repaired by HR, 
whereas repair of simple DSB is executed by NHEJ (Shibata et al., 2011, Yajima et al., 
2013). 
Unrepaired or misrepaired DSBs can lead to chromosome or chromatid 
aberrations depending on phase of cell cycle when the IR exposure took place. The 
aberrations induced by IR exposure include dicentric chromosomes, rings, anaphase 
bridges, translocations and deletions. Induction of dicentrics by IR is dose dependant 
and scoring dicentric chromosomes in stimulated human T-lymphocytes is currently a 
“gold standard” for biological dosimetry following IR exposure (IAEA, 2011). 
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1.4. Signalling cascade following IR exposure 
Cells have developed a surveillance machinery called DNA damage response 
(DDR) which coordinates DNA repair process with all cellular activities. At the heart of 
the DDR are two signalling phosphoinositide 3-kinase related protein kinases: Ataxia-
Telangiectasia mutated (ATM) and ATM and RAD3 related (ATR) which sense the 
damage and transmit a signal to effector proteins (Ciccia and Elledge, 2010). Although 
ATM and ATR have overlapping sets of substrates – large-scale proteomic analysis has 
shown that over 700 proteins are phosphorylated in response to DNA damage on ATM 
and ATR recognised sites – traditionally it is believed that they respond to different 
insults: ATM is activated by DSBs whereas ATR responds to replication protein A (RPA) 
coated single DNA strands caused by replicative stress and other forms of DNA damage 
(Matsuoka et al., 2007). However, there have been several reports showing that IR 
exposure can also activate ATR in an ATM, meiotic recombination 11 (Mre11) and cell 
cycle dependant manner (Jazayeri et al., 2006, Myers and Cortez, 2006). Moreover, 
Tomimatsu et al showed that in ATM-deficient cells, ATR is activated following IR 
exposure in an exonuclease 1 dependant manner and it is able to induce the G2/M cell 
cycle checkpoint in those cells (Tomimatsu et al., 2009).  
Upon IR exposure ATM protein undergoes a rapid autophosphorylation at 
serine 1981 causing inactive ATM dimers to dissociate to active monomers and this 
event initiates the signalling cascade. The precise nature of the signal that ATM protein 
responds to is still unclear but the change in chromatin conformation following DSB 
has been suggested (Bakkenist and Kastan, 2003). The DSBs are sensed by Mre11-
Rad50-Nbs1 (MRN) complex which further activates ATM and recruits it to the DSB site 
(Uziel et al., 2003). The fully active ATM phosphorylates a range of substrates involved 
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in signal transduction, DNA repair and cell cycle control including histone H2AX which 
takes part in DNA damage signal propagation and recruitment of DNA repair 
components to the damage site (Burma et al., 2001), checkpoint kinase 2 (CHEK2), the 
main kinase which amplifies the ATM signal (Matsuoka et al., 2000), tumor protein 
TP53 (TP53) the tumour suppressor gene which then determines the fate of damaged 
cell (Banin et al., 1998) (Canman et al., 1998), and Mdm2 TP53 binding protein 
homolog (mouse) (MDM2), the main negative TP53 protein regulator (Maya et al., 
2001) (Figure 2).  
ATM dependant phosphorylation of CHEK2 and MDM2 proteins, as well as 
TP53 protein leads to TP53 stabilisation and activation which is a key point in the 
cellular response to IR (Hirao et al., 2000). TP53 is a transcriptional factor which has an 
important role in many cellular processes, but it has been intensively studied due to its 
role as a tumour suppressor (Riley et al., 2008). In unstressed cells, TP53 protein is 
inactive; this is mainly due to MDM2 – an ubiquitin ligase which binds to TP53 blocking 
its activity and promoting its degradation. After a stress signal, MDM2 protein 
polyubiquitinylates itself which leads to its degradation and consequently to an 
increased TP53 stability (Haupt et al., 1997, Kubbutat et al., 1997). 
TP53 responds to a broad range of stress signals including DNA damage, 
oncogene activation, hypoxia, telomere erosion or nutrient deprivation and 
coordinates response to these factors with cellular metabolism (Vousden and Lane, 
2007). Stress mediators like ATM or ATR kinases activate TP53 by protein 
phosphorylation (Banin et al., 1998, Canman et al., 1998, Lakin et al., 1999, Tibbetts et 
al., 1999). In response to DNA damage, TP53 activates and represses a number of 
genes involved in cell-cycle arrest, DNA repair, stress induced premature senescence  
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Figure 2. Signalling cascade following IR exposure.  
Upon IR exposure ATM protein undergoes a rapid autophosphorylation causing 
inactive ATM dimers to dissociate to active monomers. The DSBs are sensed by MRN 
complex which further activates ATM and recruits it to the DSB site. The fully active 
ATM phosphorylates a range of substrates involved in signal transduction including 
CHEK2, γH2AX and TP53. TP53 transcriptionally activates a number of genes involved 
in cellular response to IR. Genes in red are down-regulated by TP53 following IR 
exposure. Adapted from (Sengupta and Harris, 2005). 
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(SIPS) and apoptosis (Rashi-Elkeles et al., 2011) (Figure 2). 
TP53 executes G1/S cell cycle arrest mainly due to transcriptional activation of 
cyclin-dependant kinase inhibitor 1A (CDKN1A also known as p21) which is a potent 
proliferation and apoptosis inhibitor. CDKN1A binds and inhibits CyclinE/Cdk2 and 
CyclinD/Cdk4/6 complexes critical for entry into S phase of the cell cycle, causing G1/S 
phase cell cycle arrest, giving the cell time to repair the damage; however, if damage is 
extensive, CDKN1A induces SIPS (Wiebusch and Hagemeier, 2010). Senescence is 
defined as a permanent and irreversible arrest of cell proliferation and senescent cells 
show changes in gene expression, metabolism and morphology and are resistant to 
growth factors and apoptosis (Collado et al., 2007).  
TP53 also plays a role in inducing the G2/M checkpoint upon DNA damage by 
inducing CDKN1A and growth arrest and DNA-damage-inducible alpha (GADD45A) 
(Wang et al., 1999). It also down-regulates cell division cycle 25C (CDC25C) 
phosphatase responsible for activating CyclinB/Cdk1 complex and thus preventing 
entry into mitosis (St Clair et al., 2004) and additionally it transcriptionally inhibits 
cyclins B1 and B2 (CCNB1 and CCNB2) (Innocente et al., 1999, Krause et al., 2000). 
In response to DNA damage TP53 up-regulates a number of DNA repair genes 
including damage-specific DNA binding protein 2, 48kDa (DDB2) involved in nucleotide 
excision repair (NER)  (Hwang et al., 1999) and proliferating cell nuclear antigen (PCNA) 
(Xu and Morris, 1999). Moreover, following DSB induction, TP53 transcriptionally 
down-regulates RAD51 recombinase, a crucial protein for HR repair and in result 
favouring NHEJ repair (Arias-Lopez et al., 2006).  
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If the damage is beyond repair, TP53 can induce apoptosis. Apoptosis is a form 
of programmed cell death carried out in an organised manner which has a crucial role 
in mammalian development and homeostasis and it is characterised by fragmentation 
of the nuclear DNA and cellular membrane, formation of apoptotic bodies (Degterev 
and Yuan, 2008) and exposition of phosphatidylserine on surface of the cells (Fadok et 
al., 1992). The property of Annexin V preferentially binding to negatively charged 
phospholipids like phosphatidylserine has been used to develop an assay widely used 
for early detection of apoptotic cells (Koopman et al., 1994). In response to DNA 
damage TP53 activates a number of pro-apoptotic genes including BCL2 binding 
component 3 (BBC3 also known as PUMA) (Yu et al., 2001, Nakano and Vousden, 
2001), BCL2-associated X protein (BAX) (Miyashita and Reed, 1995), phorbol-12-
myristate-13-acetate-induced protein 1 (PMAIP1 also known as NOXA) (Oda et al., 
2000) and apoptotic peptidase activating factor 1 (APAF1) (Moroni et al., 2001).  
Transcriptional activation of BBC3 accounts for majority of TP53 pro-apoptotic capacity 
following DNA damage, as lymphocytes and thymocytes obtained from Bbc3 deficient 
mice were highly resistant to IR induced apoptosis (Villunger et al., 2003). BBC3 protein 
inhibits anti-apoptotic genes and activates those which are pro-apoptotic. This event 
activates the mitochondrial apoptotic pathway involving mitochondrial outer 
membrane permeabilization, release of cytochrome c, and activation of caspases (Yu 
and Zhang, 2008).  
Different cell types have different sensitivity to IR-induced apoptosis e.g. CD8+ 
T-lymphocytes are more sensitive than CD4+ (Schmitz et al., 2007, Finnon et al., 2012), 
whereas fibroblasts do not undergo apoptosis even after high doses of IR (i.e. 10 Gy 
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and above); instead they undergo TP53-dependant permanent cell cycle arrest (Tsuboi 
et al., 2007). 
1.5. Ataxia-Telangiectasia 
In humans, mutations in ATM gene cause the autosomal recessive 
neurodegenerative disorder, Ataxia-Telangiectasia (AT) (Savitsky et al., 1995). 
Characteristic symptoms of AT are cerebral ataxia, oculocutaneous telangiectasia, 
immunodeficiency, predisposition for cancer, mainly of lymphoid origin and severe 
radiosensitivity (Lavin, 2008). The majority of the mutations in the ATM gene are 
unique, so far over 400 different mutations have been reported and they usually lead 
to production of a truncated protein or no protein product at all (Campbell et al., 
2003). However, leaky splice mutations or missense mutations usually give milder 
phenotype with later onset, slower progression and extended lifespan when 
comparing to classical AT, due to presence of residual ATM kinase activity (Saviozzi et 
al., 2002). 
It is estimated that between 0.5 and 1 % of population caries a mutation in 
ATM gene (Swift et al., 1991). The majority of AT carriers show no clinical symptoms 
because truncated proteins are highly unstable and only wild type proteins are present 
in the cell, however they have higher risk of developing breast cancer than general 
population (Renwick et al., 2006), higher risk of dying from ischemic heart disease and 
they seem to die earlier than non-carriers (Su and Swift, 2000). Moreover, 
heterozygosity in the ATM gene accelerates chronic lymphocytic leukaemia 
progression due to loss of the remaining ATM allele (Skowronska et al., 2012).  
 Cells derived from AT patients display a characteristic phenotype, including 
hypersensitivity to ionising radiation, chromosomal instability (Taylor et al., 1975) and 
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are defective in cell cycle checkpoint induction following DNA damage (Kastan et al., 
1992). Unstimulated lymphocytes from AT patients show poor induction of apoptosis 
by IR exposure compared to cells obtained from healthy donors, whereas lymphocytes 
from obligate AT carriers show intermediate level of radiation-induced apoptosis 
(Duchaud et al., 1996, Barber et al., 2000). In contrast, mitogen-stimulated 
lymphocytes obtained from AT-carriers show higher level of apoptosis following IR 
exposure (Finnon et al., 2008). 
 Following IR exposure, TP53 is also activated in ATM deficient cells although in 
delayed manner (Canman et al., 1994) suggesting that other kinases can activate DDR 
in response to DSBs with slower kinetics (Tibbetts et al., 1999).  
1.6. Gene expression changes following IR exposure 
The first reported mammalian IR induced protein coding gene – tumor necrosis 
factor (TNF) was identified in the late eighties (Hallahan et al., 1989). In the early 
nineties several other IR-responsive genes were identified by northern blotting 
including β-actin, interleukin 1 (Woloschak et al., 1990), FBJ murine osteosarcoma viral 
oncogene homolog (FOS) (Munson and Woloschak, 1990), jun proto-oncogene (JUN) 
(Sherman et al., 1990), GADD45A (Papathanasiou et al., 1991), CDKN1A (Di Leonardo 
et al., 1994), BAX (Zhan et al., 1994), MDM2 (Chen et al., 1994) and cyclin G1 (CCNG1) 
(Okamoto and Beach, 1994). With the development of microarray technology, allowing 
the screening of hundreds of genes simultaneously (Schena et al., 1995), it became 
clear that many more genes are modulated in response to IR (Amundson et al., 1999a, 
Amundson et al., 2000, Park et al., 2002, Jen and Cheung, 2005, Zschenker et al., 2006, 
Gruel et al., 2006, Landmark et al., 2007, Turtoi et al., 2008)  mostly in TP53 dependant 
manner for high doses of radiation (Rashi-Elkeles et al., 2011).  
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Experiments with mouse knockouts revealed that the transcriptional response 
to IR exposure depends in part on TP53 and ATM status, where the expression of both 
proteins’ downstream targets following irradiation is significantly reduced when 
compared to wild type (Bouvard et al., 2000, Kabacik et al., 2011b). Gene expression of 
IR responsive genes is also tissue dependent (Bouvard et al., 2000, Fei et al., 2002, 
Burns and El-Deiry, 2003)  and cell population dependent (Mori et al., 2005, Gruel et 
al., 2008, Kabacik et al., 2011a, Riecke et al., 2012). Moreover, it has been reported 
that developmental stage influences transcription of TP53-dependent radiation-
responsive genes (Gottlieb et al., 1997, Komarova et al., 1997).  
The level of expression of a specific radiation-responsive gene is dose-
dependent and dose-response curves have been obtained for many genes (Amundson 
et al., 2000, Gruel et al., 2006, Manning et al., 2013). Gene expression modulation was 
detected after exposure to very low doses e.g. CD4+ T-lymphocytes irradiated ex-vivo 
with a dose of 50 mGy of γ-ray show changes in expression of a number of genes 
(Gruel et al., 2008) and linear dose-responses for several genes have been obtained 
down to 5 mGy X-ray in human blood irradiated ex-vivo (Manning et al., 2013) and in 
human CD4+ T-lymphocytes (Nosel et al., 2013). Exposure to low doses of radiation 
seems to activate different genes than exposure to higher doses in normal human 
epidermal keratinocytes (Franco et al., 2005), normal human fibroblasts (Ding et al., 
2005) and human skin exposed ex-vivo (Albrecht et al., 2012), hinting that IR can act 
differently depending on dose range. Recently, experiments on mice exposed 
chronically to a dose of 0.05 mGy/day over a period of 401 days receiving a total dose 
of 20 mGy which is an annual limit for radiation workers, showed modulation of 
expression of three genes involved in circadian rhythm, protein glycosylation and 
31 
 
ubiquitin cycle (Uehara et al., 2010) showing that cells can detect even extremely low 
doses of radiation. Also gene expression changes were detected in people 
occupationally exposed to cumulative IR doses lower than 40 mSv (Morandi et al., 
2009, Fachin et al., 2009).  
The long term effects of exposure to low doses are a matter of great concern 
with increased use of diagnostic techniques in medicine. A typical organ dose for CT 
scan, positron emission tomography or fluoroscopy procedure is between 5 and 100 
mGy (Brenner, 2014) and there is still controversy over the cancer risk following low 
dose exposure as epidemiological data provide measurements only down to around 
100 mGy (extensively reviewed in (Mullenders et al., 2009) and (Dauer et al., 2010)). 
However, recently, a retrospective study by Pearce et al showed that children exposed 
to CT scans carry a small increase in cumulative risk of leukaemia and brain tumours 
(Pearce et al., 2012) and 12% excess relative risk of childhood leukaemia per mSv of 
cumulative red bone marrow dose from gamma radiation of natural origin was 
reported (Kendall et al., 2013). Also, a significant dose response relationship between 
increase in childhood cancer risk and a number of CT scans was described (Mathews et 
al., 2013). 
Expression of radiation-responsive genes also varies with time and for many 
genes time-course curves have been produced from exposed human peripheral blood 
lymphocytes (PBLs) (Amundson et al., 2000), lymphoblastoid cell lines (Jen and 
Cheung, 2003), human normal epidermal keratinocytes (Franco et al., 2005), and the 
human myeloid leukaemia cell line ML-1 (Amundson et al., 1999b). Exposure to IR 
induces different temporal profiles which are gene dependent and genes involved in 
one pathway tend to show similar temporal profiles (Jen and Cheung, 2003). The 
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modification of gene expression following IR exposure can be long-lasting; an up-
regulation of Cdkn1a gene persisted for at least two months in the liver of mice 
exposed to IR (Pawlik et al., 2009) and modification of gene expression can be 
detected 7, 17 and 55 days post irradiation in cultured human T-lymphocytes (Falt et 
al., 2003). 
Certain genes show different transcriptional response to IR depending on dose 
rate (Amundson SA, 2003) and respond differently to high- and low-LET radiation 
(Woloschak and Chang-Liu, 1990, Turtoi et al., 2008, Turtoi et al., 2010).  Moreover, 
gene expression signatures after IR exposure are specific and can be distinguished 
from different types of genotoxic stress (Park et al., 2002, Amundson et al., 2005, 
Meadows et al., 2008)  .  
Unfortunately, gene expression is also prone to confounding factors, some IR-
responsive genes were altered in smokers versus non-smokers (Paul and Amundson, 
2011), also LPS-induced inflammation can confound the expression of IR-responsive 
genes in mice (Tucker et al., 2012) and human (Budworth et al., 2012). It has been also 
reported that transcriptional response to IR exposure varies greatly among individuals 
(Kabacik et al., 2011a, Kabacik et al., 2011b, Manning et al., 2013) showing the 
complexity of gene expression regulation after irradiation. 
1.7. microRNA biogenesis and function  
MicroRNAs (miRNAs) are class of small non-coding RNA which post-
transcriptionally regulate gene expression (Filipowicz et al., 2008). They were 
discovered over twenty years ago in C. elegans (Lee et al., 1993, Wightman et al., 
1993) and subsequently in almost all eukaryotic organisms including unicellular algae 
(Zhao et al., 2007) and even in some DNA viruses (Pfeffer et al., 2004) and retroviruses 
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(Klase et al., 2007). miRNAs are single stranded, 18-22 nucleotide long RNAs encoded 
by genomic DNA as an independent, very often polycistronic transcript which is usually 
transcribed by polymerase II, capped and polyadenylated (Lee et al., 2004). miRNAs 
can be also located in the introns and co-expressed with the host gene (Ruby et al., 
2007). The intergenic transcripts coding for miRNAs, called pri-miRNA, are processed 
by nuclear complex containing ribonuclease type III enzyme – DROSHA, which cuts the 
pri-miRNA transcript to produce approximately 70 nucleotide long double stranded 
hairpins (pre-miRNAs) (Denli et al., 2004, Gregory et al., 2004). Some intronic miRNAs 
can bypass DROSHA cleavage and are processed by alternative pathway utilising the 
spliceosome which creates pre-miRNAs without DROSHA involvement (Ruby et al., 
2007). The pre-miRNAs are transported from the nucleus to the cytoplasm by exportin 
5 protein in a sequence independent manner (Lund et al., 2004) and in the cytoplasm 
the pre-miRNAs are further processed by another ribonuclease type III – DICER1, which 
creates about 18-22 nucleotide long duplexes containing mature miRNAs (Hutvagner 
et al., 2001). Mature miRNAs are then loaded into the RNA-induced silencing complex 
(RISC), where they posttranscriptionally regulate gene expression (Filipowicz et al., 
2008). The 5’ and 3’ mature miRNAs derived from DICER1 cleavage have different 
thermodynamic properties and although one strand is usually preferentially loaded 
into RISC complex, both of the strands can be used for regulation of gene expression 
(Okamura K, 2008) (Figure 3). 
miRNAs act mainly as negative regulators of gene expression, however, in 
specific circumstances they can activate translation as well (Vasudevan et al., 2007, 
Henke et al., 2008). Target recognition occurs by partial miRNA binding to the 3’ 
untranslated region (UTR) in the target mRNA and seven nucleotides at 5’ end of the  
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Figure 3. miRNA biogenesis. 
The independent miRNA transcripts (pri-miRNas) and miRNAs located in introns 
are processed by DROSHA ribonuclease to produce hairpin structure called pre-miRNA. 
Some miRNAs located in introns are processed by non-canonical pathway involving 
spliceosome to produce pre-miRNA. Pre-miRNAs are exported from the nucleus by 
exportin 5, where they are further processed by DICER 1 complex to produce mature 
miRNAs, which are subsequently loaded into RISC complex, where they regulate gene 
expression. Adapted from (O'Carroll and Schaefer, 2013)  
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miRNA (numbers 2-8), called the seed region, provide most specificity for target 
recognition (Filipowicz et al., 2008). Due to the short length of the seed sequence, one 
miRNA can target many mRNAs and one mRNA can be targeted by many different 
miRNAs (Chi et al., 2009). The mechanism of miRNA mediated repression is still 
debatable but inhibition of initiation of translation seems to be a critical event 
(Mathonnet et al., 2007, Meijer et al., 2013). 
1.8. Effects of IR exposure on miRNA expression 
Since their discovery, miRNAs have been implicated virtually in every process 
investigated in the cell (Filipowicz et al., 2008). Widespread reduction of microRNA 
gene expression has been reported in cancer (Lu et al., 2005). A number of miRNAs 
which target DDR components have been identified: miR-100, miR-101 and miR-421 
down-regulate ATM expression (Ng et al., 2010, Yan et al., 2010, Hu et al., 2010a), miR-
125b and miR-504 directly regulate TP53 expression (Le et al., 2009, Hu et al., 2010b)  
and miR-605 and miR-661 target MDM2 gene (Xiao et al., 2011, Hoffman et al., 2014). 
Moreover, following DNA damage, TP53 increases rate of pri-miRNA processing of 
several growth suppressing miRNAs via interaction with DROSHA (Suzuki et al., 2009). 
Additionally, upon DSB induction, ATM directly activates KH-type splicing regulatory 
protein (KSRP) which interacts with DROSHA and DICER1 complexes regulating 
biogenesis of subset of miRNA and increases global miRNA processing (Zhang et al., 
2011). miRNAs seem to be essential for cellular response to IR, as global miRNA 
reduction achieved by down-regulation of DICER, reduces cell survival following 
radiation mediated by impaired cell cycle checkpoint activation and increased 
apoptosis (Kraemer et al., 2011). 
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The pioneering work of Marsit et al showed that γ-ray exposure, in contrast to 
folate deprivation and arsenite exposure, did not induce significant alteration in global 
miRNA expression measured by microarray method in a human lymphoblastoid cell 
line (Marsit et al., 2006). In 2007, He et al reported that miRNAs belonging to miR-34 
family were induced in a TP53-dependent manner by IR in a variety of mouse tissues 
(He et al., 2007). This publication sparked the search for other IR-responsive miRNAs. 
Experiments on human primary foreskin fibroblasts revealed a very modest response 
of 29 miRNAs to X-ray exposure although they seemed to be dose- and time-point 
specific (Maes et al., 2008). Shin et al investigated miRNA responses to IR in human 
colon carcinoma cell lines differing with wild-type or knockout TP53 gene and 
concluded that majority of observed miRNA differences were due to TP53 status rather 
than IR exposure, with only one miRNA (miR-548c) classified as radiation-responsive 
(Shin et al., 2009). The same group investigated miRNA expression after IR exposure in 
a human B lymphoblastic cell line utilising the same experimental approach and they 
found 87 miRNAs the expression of which was significantly different in irradiated cells 
(Cha et al., 2009). Interestingly, miR-548c was not reported, although some of the TP53 
status responsive miRNAs from the human colon carcinoma cell line seemed to be 
radiation responsive in this cell line. Simone et al investigated miRNA expression 
following treatment with hydrogen peroxide, etoposide and γ-ray in normal human 
fibroblasts, they reported 17 IR-responsive miRNAs, and interestingly all of these 
miRNAs were responsive to hydrogen peroxide and/or etoposide as well, suggesting 
that they play a role in general stress response (Simone et al., 2009). Only ten miRNAs 
showed small changes in expression after IR exposure in human endothelial cells, six of 
them: let-7g, miR-16, miR-18a, miR-20a, miR-21 and miR-29c were identified in at least 
one of the previous studies (Wagner-Ecker et al., 2010). 
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The experiments of Chaudhry et al with human cell lines differing in the TP53 
and DNA-dependent protein kinase (DNA-PK) status seem to confirm that miRNA 
response to IR is specific to dose of radiation, time-point and genetic background 
(Chaudhry et al., 2010a, Chaudhry et al., 2010b). Moreover, the miRNA response to IR 
exposure depends on cell or tissue type (Table 1) and gender (Ilnytskyy et al., 2008, 
Koturbash et al., 2008, Koturbash et al., 2011). The miRNA response to IR can be long 
lasting as Shi et al reported increasing expression of miR-21 in brain of irradiated mice 
up to a year post exposure (Shi et al., 2012). 
Very importantly Jacob et al showed that miR-150 exhibits dose- and time-
dependent expression in serum of mice exposed to whole body doses of γ-ray which 
makes this miRNA particularly promising candidate for radiation biodosimetry (Jacob 
et al., 2013).  
1.9. Long non-coding RNAs 
The definition of long non-coding RNA (lncRNA) is very broad and unspecific: 
every RNA molecule longer than 200 nucleotides which is not ribosomal RNA or 
transfer RNA and lacks significant protein coding potential is defined as lncRNA 
(Mercer and Mattick, 2013). The first lncRNA – the H19, imprinted maternally 
expressed transcript (non-protein coding) (H19) was discovered in early nineties 
(Brannan et al., 1990) and discovery of the X inactive specific transcript (non-protein 
coding) (Xist) lncRNA followed the next year (Brockdorff et al., 1991); however, at the 
time it was believed that the majority of genes code for proteins, therefore these 
molecules were treated as curiosities for almost a decade. This view changed with the 
initial papers published by FANTOM consortium (Kawai et al., 2001, Okazaki et al., 
2002) when for the first time it became clear that lncRNAs are much more common 
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Table 1. miRNAs showing altered expression following IR exposure in different cell 
lines adapted from (Metheetrairut and Slack, 2013)  
Increase Decrease 
let-7a M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b) 
let-7a IM9 human lymphoblast line (Cha et al., 
2009), normal human fibroblasts (Simone et al., 
2009) and A549 lung cancer cell line (Weidhaas et al., 
2007) 
let-7b  M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b) 
let-7b  normal human fibroblasts (Simone et al., 
2009) and A549 lung cancer cell line  (Weidhaas et al., 
2007) 
let-7c  normal human thyroid cells (Nikiforova et 
al., 2011) and M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b) 
let-7c  IM9 human lymphoblast line (Cha et al., 
2009) and A549 lung cancer cell line (Weidhaas et al., 
2007) 
let-7d normal human thyroid cells (Nikiforova et 
al., 2011), normal human fibroblasts (Simone et al., 
2009) and M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b) 
let-7d AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), and A549 lung cancer cell line 
(Weidhaas et al., 2007) 
let-7e AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), normal human fibroblasts 
(Simone et al., 2009) and M059K – human glioblstoma 
cell line (Chaudhry et al., 2010b) 
let-7e , IM9 human lymphoblast line (Cha et al., 
2009), human peripheral blood lymphocytes (Girardi et 
al., 2012) and A549 lung cancer cell line (Weidhaas et al., 
2007) 
let-7f b M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b) and blood (Templin et al., 
2011b) 
let-7f IM9 human lymphoblast line (Cha et al., 
2009), normal human thyroid cells (Nikiforova et al., 
2011) and A549 lung cancer cell line (Weidhaas et al., 
2007) 
let-7g normal human thyroid cells (Nikiforova et al., 
2011), normal human fibroblasts (Simone et al., 2009), 
M059K – human glioblstoma cell line (Chaudhry et al., 
2010b), blood (Templin et al., 2011b), U87MG human 
malignant glioma cell line (Chen et al., 2010) and human 
dermal microvascular endothelial cells (Wagner-Ecker et 
al., 2010) 
let-7g TPC-1 papillary thyroid carcinoma (Abou-El-
Ardat et al., 2012) 
let-7i AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), normal human fibroblasts 
(Simone et al., 2009) and M059K – human glioblstoma 
cell line (Chaudhry et al., 2010b) 
let-7i A549 lung cancer cell line (Weidhaas et al., 
2007) 
 
miR-10a TPC-1 papillary thyroid carcinoma (Abou-
El-Ardat et al., 2012) and human peripheral blood 
lymphocytes (Girardi et al., 2012) 
miR-15a AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), M059K – human glioblstoma cell 
line (Chaudhry et al., 2010b), A549 lung cancer cell line 
(Weidhaas et al., 2007) 
 
miR-16 human peripheral blood lymphocytes 
(Girardi et al., 2012), M059K – human glioblstoma cell 
line (Chaudhry et al., 2010b), blood (Templin et al., 
2011b), human dermal microvascular endothelial cells 
(Wagner-Ecker et al., 2010) and A549 lung cancer cell 
line (Weidhaas et al., 2007) 
miR-16 IM9 human lymphoblast line (Cha et al., 
2009) 
miR-17-3p TPC-1 papillary thyroid carcinoma 
(Abou-El-Ardat et al., 2012), AG1522 normal human skin 
fibroblasts (Chaudhry et al., 2012), M059K – human 
glioblstoma cell line (Chaudhry et al., 2010b) and blood 
(Templin et al., 2011b) 
miR-17 human peripheral blood lymphocytes 
(Girardi et al., 2012)  
miR-17-5p TPC-1 papillary thyroid carcinoma 
(Abou-El-Ardat et al., 2012), AG1522 normal human skin 
fibroblasts (Chaudhry et al., 2012), M059K – human 
glioblstoma cell line (Chaudhry et al., 2010b), blood 
(Templin et al., 2011b), A549 lung cancer cell line 
(Weidhaas et al., 2007) and HUVEC human umbilical 
vein endothelial cells (Vincenti et al., 2011) 
miR-17-5p IM9 human lymphoblast line (Cha et al., 
2009) 
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miR-18a human dermal microvascular endothelial 
cells  (Wagner-Ecker et al., 2010) and normal human 
fibroblasts (Maes et al., 2008) 
miR-19a M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b), blood (Templin et al., 2011b), 
A549 lung cancer cell line (Weidhaas et al., 
2007) and HUVEC human umbilical vein endothelial cells 
(Vincenti et al., 2011) 
 
miR-19b AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), M059K – human glioblstoma cell 
line (Chaudhry et al., 2010b), A549 lung cancer cell 
line (Weidhaas et al., 2007) and HUVEC  human 
umbilical vein endothelial cells (Vincenti et al., 2011) 
miR-19b human peripheral blood lymphocytes 
(Girardi et al., 2012) and IM9 human lymphoblast line 
(Cha et al., 2009) 
miR-20a blood (Templin et al., 2011b),(Wagner-
Ecker et al., 2010) and HUVEC  human umbilical vein 
endothelial cells (Vincenti et al., 2011) 
miR-20a IM9 human lymphoblast line (Cha et al., 
2009) 
miR-20b blood (Templin et al., 2011b) and A549 
lung cancer cell line (Weidhaas et al., 2007)  
miR-21 AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), normal human fibroblasts 
(Simone et al., 2009), M059K – human glioblstoma cell 
line (Chaudhry et al., 2010b), blood (Templin et al., 
2011b), human dermal microvascular endothelial 
cells  (Wagner-Ecker et al., 2010), (Mueller et al., 2013), 
HUVEC  human umbilical vein endothelial cells (Vincenti 
et al., 2011) 
miR-21 IM9 human lymphoblast line (Cha et al., 
2009) 
miR-22 U87MG human malignant glioma cell line 
(Chen et al., 2010), A549 lung cancer cell line (Weidhaas 
et al., 2007) and LNCaP human prostate cancer cell lines 
(Li et al., 2011) 
 
miR-24 blood (Templin et al., 2011b), A549 lung 
cancer cell line (Weidhaas et al., 2007) and LNCaP 
human prostate cancer cell lines (Li et al., 2011) 
miR-24 normal human fibroblasts (Simone et al., 
2009) and IM9 human lymphoblast line (Cha et al., 2009) 
miR-26b normal human fibroblasts (Simone et al., 
2009) and blood (Templin et al., 2011b)  
miR-27a blood (Templin et al., 2011b) and A549 
lung cancer cell line (Weidhaas et al., 2007)  
miR-27b TPC-1 papillary thyroid carcinoma (Abou-
El-Ardat et al., 2012), A549 lung cancer cell 
line  (Weidhaas et al., 2007) and HUVEC human 
umbilical vein endothelial cells (Vincenti et al., 2011) 
 
miR-29a blood (Templin et al., 2011b) and HUVEC 
human umbilical vein endothelial cells (Vincenti et al., 
2011) 
 
miR-29c blood (Templin et al., 2011b), human 
dermal microvascular endothelial cells (Wagner-Ecker et 
al., 2010), IM9 human lymphoblast line (Cha et al., 2009) 
and HUVEC human umbilical vein endothelial cells 
(Vincenti et al., 2011) 
 
miR-30a-5p A549 lung cancer cell line (Weidhaas et 
al., 2007) and LNCaP human prostate cancer cell lines (Li 
et al., 2011) 
 
miR-34a human peripheral blood lymphocytes 
(Girardi et al., 2012), A549 human non-small cell lung 
cancer cells (Shin et al., 2009), IM9 human lymphoblast 
line (Cha et al., 2009) and normal human thyroid cells 
(Nikiforova et al., 2011) 
 
miR-34b* human peripheral blood lymphocytes 
(Girardi et al., 2012), normal human thyroid cells 
(Nikiforova et al., 2011) and A549 human non-small cell 
lung cancer cells (Shin et al., 2009) 
 
miR-34c LNCaP and C4-2 human prostate cancer 
cell lines (Josson et al., 2008)  
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miR-99a A549 lung cancer cell line (Weidhaas et al., 
2007) and MCF7 breast cancer cell line (Mueller et al., 
2013) 
miR-99a human peripheral blood lymphocytes 
(Girardi et al., 2012)  
miR-100 MCF7 breast cancer cell line (Mueller et 
al., 2013)  
miR-100 human peripheral blood lymphocytes 
(Girardi et al., 2012), normal human fibroblasts (Simone 
et al., 2009) and LNCaP and C4-2 human prostate cancer 
cell lines (Josson et al., 2008) 
miR-106a blood (Templin et al., 2011b) and A549 
lung cancer cell line (Weidhaas et al., 2007) 
miR-106a TPC-1 papillary thyroid carcinoma (Abou-
El-Ardat et al., 2012), IM9 human lymphoblast line (Cha 
et al., 2009) and A549 human non-small cell lung cancer 
cells (Shin et al., 2009) 
 
miR-106b LNCaP human prostate cancer cell lines 
(Li et al., 2011) and IM9 human lymphoblast line (Cha et 
al., 2009) 
 
miR-107 U87MG human malignant glioma cell line 
(Chen et al., 2010), IM9 human lymphoblast line (Cha et 
al., 2009) and LNCaP and C4-2 human prostate cancer 
cell lines (Josson et al., 2008) 
 
miR-125a human dermal microvascular endothelial 
cells  (Wagner-Ecker et al., 2010) and A549 lung cancer 
cell line (Weidhaas et al., 2007) 
miR-126 blood (Templin et al., 2011b) and HUVEC 
human umbilical vein endothelial cells (Vincenti et al., 
2011) 
 
 
miR-133b LNCaP and C4-2 human prostate cancer 
cell lines (Josson et al., 2008) 
miR-142-3p AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012) and M059K – human glioblstoma 
cell line (Chaudhry et al., 2010b) 
miR-142-3p IM9 human lymphoblast line (Cha et 
al., 2009) 
miR-142-5p AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), M059K – human glioblstoma cell 
line (Chaudhry et al., 2010b) and blood (Templin et al., 
2011b) 
miR-142-5p IM9 human lymphoblast line (Cha et 
al., 2009) 
miR-143 AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), M059K – human glioblstoma cell 
line (Chaudhry et al., 2010b) 
miR-143 blood (Templin et al., 2011b) and LNCaP 
and C4-2 human prostate cancer cell lines (Josson et al., 
2008) 
miR-145 AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), human peripheral blood 
lymphocytes (Girardi et al., 2012) and blood (Templin et 
al., 2011b) 
miR-145 LNCaP and C4-2 human prostate cancer 
cell lines (Josson et al., 2008)  
miR-148a blood (Templin et al., 2011b) and A549 
lung cancer cell line (Weidhaas et al., 2007)  
 
miR-152 TPC-1 papillary thyroid carcinoma (Abou-
El-Ardat et al., 2012) and human peripheral blood 
lymphocytes (Girardi et al., 2012) 
miR-155 M059K – human glioblstoma cell line 
(Chaudhry et al., 2010b) 
miR-155 AG1522 normal human skin fibroblasts 
(Chaudhry et al., 2012), A549 lung cancer cell line 
(Weidhaas et al., 2007) and IM9 human lymphoblast line 
(Cha et al., 2009) 
 
miR-181a human peripheral blood lymphocytes 
(Girardi et al., 2012) and U87MG human malignant 
glioma cell line (Chen et al., 2010) 
miR-188-5p human peripheral blood lymphocytes 
(Girardi et al., 2012) and normal human thyroid cells 
(Nikiforova et al., 2011) 
miR-188-5p normal human fibroblasts (Maes et al., 
2008) 
 
miR-196a human peripheral blood lymphocytes 
(Girardi et al., 2012) and LNCaP and C4-2 human 
prostate cancer cell lines (Josson et al., 2008) 
miR-191 U87MG human malignant glioma cell line 
(Chen et al., 2010) and LNCaP human prostate cancer 
cell lines (Li et al., 2011) 
 
miR-221 human peripheral blood lymphocytes 
(Girardi et al., 2012), blood (Templin et al., 2011b), A549 
lung cancer cell line (Weidhaas et al., 2007) and HUVEC  
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human umbilical vein endothelial cells (Vincenti et al., 
2011) 
miR-222 blood (Templin et al., 2011b) and HUVEC 
human umbilical vein endothelial cells (Vincenti et al., 
2011) 
miR-222 normal human fibroblasts (Simone et al., 
2009)  
miR-365 normal human thyroid cells (Nikiforova et 
al., 2011) and A549 lung cancer cell line (Weidhaas et 
al., 2007) 
 
miR-379 U87MG human malignant glioma cell line 
(Chen et al., 2010) and LNCaP and C4-2 human prostate 
cancer cell lines (Josson et al., 2008) 
 
 
miR-521 U87MG human malignant glioma cell line 
(Chen et al., 2010) and LNCaP and C4-2 human prostate 
cancer cell lines (Josson et al., 2008) 
miR-601 human peripheral blood lymphocytes 
(Girardi et al., 2012) and U87MG human malignant 
glioma cell line (Chen et al., 2010) 
 
miR-663 human peripheral blood lymphocytes 
(Girardi et al., 2012), IM9 human lymphoblast line (Cha 
et al., 2009) and normal human fibroblasts (Simone et 
al., 2009) 
miR-663 normal human fibroblasts (Maes et al., 
2008) 
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and transcription is much more pervasive than previously thought. The same group 
reported that for many protein coding genes antisense RNAs are transcribed from the 
opposite strand which can regulate their transcription (Katayama et al., 2005) and that 
the majority of the mammalian genome is transcribed (Carninci et al., 2005). Instantly, 
questions about the nature of this transcription followed. The overwhelming majority 
of lncRNAs show no sequence conservation between species (Pang et al., 2006) and 
they are expressed at very low levels (Ravasi et al., 2006). These observations led some 
researchers to hypothesise that observed ubiquitous non-coding transcripts are non-
functional and represent transcriptional noise (Struhl, 2007, Ebisuya et al., 2008). 
Nonetheless, lncRNAs show highly tissue-specific expression (Mercer et al., 2008) and 
precise functions for individual lncRNAs have been identified (Penny et al., 1996, 
Sleutels et al., 2002). 
Guttman et al used chromatin structures associated with active polymerase II 
transcription to map unknown transcripts in the intergenic regions of the mouse 
genome and they discovered about 1600 new highly conserved lncRNAs and 
associated their likely functions with various cellular processes (Guttman et al., 2009). 
The completion of Encyclopedia of DNA Elements (ENCODE) project revealed that 75 % 
of the human genome is transcribed in some cell types and at some point in 
development and that majority of non-coding transcripts show nuclear localisation 
(Djebali et al., 2012). The number of non-coding RNAs, in contrast to protein coding 
sequences, does correlate with the complexity of multicellular organisms and it has 
been proposed that RNA played a central role in evolution of eukaryotic organisms 
(Taft et al., 2007). 
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lncRNAs exhibit various mechanisms of action. They can act as RNA decoys for 
miRNAs (Poliseno et al., 2010, Cesana et al., 2011) or repressive proteins (Zhao et al., 
2008, Klattenhoff et al., 2013), scaffold for protein complexes (Sharma et al., 2011, 
Yoon et al., 2013), co-activators (Hube et al., 2011) or co-repressors (Rinn et al., 2007) 
(Figure 4). Although the function of the overwhelming majority of lncRNAs is still 
unknown, those characterised seem to play very diverse roles in genomic imprinting 
(Sleutels et al., 2002), chromosome X dosage compensation (Penny et al., 1996), 
growth arrest (Mourtada-Maarabouni et al., 2008), control of pluripotency and 
differentiation (Guttman et al., 2011), apoptosis (Yan et al., 2005), gene expression 
(Zhou et al., 2007) and DNA methylation (Imamura et al., 2004) just to name a few. 
1.10. DNA damage responsive lncRNAs 
The lncRNA concept is relatively new in radiation biology and only a handful of 
IR-responsive lncRNAs has been identified so far. Majority of experiments have been 
performed using radiomimetic drugs which induce DSBs like doxorubicin, bleomycin or 
etoposide. The first lncRNA showing modification of expression upon induction of DSBs 
was TP53 target 1 (non-protein coding) (TP53TG1) (Takei et al., 1998). The TP53TG1 
transcript did not possess significant protein coding potential and was up-regulated in 
normal human fibroblasts in TP53 dependent manner upon ultraviolet light exposure 
or bleomycin treatment. Huarte et al identified another direct TP53 target lncRNA – 
tumor protein p53 pathway corepressor 1 (Trp53cor1) which was induced upon 
doxorubicin treatment in a range of mouse cell lines and human fibroblasts and acted 
as a repressor in TP53 pathway (Huarte et al., 2010). 
Several other lncRNAs have been found to be up-regulated following 
doxorubicin treatment in various cell lines, for example the non-protein coding RNA, 
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Figure 4. Mechanisms of action for lncRNAs. 
lncRNAs can be divided in three functional categories, activators, repressors and 
structural. Copied from (Krishnan and Mishra, 2014).  
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associated with MAP kinase pathway and growth arrest (NAMA) in human papillary 
thyroid cancer and colon cancer cell lines (Yoon et al., 2007), the promoter of CDKN1A 
antisense DNA damage activated RNA (PANDAR) induced in normal human fibroblasts 
which negatively regulates apoptosis in TP53-dependent manner (Hung et al., 2011), 
the long intergenic non-protein coding RNA, regulator of reprogramming (linkRNA-
RoR) induced in a TP53-dependent manner in several human cancer cell lines, involved 
in controlling TP53 level after DNA damage (Zhang et al., 2013), the urothelial cancer 
associated 1 (non-protein coding) lncRNA (UCA1) up-regulated by in TP53-independent 
manner in human breast cancer cell line (Huang et al., 2014). Also E2F1-regulated 
lncRNA XLOC 006942 (ERIC) was found to be up-regulated after etoposide treatment in 
a human osteosarcoma cell line (Feldstein et al., 2013). 
Wan et al screened a human lymphoblastoid cell line for lncRNAs showing 
modification of expression following treatment with a radiomimetic drug (Wan et al., 
2013b). The authors reported significant ATM-dependent up-regulation of the CDKN2B 
antisense RNA 1 (CDKN2B-AS1 also known as ANRIL) following DNA damage, also 
down-regulation of H19 and modest up-regulation of taurine up-regulated 1 (non-
protein coding) (TUG1) and lncRNA transcribed from the promoter region encoding 
cyclin D1 (lncRNA-CCND1) was reported (Wan et al., 2013b). The same group identified 
a novel JADE1 adjacent regulatory RNA (JADRR) lncRNA which is induced following 
DNA damage in an ATM-dependent manner (Wan et al., 2013a). 
Mizutani et al identified 25 novel genotoxic stress-inducible nuclear lncRNAs 
and six of them showed modulation of expression following doxorubicin treatment in 
HeLa cells, however they have not been annotated yet and their function is unknown 
(Mizutani et al., 2012). 
46 
 
 The first reported lncRNA induced by IR-exposure was lncRNA-CCND1, it forms 
a ribonucleoprotein complex and represses CCND1 transcription following DNA 
damage (Wang et al., 2008). Chaudhry et al investigated the temporal response of five 
lncRNAs, for which TaqMan assays were commercially available, following exposure to 
2 Gy of X-ray, in human lymphoblastoid cell lines, however only SOX2 overlapping 
transcript (non-protein coding) (SOX2-OT) shown modification of expression more than 
2 fold (Chaudhry, 2013).  
Özgür et al investigated expression of ten well characterised lncRNAs playing 
roles in the TP53 pathway or DNA damage following γ-radiation exposure or bleomycin 
treatment in human cervical and breast cancer cell lines (Ozgur et al., 2013). They 
observed cell line dependent differences in expression of investigated lncRNAs and 
differences in transcriptional response to bleomycin and IR, although it should be 
noted that doses of bleomycin used induced much higher apoptotic response than IR 
indicating that doses of the drug and radiation were not equivalent. Nonetheless, 
three lncRNAs – CDKN2B-AS1, lncRNA-CCND1 and growth arrest-specific 5 (non-protein 
coding) (GAS5) were significantly up-regulated by IR exposure at least in one cell line. 
Interestingly, contrary to the previous report (Hung et al., 2011), PANDAR was not 
responsive to bleomycin or IR treatment in neither of the cell lines, what can indicate 
tissue specific transcriptional response to DNA damaging agents (Ozgur et al., 2013).  
1.11. Biomarkers of radiation exposure 
According to the National Institute of Health, a biomarker is “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” (Biomarkers Definitions Working, 2001). A biomarker of radiation 
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exposure should allow exposed individuals to be distinguished from non-exposed ones 
and ideally should be able to provide an estimated absorbed dose. Cytogenetic 
biomarkers used in radiation biology take advantage of the fact that IR induces wide 
range of chromosomal aberrations in peripheral blood lymphocytes (PBL) like dicentric 
chromosomes, rings and translocations (IAEA, 2011).  
Dicentric aberrations result from erroneous joining of DSBs from two different 
chromosomes and give rise to a chromosome with two centromeres and an acentric 
fragment which can be visualised in metaphases (IAEA, 2011). Dicentric aberrations 
arise almost exclusively due to IR exposure, have very low spontaneous occurrence 
and show linear-quadratic dose-response up to around 5 Gy what makes them a good 
biomarker for IR exposure (Romm et al., 2009). The lower limit of detection for 
dicentric assay is around 0.1 Gy of whole body exposure and it is possible to estimate a 
dose for partial exposure based on the dicentric distribution in scored methaphases 
(IAEA, 2011). All these features make dicentric assay the “gold standard” for radiation 
biodosimetry, however the biggest disadvantages of this method are low throughput 
and requirement for highly trained staff for scoring dicentric chromosomes (Wojcik et 
al., 2010). The necessity of culturing PBLs for 48 h before the assay can be performed 
implies that the sample preparation takes at least 51 h; additionally, the subsequent 
analysis takes between 5 and 25 h per sample for 500 scored metaphases depending 
on level of automation (Romm et al., 2009). 
The cytokinesis-blocked micronucleus (CBMN) assay has been also used for 
radiation biodosimetry. Micronuclei are acentric chromosome fragments or whole 
chromosomes which have been left in the cytoplasm after mitosis and are visible in the 
cell as spherical small object (IAEA, 2011). Formation of micronuclei is not specific to 
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radiation, however IR-induced micronuclei consist mostly of acentric chromosome 
fragments therefore by using centromere specific probe in the CBMN assay and 
scoring only acentric micronuclei the lower limit of detection of around 0.1 Gy can be 
obtained (Vral et al., 1997). The CBMN assay is easy to perform and does not need 
highly trained personnel, however due to the requirement of three day culture of PBLs 
it takes longer than dicentric assay to obtain dose estimates and it does not allow 
estimating the partial body exposure (Fenech, 1993). 
Another cytogenetic-based method for dose assessment is the premature 
chromatin concentration (PCC) assay, where the chromosomal aberrations are 
visualised in prematurely condensed interphase chromatin by using either chemical 
reagents or fusion with mitotic cells (IAEA, 2011). Although the dose estimations can 
be obtained much quicker with the fusion-based method, the technical difficulties 
make it a less common choice whereas for chemical-induction of PCC, PBLs have to be 
stimulated beforehand (Hatzi et al., 2006). In the PCC assay cells do not have to enter 
mitosis, therefore the most damaged cells are not lost from the population and this 
assay enables estimation of much higher doses than dicentric or CBMN assays; it is also 
suitable for partial body exposure (Lindholm et al., 2010) 
The dicentric chromosomes and rings are unstable aberrations which are not 
passed to the daughter cell after division and disappear within around three years 
which is the average lifespan of the lymphocytes (IAEA, 2011). Alternatively, stable 
translocations which are exchanges between fragments of two or more chromosomes 
are passed to the next generation of cells and can be detected years after exposure by 
using fluorescent in-situ hybridisation (FISH) assay (Tawn and Whitehouse, 2003). In 
the FISH assay some or all of the chromosomes are painted in different colours using 
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fluorescent probes making any exchanges easily visible. There are many confounding 
factors such as age or smoking (Sigurdson et al., 2008), therefore the lower limit of 
detection is around 0.5 Gy. Additionally, this technique is also labour intense and 
needs at least five days to provide the dose estimates and for those reasons FISH assay 
is mainly used for occupational or historical dosimetry (Edwards et al., 2005) 
Another developing non-cytogenetic based assay for radiation biodosimetry is 
the γ-H2AX assay. It takes advantage of the fact that histone H2AX is rapidly 
phosphorylated in response to DSBs formation and this phosphorylation can be 
detected by using specific antibodies and fluorescent microscopy (Burma et al., 2001). 
The γ-H2AX assay is the most sensitive technique described so far, capable of detecting 
1 mGy exposure when the pre-exposed levels of foci are known (Rothkamm and 
Lobrich, 2003), therefore it is mostly applicable for dosimetry of planned exposures in 
medical diagnostic (Rothkamm et al., 2007) and therapy (Sak et al., 2007). The 
phosphorylation of γ-H2AX peaks at 1 h post exposure and then rapidly declines to the 
baseline limiting the use of this assay for triage purpose (Rothkamm and Horn, 2009). 
Using gene expression signatures for radiation dosimetry was suggested for the 
first time by Amundson et al (Amundson et al., 2000) and since then this possibility has 
been under intense investigation. Although studies investigating gene expression 
changes following IR have been conducted using different cell types or tissues and 
involved broad dose range and time-points, several genes have been found constantly 
up-regulated in human blood like CDKN1A, phosphohistidine phosphatase 1 (PHPT1), 
GADD45A, DDB2, CCNG1 or ferredoxin reductase (FDRX) (Amundson et al., 2000, Paul 
and Amundson, 2008, Kabacik et al., 2011a, Manning et al., 2013) and these radiation-
responsive genes are candidate IR biomarkers.  
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Gene expression assays are quick to perform – a dose estimate can be provided 
within 8 h of receiving the samples, although there are large differences between 
laboratories both in time of reporting and precision of dose estimates (Badie et al., 
2013). A recent comparison of established and developing assays for radiation 
biodosimetry indicated that under optimal conditions gene expression assay 
outperformed the γ-H2AX assay and was as accurate as the CBMN assay in dose 
estimation although still about 2.5 times less precise than the dicentric assay 
(Rothkamm et al., 2013). However, when doses were grouped into binary categories 
relevant from a medical point of view, gene expression assay performed almost as well 
as the dicentric assay but produced the dose estimates around 8 times quicker 
(Rothkamm et al., 2013) revealing its potential in triage scenario.  
1.12. Using gene expression profiles as a biomarker of IR exposure 
The possibility of using gene expression biomarkers for dose estimation has 
been intensively investigated over the recent decade. Most of the studies utilise whole 
blood (Amundson SA, 2004, Paul and Amundson, 2008, Manning et al., 2013)  or PBLs 
(Dressman et al., 2007, Kabacik et al., 2011a) as blood is relatively easily accessible 
tissue in case of mass causality scenario.  
Microarray technology enables the measurement of the expression level of 
thousands of genes simultaneously and many research groups have employed this 
method to find dose- and time-specific gene signatures and use them for dose 
estimation. Gruel et al used gene signatures specific to different doses of γ-radiation 
ranging from 20 mGy to 5 Gy and correctly estimated dose of IR received by the test 
mice with 83 to 100 % accuracy depending on the dose (Gruel et al., 2006). Another 
group using their gene signatures distinguished with 100 % efficiency control mice 
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from mice irradiated with 0.5 Gy and they correctly estimated doses of radiation 
within medically relevant dose ranges (Dressman et al., 2007, Meadows et al., 2008). 
Moreover, they were also able to distinguish with 94 % efficiency non-exposed human 
from patients undergoing total body radiotherapy using human specific gene 
expression signatures (Dressman et al., 2007). The same group reported gene 
signatures allowing prediction of radiation status of part body exposed mice with 79 – 
100 % accuracy although they could not distinguish between doses of 0.5, 2 and 10 Gy 
X-ray (Meadows et al., 2010). Importantly, the gene signatures used for dose 
estimation in total body irradiation completely failed to predict radiation status in 
partially exposed mice (Meadows et al., 2010).  
Gene signatures have also been described in human. Paul et al developed a 74 
gene signature in human blood exposed to IR ex vivo which enabled estimation of the 
doses of 0.5, 2, 5 and 8 Gy of γ-ray with high accuracy between 6 and 48 h post 
exposure ex vivo (Paul and Amundson, 2008, Paul et al., 2013) and they used this 
signature to estimate the total body doses in radiotherapy patients with 98 % accuracy 
(Paul et al., 2011). Moreover, Knops et al used a 9-gene signature from PBLs exposed 
ex-vivo to estimate with 86.7 % accuracy a dose of 20 mGy and with 100 % accuracy 
dose of 100 mGy in blood irradiated ex-vivo (Knops et al., 2012). 
miRNA signatures were also tested for potential use in radiation biodosimetry. 
Templin et al developed miRNA signatures in mice which distinguished between 
different types of radiation with 81 % accuracy and allowed dose estimation with 88 – 
100 % accuracy depending on type of radiation (Templin et al., 2011a, Templin et al., 
2012). The same group reported miRNA signatures in human which allowed total body 
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doses of 1.25 Gy of X-ray to be distinguished with 100 % accuracy in eight radiotherapy 
patients (Templin et al., 2011b).  
Gene expression signatures obtained by microarray experiments hold great 
potential in radiation dosimetry, however, they usually consists of dozens of genes per 
dose/time-point with very little overlap (Dressman et al., 2007, Meadows et al., 2010). 
Moreover, the microarray technique is time consuming, quite expensive and data 
analysis is complicated which would be a disadvantage in triage scenario, therefore, 
some groups focused their interest on a gene or genes which show clear dose 
responses to IR and could be analysed by the quicker quantitative polymerase chain 
reaction (qPCR) technique and doses estimated using linear regression analysis.   
Dose-responses for IR-responsive genes expressed in human blood exposed ex-
vivo are best fitted with the linear quadratic model (Paul and Amundson, 2008, 
Manning et al., 2013), therefore if a calibration curve is present, a linear regression 
analysis can be employed to estimate the dose of radiation received by the unknown 
samples. Manning et al used a combination of two genes (FDXR and DDB2) in a high 
dose range (0.1 – 4 Gy) to produce a mean dose estimate of 0.7 Gy and 1.4 Gy for 
‘unknown’ blood samples irradiated with respectively 1 Gy and 2 Gy of X-ray and a 
combination of three genes (FDXR, DDB2 and CCNG1) for the low dose range (5 mGy – 
100 mGy) to produce a mean dose estimate of 98 mGy for 100 mGy exposure 
(Manning et al., 2013). Another group used sets of three and four genes to accurately 
predict doses ranging from 0.5 to 6 Gy of γ-irradiated human blood samples up to two 
days post irradiation (Tucker et al., 2014)  and up to seven days post irradiation in mice 
exposed to the same doses of γ-ray in vivo (Tucker et al., 2013). Filiano et al used 
expression of two genes CDKN1A and CCNG1 and linear regression analysis to estimate 
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the dose of radiation in mice exposed to IR in vivo and the average predicted doses for 
the 0, 1, 2, 4, 6, and 8 Gy treatment groups were 0.0 (± 0.2), 1.6 (± 1.0), 2.9 (± 1.4), 5.1 
(± 2.0), 5.3 (± 0.7), and 10.5 (± 5.6) Gy, respectively (Filiano et al., 2011). Table 2 
contains compiled dose responses in human samples published for biodosimetry 
purposes. 
Recently, a portable device was developed enabling measurement of gene 
expression changes in small volumes of blood and this device was capable of 
distinguishing irradiated samples from non-irradiated and would be suitable for triage 
scenarios (Brengues et al., 2010). 
1.13. Common methods for measuring gene expression 
qPCR is the “gold standard” technique for measuring and quantifying 
expression of genes (Derveaux et al., 2010). In this method RNA is reverse transcribed 
to complementary DNA (cDNA), then amplified using specific primers and a fluorescent 
reporter such as an intercalating dye or a specific probe, which allow real time 
detection of the amplified product (Bustin, 2004) (Figure 5). This technique is quick, 
straightforward, relatively inexpensive and when properly optimised and performed is 
sensitive enough to detect minute quantities of the template (Nolan et al., 2006). 
However, despite its simplicity, there are many factors which can influence qPCR 
results like assay design (Bustin, 2004, Derveaux et al., 2010), RNA quality (Perez-Novo 
et al., 2005, Fleige et al., 2006, Vermeulen et al., 2011), RT reaction (Stahlberg et al., 
2004, Nolan et al., 2006), operator’s experience (Bustin, 2002), normalisation approach 
(Perez-Novo et al., 2005, Smits et al., 2009, Hruz et al., 2011) and data analysis (Bustin, 
2004, Fleige et al., 2006). All these issues have to be addressed in order to obtain 
reliable, sensitive and meaningful data. In response to a lack of consensus on how 
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Table 2. Dose responses in human samples published for biodosimetry purposes 
Gene 
Time post 
exposure 
Doses and type of IR Sample Publication 
DDB2 
CDKN1A 
XPC 
4, 24, 48 and 
72 h 
0, 0.2, 0.5, 1 and 2 Gy γ-
rays 
peripheral blood 
lymphocytes 
(Amundson et 
al., 2000) 
CDKN1A  
CXCL10 DDB2 
FCGR1A  
6, 12, 18, 24, 
30, 36 h 
0 and 1.5 Gy X-ray 
fractionated every 6 h up 
to 9 Gy 
peripheral blood 
of patients 
undergoing total 
body irradiations 
(Amundson et 
al., 2004) 
FDXR 
CDKN1A 
PHPT1 
BBC3 
SESN1 
6 and 24 h 0, 0.5, 2, 5 and 8 Gy γ-rays peripheral blood 
(Paul and 
Amundson, 
2008) 
RPL19 
RPS6 
ATP5E 
COX8A 
NDUFA4 
RPL21 
3 h 0, 0.05 and 0.5 Gy  γ-rays 
CD4+ T-
lymphocytes 
(Gruel et al., 
2008) 
DDB 
CDKN1A 
APOBEC3H 
6 h 0, 0.1, 0.5, and 2 Gy γ-rays peripheral blood 
(Paul and 
Amundson, 
2011) 
FDXR 
PFKFB3 
24 and 48h 0, 0.02 and 0.1 γ-rays 
peripheral blood 
lymphocytes 
(Knops et al., 
2012) 
FDXR 
PHPT1 
DDB2 
GADD45A 
CCNG1 
CDKN1A 
BBC3 
MDM2 
SESN1 
TIGAR 
FAS 
PCNA 
MYC 
2 and 24 h 
0, 0.005, 0.01, 0.02, 0.05, 
0.075, 0.1, 0.5, 1, 2 and 4 
Gy X-ray 
peripheral blood 
(Manning et 
al., 2013) 
MDM2 
XPC 
FDXR 
ND2 
MEX3D 
ANKRD33 
TFAM  
2.5, 5, 7.5 
and 10 h 
0, 5, 10, 25, 50, 100 and 
500 mGy  γ-rays 
CD4+ T-
lymphocytes 
(Nosel et al., 
2013) 
CDKN1A 
DDB2 
PCNA 
PHPT1 
GNLY 
GZMA 
NKG7  
48 h 0, 0.5, 2, 5 and 8 Gy γ-rays peripheral blood 
(Paul et al., 
2013) 
ASTN2 
CDKN1A 
GDF15 
ATM  
12, 24 and 
48 h 
0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 
6, 8 and 10 Gy γ-rays 
peripheral blood 
(Tucker et al., 
2014) 
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Figure 5. Common methods used for measuring changes in gene expression. 
The first step in measuring gene expression is RNA extraction form the samples, next 
the RNA is reverse transcribed to cDNA which is then used in the downstream assays. 
Microarrays experiments utilise arrays with thousands of gene specific probes are 
immobilised on a solid surface. The fluorescently labelled cDNA is hybridised to the 
arrays and then detected with a laser scanner. PCR based methods amplify cDNA using 
specific primers and a fluorescent reporter such as an intercalating dye or a specific 
probe, which allow real time detection of the amplified product. In qPCR up to several 
genes can be measured in many samples whereas TaqMan low density arrays contain 
all the reagents necessary to perform a qPCR experiment aliquoted in the plate or card 
based system which allowing the expression of up to 360 genes to be assessed in one 
sample. Digital droplet PCR takes advantage of the fact that when aqueous solutionis 
mixed with oil, an emulsion is created. The PCR reaction is partitioned into tiny 
droplets containing on average 0 to 1 template molecule before amplification, then 
thermo cycled and positive droplets are scored with laser scanner. Deep sequencing of 
RNA allows sequencing of the whole transcriptome. The RNA is fragmented, reverse 
transcribed and ligated to adaptors with known sequence which allow PCR-based 
amplification and then sequenced. The short sequenced fragments are then mapped 
to the reference genome and the number of fragments mapped to a particular 
transcript reflects its expression level. The NanoString nCounter gene expression 
system utilises probes labelled with unique barcodes which are hybridised directly to 
RNA thus bypassing the need for any enzymatic reaction. The probe-target complexes 
are immobilised on cartridges, aligned and scored producing absolute copy number for 
tested gene. Highlighted in bold are techniques used in this thesis. 
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the qPCR experiments should be performed and analysed, a Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines have been 
published to address these issues (Bustin et al., 2009).  
Very recently a modified qPCR technique called digital droplet PCR (ddPCR) was 
developed. The PCR reaction is partitioned into tiny droplets containing on average 0 
to 1 template molecule before amplification what enables absolute quantification of 
PCR product (Hindson et al., 2013) (Figure 5). This is especially useful in detecting rare 
events. 
Although using TaqMan™ probes allow simultaneous expression measurement 
of up to six genes, generally the qPCR method is not suited for looking at expression of 
many genes. Recently, low density arrays (LDA) have been commercially introduced 
which contain all the reagents necessary to perform a qPCR experiment aliquoted in 
the plate or card based system allowing the expression of up to 360 genes to be 
assessed (Abruzzo et al., 2005) (Figure 5). The LDA have similar sensitivity and yield 
comparable results to conventional qPCR; however, the biggest drawback is that the 
assay design is very often confidential and controlling for PCR efficiency requires many 
samples what significantly increases the cost of the LDA assays (Goulter et al., 2006).  
With the development of microarray technology (Schena et al., 1995), it 
became possible to look at gene expression on a global scale. In the microarray 
experiment thousands of gene specific probes are immobilised on a solid surface and 
fluorescently labelled cDNA are hybridised to these probes. Following several washes, 
transcripts complementary to the probes are retained on the array and can be 
detected with a laser scanner (Malone and Oliver, 2011) (Figure 5). As large differences 
between different microarray platforms were identified (Irizarry et al., 2005), a 
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standardization tool regarding data analysis, proper control and assay design has been 
published (Consortium et al., 2006), which significantly improved microarray 
experiments reproducibility.  
Deep sequencing of RNA (RNA-Seq) is a relatively new technique enabling rapid 
sequencing of total transcriptome. The RNA is fragmented, reverse transcribed and 
ligated to adaptors with known sequence which allow PCR-based amplification and 
then sequenced. The short sequenced fragments are then mapped to the reference 
genome and the number of fragments mapped to a particular transcript reflects its 
expression level (Malone and Oliver, 2011) (Figure 5). This technique is more powerful 
in terms of detecting new transcripts, splicing isoforms and obtaining data from not 
yet annotated organisms, however it requires a dedicated bioinformatics staff to 
analyse the results (Malone and Oliver, 2011). 
All the methods described above rely on enzymatic reaction (PCR amplification 
or reverse transcription) which is bound to introduce some bias. The NanoString 
nCounter gene expression system utilises probes labelled with unique barcodes which 
are hybridised directly to RNA thus bypassing the need for any enzymatic reaction 
(Figure 5). The technology enables to multiplex up to 800 targets in one reaction with 
sensitivity comparable to qPCR (Geiss et al., 2008, Manning et al., 2011).  
1.14. Objectives of the project 
The current, cytogenetics-based methods for dose estimation are not suitable 
for large scale radiological emergency, therefore a lot of effort has been put in finding 
new, accurate, sensitive, high-throughput assays for biological dosimetry purposes. 
Exposure to IR induces time- and dose-dependent changes in gene expression 
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(Amundson et al., 2000, Kabacik et al., 2011a, Manning et al., 2013) which can be 
accurately and quickly measured by qPCR.  
The aim of this project was to investigate the possibility of using gene 
expression assay for radiation biodosimetry purposes. The work presented in this 
thesis includes: 
1. Extensive optimisation of qPCR protocol 
2. Identification of IR responsive genes suitable for biodosimetry purposes 
3. Characterisation of temporal- and dose-responses of IR-responsive 
transcripts 
4. Validation of the qPCR assay for dose estimation in vitro and in vivo 
  
59 
 
 
 
 
 
 
 
 
 
Chapter 2. Materials and methods 
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2.1. Common reagents and equipment 
All microcentrifuge tubes and pipette tips were purchased from STARLAB 
(STARLAB UK Ltd., Milton Keynes, UK), 15 ml and 50 ml conical bottom tubes, tissue 
culture flasks and sterile pipettes were purchased from SARSTEDT (SARSTEDT Ltd. 
Leicester, UK). Tissue culture plates and cryovials were purchased from Nunc/Thermo 
Scientific (Thermo Scientific, Hemel Hempstead, UK). RNALater was purchased from 
Ambion/Life Technologies (Life Technologies Ltd., Paisley, UK, cat. AM7020). 
Fluorescent double-dye probes for qPCR were purchased from Eurogentec (Eurogentec 
Ltd., Southampton, UK), primers were purchased from Integrated DNA Technologies 
(Integrated DNA Technologies Ltd, Glasgow, UK). Microcentrifuge tubes were 
centrifuged in MicroStar 17R centrifuge (VWR International Ltd., Lutterworth, UK), 
conical bottom tubes in Sorvall Legend RT (Thermo Scientific).  
2.2. Samples 
2.2.1. Human blood  
2.2.1.1. Fresh blood 
For the blood collection tube comparison, two blood samples were collected 
from one healthy donor into lithium heparin or ethylenediaminetetraacetic acid 
(EDTA) blood collection tubes (BD Becton Dickinson, Oxford, UK, cat. 366643). 100 µl 
aliquots were sham irradiated or exposed to a dose of 4 Gy X-ray and collected 24 h 
post exposure. 
For biomarkers identification 20 ml of peripheral blood samples were obtained 
anonymously from three healthy female working individuals (age range 37–53 years 
old) on three independent occasions with informed consent and ethical approval from 
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Berkshire Research Ethics Committee (reference number 09/HO505/87). Peripheral 
blood was collected via venipuncture into anticoagulant EDTA vacutainer tubes 
(Becton Dickinson) and kept on ice for a maximum of two hours until 30 minutes prior 
to irradiation. 5 ml of blood from each donor was aliquoted into two 5 ml cell culture 
tubes and placed at 37 °C 30 min prior irradiation. The rest of blood was used to set up 
T-lymphocyte cultures. Blood samples were sham irradiated or exposed to 2 or 4 Gy of 
X-ray and collected 2 or 24 h post exposure. 
For assessment of inter-and intra-individual variability peripheral blood samples 
were obtained anonymously on three independent occasions from 32 healthy blood 
donors with informed consent and ethical approval from Berkshire Research Ethics 
Committee (reference number 09/HO505/87). Peripheral blood was collected via 
venipuncture into anticoagulant EDTA vacutainer tubes (Becton Dickinson) and kept on 
ice for a maximum of two hours until 30 minutes prior to irradiation. 500 μl of blood 
from each donor was aliquoted into two 2 ml screw-cap tubes and placed at 37 °C 30 
min prior to irradiation. Samples were sham irradiated or exposed to a dose of 2 Gy X-
ray and collected 2 h post irradiation.  
2.2.1.2. Cultured blood 
The sample preparation was performed in the laboratory of Prof. Michael 
Abend at Bundeswehr Institute of Radiobiology, (Munich, Germany). Briefly, 2-3 ml of 
whole blood from one healthy male individual (age 29) was collected into heparinized 
tubes (Becton Dickinson, cat. 367874) on two separate occasions. Blood was taken 
with informed consent and the approval of a local ethics committee. The blood was 
diluted 1:2 with Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10 % 
foetal bovine serum (FBS) (all from GIBCO/Life Technologies Ltd., Paisley, UK, cat. 
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22409-015 and 10500-064 respectively) and incubated for 24 h at 37 °C before 
irradiation. One batch of blood was used to construct a calibration curve, the second 
batch represented “unknown” samples. Seven calibration curve samples were 
irradiated with a sham dose, 0.25 Gy, 0.5 Gy, 1 Gy, 2 Gy, 3 Gy and 4 Gy and collected 
24 h post irradiation. Ten unknown samples were irradiated with doses ranging from 0 
to 6.4 Gy and collected 24 h post irradiation. 
2.2.1.3. Cancer patients 
Blood collection from cancer patients was performed at University Hospital 
Hradec Kralove (Hradec Kralowe, Czech Republic) by Dr Ales Tichy. Peripheral blood 
samples were obtained anonymously from two cancer patients (two females, age 65-
72) undergoing radiotherapy for endometrial cancer with informed consent and ethical 
approval from University Hospital Hradec Kralove Ethics Committee (Hradec Kralove, 
Czech Republic, reference number 201401-S15P). Neither of the patients had previous 
radiotherapy or chemotherapy treatment. 2.5 ml of peripheral blood was collected via 
venipuncture into PAXgene RNA blood tubes (Becton Dickinson, cat. 762165) before 
first dose of radiotherapy and 24 h after first 1.9 Gy fraction. After blood collection, the 
blood samples were mixed several times by inversion and incubated at room 
temperature for 2 h, then frozen at -20 °C and shipped to our lab on dry ice. 
2.2.2. Mouse blood 
For the RT validation experiments, blood from a C57Bl/6 mouse was collected 
by cardiac puncture into EDTA blood collection tubes (Becton Dickinson) and then 5 µl, 
10 µl, 25 µl, 50 µl, 75 µl and 100 µl aliquots were transferred to 2 ml screw-cap tubes 
containing 0.5 ml of RNALater and stored at -80 °C until further analysis. The 
experiment was repeated twice. 
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2.2.3. Human stimulated T-lymphocytes 
2.2.3.1. RNA extraction kit comparison 
For the RNA extraction kit comparison, stimulated human T-lymphocytes 
obtained from healthy donor C2 were used. Cells were sham irradiated or exposed to a 
dose of 4 Gy X-ray (6 x 106 cells per dose) and collected 4 h post exposure. 
2.2.3.2. Biomarkers identification 
T-lymphocytes obtained from three blood donors described in chapter 2.2.1.1 
were used. Cells were sham irradiated or exposed to 2 or 4 Gy of X-ray and collected 2 
or 24 h post exposure. Three independent repeats were performed. 
2.2.3.3. Time course and dose-response experiments 
For time course and dose response experiments, human stimulated T-
lymphocytes from two healthy donors (C1 and C2, both females, age range 39-41) and 
one Ataxia – Telangiectasia patient (AT, a gift from Dr. Colin Arlett, University of 
Sussex, UK) were studied; 2 x 106 cells were used for each sample. 
For time course experiments cells were sham irradiated or with a dose of 2 Gy  
X-ray and samples were collected at 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h 
and 24 h post irradiation. The experiment was repeated three times, samples for the 
first repeat were cultured and prepared by Ms Claudine Raffy. 
For high dose-response experiments cells were sham irradiated or exposed to a 
doses 0.1 Gy, 0.2 Gy, 0.3 Gy, 0.4 Gy, 0.5 Gy, 1 Gy, 2 Gy, 3 Gy, 4 Gy and 5 Gy of X-ray 
and collected at two different time-points – 2 h and 24 h. The experiment was 
repeated two times, samples for the first repeat were cultured and prepared by Ms 
Claudine Raffy. 
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For low dose-response experiments only T-lymphocytes obtained from donor 
C1 were used. Cells were sham irradiated or exposed to a doses 5 mGy, 10 mGy, 20 
mGy, 30 mGy, 40 mGy, 50 mGy, 75 mGy and 100 mGy of X-ray and collected at two 
different time points – 2 h and 24 h. The experiment was repeated four times, samples 
for the first repeat at 2 h were cultured and prepared by Ms Claudine Raffy, two other 
repeats were performed by Ms Grainne Manning. 
2.3. Cell counting and viability 
For all cell counting and viability, the ADAM cell counter (Labtech International 
Ltd., Uckfield, UK) was used. Briefly, for every cell count, two 0.5 ml tubes were 
prepared. 20 µl of T solution was aliquoted into one and 20 µl of N solution into 
second tube. Cells for counting were disaggregated by vigorous shaking, then two 20 µl 
aliquots were taken and mixed in tubes containing proprietary N and T solutions (cat. 
ADR-1000) respectively and samples were incubated for 2 min at room temperature. 
After incubation samples were loaded into appropriate T and N positions in the 
cartridge and loaded into counter. The cell counter provides a value for total cell 
number (T), dead cell number (N) and percentage of viable cells.  
2.4. Cell growth 
2.4.1. Lymphoblastoid cell lines 
A cryovial containing 3 x 106 cells was thawed at 37 °C in a water bath for 
around two minutes and then the cells were transferred with sterile pastette into a 15 
ml conical bottom tube containing 10 ml of lymphoblastoid cell growth medium 
(LCGM) consisting of RPMI 1640 (Dutch modification) supplemented with 20 % heat 
inactivated FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin (all from Invitrogen/Life Technologies, cat. 11360-070, 25030-081 
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and 15140-122 respectively). Cells were mixed by inverting the tube and centrifuged 
for 5 min at 1200 rpm. The supernatant was aspirated, the cell pellet resuspended in 
10 ml of LCGM and transferred into a vented 25 cm2 culturing flask. Flasks were 
incubated at 37 °C with 5 % C02 in the upright position for 3 days. At this stage, cells 
were disaggregated and counted at daily intervals.  
When cell numbers reached 0.8 x 106, 10 ml of fresh LCGM was added and the 
cells were transferred to 75 cm2 flask. The cell number was maintained between 0.6 
and 0.8 x 106 per ml by adding fresh medium. 
2.4.2. Human T-lymphocytes 
2.4.2.1. Feeder cell preparation 
Lethally irradiated lymphoblastoid GM1899A cells were used as feeder cells for 
human T-lymphocytes. The culturing conditions for this lymphoblastoid cell line are 
described in the section 2.4.1. The feeder cells were prepared as follows: when the 
culture reached at least 5 x 107 cells, the cells were transferred into one or two 50 ml 
conical bottom tubes (depending on the volume) and centrifuged at room 
temperature for 5 min at 1200 rpm. The supernatant was aspirated and cell pellets 
were resuspended in 5 ml of LCGM. The cells were lethally irradiated at room 
temperature with a dose of 40 Gy X-ray at dose rate 1.7 Gy per min. The lethally 
irradiated feeders were diluted with freeze mix consisting of 10 % dimethyl sulfoxide 
(DMSO, Sigma-Aldrich Company Ltd., Gillingham, UK, cat. 472301-100ML) and 90 % of 
FBS (Life Technologies) to 3 x 106 cells per ml. One ml aliquots of the cell suspension 
were transferred into cryovials and frozen at -80 °C in Mr. FrostyTM (Thermo Scientific, 
cat. 5100-0001) containers which allow cooling at rate of 1 °C per minute. The next day 
vials were transferred to the liquid nitrogen container for long term storage. 
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2.4.2.2. Preparation of human stimulated T-lymphocytes 
The stimulated human T-lymphocytes were prepared as follows: 10 ml of blood 
from a donor was collected into BD Vacutainer® lithium heparin tubes (Becton 
Dickinson). For each donor 5 ml of Histopaque-1077 (Sigma-Aldrich, cat. 10771-100ML) 
pre-warmed to room temperature was aliquoted into four 15 ml conical bottom 
centrifuge tubes. 10 ml of blood was mixed with 10 ml of Hank's Balanced Salt Solution 
(HBSS, Life Technologies, cat. 14170088) pre-warmed to room temperature in a 50 ml 
conical bottom tube. 5 ml of diluted blood was layered slowly onto each of the four 
tubes containing Histopaque-1077 using a sterile pastette (Alpha Laboratories, 
Eastleigh, UK, cat. LW4005). Tubes were centrifuged at room temperature at 1600 rpm 
for 20 min. After phase separation the top serum layer was aspirated from each tube 
leaving around 0.5 cm of liquid above the buffy coat cell layer. The buffy coats from 
two tubes for each donor were collected using sterile pastette and transferred into 
one fresh 15 ml tube with 10 ml of HBSS and mixed by inverting.  The tubes were 
centrifuged at room temperature at 1200 rpm for 5 min. The supernatant was 
aspirated and cell pellet was re-suspended in 5 ml of HBSS. Cell suspensions from two 
tubes for each donor were combined into one tube and centrifuged again at room 
temperature at 1200 rpm for 5 min. The supernatant was aspirated, cells were washed 
with 10 ml of HBSS and two 20 µl aliquots of cell suspension were taken for cell 
counting. The tube was centrifuged at room temperature at 1200 rpm for 5 min and 
the supernatant was aspirated. Next the cells were re-suspended at concentration 3 x 
106 cells per ml in freeze mix and frozen at -80 °C, 1 ml per cryogenic vial in Mr. 
FrostyTM container (Thermo Scientific). The next day vials were transferred to liquid 
nitrogen container for long term storage. 
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2.4.2.3. Culturing conditions 
A cryovial containing 3 x 106 cells was thawed at 37 °C in a water bath for 
around two minutes and then the cells were transferred with sterile pastette into 15 
ml conical bottom tube containing 10 ml of stimulating growth medium (SR10) 
comprised of RPMI 1640 (Dutch modification) supplemented with 10 % heat 
inactivated FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, 50 µM 2-mercaptoethanol (GIBCO/Life Technologies, cat. 21985-
023), 250 IU/ml recombinant interleukin-2 (Novartis Pharmaceuticals UK Ltd., 
Camberley, UK, cat. PL-00101/0936) and 0.4 µg/ml phytohaemagglutinin (PHA; Remel 
Ltd., Lenexa, USA, cat. R30852801). Cells were mixed by inverting the tube and 
centrifuged at room temperature for 5 min at 1200 rpm. The supernatant was 
aspirated, cell pellet was re-suspended in 10 ml of SR10 and centrifuged at room 
temperature for 5 min at 1200 rpm. In the meantime a cryovial of feeder cells was 
thawed in the water bath at 37 °C for around two minutes. The supernatant from T-
lymphocytes was aspirated and the cells were re-suspended in 10 ml of SR10. The 
feeder cells were transferred with sterile pastette into a 15 ml conical bottom tube 
containing T-lymphocytes, mixed by inverting the tube several times and centrifuged 
at room temperature for 5 min at 1200 rpm. The supernatant was aspirated and the 
cell pellet was re-suspended in 10 ml of SR10. The cell suspension was transferred into 
vented 25 cm2 flask and incubated at 37 °C with 5 % C02 at an angle of about 10 ° from 
horizontal position. Cells were left undisturbed for 4 days and thereafter they were 
disaggregated and counted daily. When the cells reached a density of 0.8 x 105 cells 
per ml they were diluted 1:2 with growth medium (GR10) which comprised of SR10 
without PHA. 
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2.5. Irradiations  
2.5.1. Blood 
2.5.1.1. Human blood 
Fresh whole blood samples for biomarkers identification were irradiated at 2 or 
4 Gy using a Siemens Stabilipan (Siemens AG, Munich, Germany) therapy X-ray set 
(output 14 mA, 250 kV peak, 1.2 mm Cu HVL, 0.7 Gy min71) at room temperature at 
the Medical Research Council, Harwell. Blood samples were maintained at 37 °C at 
least 30 min prior to irradiation and then until agreed time-point after irradiation. At 2 
or 24 h time-point blood leukocytes were trapped on LeukoLOCK™ filters, washed 
twice with ice-cold PBS and submerged in RNA Later according to manufacturer’s 
instructions (all from Ambion/Life Technologies, cat. AM1923). Leukocytes trapped on 
filters were kept at -80 °C until RNAs were extracted. 
The irradiations of 32 healthy blood donors samples were performed at room 
temperature with an A.G.O. HS X-ray system. After irradiation samples were incubated 
at 37 °C for 2 or 4 h and then 1.3 ml of RNALater was added. Samples were mixed by 
inverting the tubes several times and stored at - 80 °C. 
Cultured blood samples were irradiated at the Bundeswehr Institute of 
Radiobiology, (Munich, Bavaria, 80937, Germany). The samples were irradiated at 37 
°C using single doses of X rays with mean photon energy of 100 keV (240 kVp; X-ray 
tube type MB 350/1 in Isovolt 320/10 protection box; Agfa NDT Pantak Seifert GmbH & 
Co.KG, Ahrensburg, Germany) filtered with 7.0 mm beryllium and 2.0 mm aluminum. 
The absorbed dose was measured using a duplex dosimeter (PTW, Freiburg, Germany). 
The dose-rate was approximately 1.0 Gy per min at 13 mA. 
69 
 
2.5.2. Cells 
 Stimulated T-lymphocytes were disaggregated and 2 x 106 cells were seeded at 
a density of 4 x 105 cells per ml in 25 cm2 cell culture flasks containing the appropriate 
growing medium. Cells were irradiated at room temperature, using a Siemens 
Stabilipan [Siemens AG, Munich, Germany] therapy X-ray set (output 14 mA, 250 kV 
peak, 1.2 mm Cu HVL, 0.7 Gy min-1) at the Medical Research Council, Harwell or an 
A.G.O. HS X-ray system (Aldermaston, Reading, UK) (output 13 mA, 250 kV peak, 0.5 
Gy/min for doses 0.1 – 5 Gy and 0.2 mA 4.9 mGy/min for doses up to 100 mGy) at 
Public Health England. Cell cultures were maintained at 37 °C after irradiation until the 
agreed time-point, and then cells were washed twice with ice-cold PBS (Sigma-Aldrich). 
For gene expression experiments cells were resuspended in 1 ml of RNALater and 
stored at - 80 °C.  
2.5.3. Cancer patients 
The two endometrium cancer patients were irradiated with a dose of 1.9 Gy of 
X-ray using Clinac 2100C Linear Accelerator (Varian Medical Systems International AG, 
Cham, Switzerland). 
2.6. RNA extraction  
2.6.1. Human blood  
2.6.1.1. Human blood leukocytes trapped on LeukoLOCK™ filters 
Human blood leukocytes stabilised on LeukoLOCK™ filters were extracted by 
using LeukoLOCK™ Total RNA Isolation System (Ambion/Life Technologies, cat. 
AM1923). The manufacturer’s protocol with optional DNase I treatment was followed 
exactly, samples were eluted with 100 µl of preheated elution solution. After RNA  
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quantification and quality assessment samples were stored at – 80 °C. 
2.6.1.2. Human blood samples stored in RNAlater 
Human blood samples stabilised in RNALater were extracted by using 
RiboPure™-Blood RNA Isolation Kit (Ambion/Life Technologies, cat. AM1928). The 
manufacturer’s protocol with optional DNase I treatment was followed exactly, 
samples were eluted with 50 µl of preheated elution solution. After RNA quantification 
and quality assessment samples were stored at – 80 °C. 
2.6.1.3. Cultured human blood 
RNA extraction from cultured human whole blood was done by using QIAamp 
RNA Blood Mini kit (Qiagen, cat. 52304) according to manufacturer’s protocol: 
“Purification of Total Cellular RNA from Human Whole Blood”. Red blood cell lysis and 
leukocyte lysis were performed in Prof. Michael Abend’s lab (Bundeswehr Institute of 
Radiobiology, Germany). The cell lysates were frozen and shipped to Public Health 
England laboratories on dry ice. Before extraction frozen lysates were incubated at 37 
°C in a block heater (Bibby Scientific Ltd., Stone, UK) until completely thawed and any 
salts dissolved. Then the manufacturer’s protocol was followed exactly, samples were 
eluted in 50 µl of RNase free water. 
DNA contamination was removed by using Ambion® DNA-free™ (Ambion/Life 
Technologies, cat. AM1906). Briefly, 5 µl of 10X DNase I Buffer and 1 μl of DNase I were 
added to each sample and mixed gently, then samples were incubated for 30 min at 37 
° C in a block heater. After incubation 5 µl of resuspended DNase Inactivation Reagent 
was added and mixed well. Samples were incubated at room temperature for 2 min 
with occasional flicking and centrifuged at 10 200 rpm for 1.5 min to pellet the beads. 
The supernatant was transferred into a fresh 0.5 ml tube and after quality control  
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frozen at – 80 °C. 
2.6.1.4. Blood collected into PAXgene blood RNA tubes 
Human blood samples collected into PAXgene blood RNA tubes were extracted 
by using PAXgene Blood miRNA Kit (Qiagen Ltd., Crawley, UK, cat. 763134). The 
manufacturer’s protocol with DNase I treatment was followed exactly, samples were 
eluted with 100 µl of elution solution. After RNA quantification and quality assessment 
samples were stored at – 80 °C. 
2.6.2. Human cell lines  
2.6.2.1. mRNA and lncRNA analysis 
RNA from human T-lymphocytes for mRNA and lncRNA analysis was extracted 
with RNAqueous®-4PCR kit (Ambion/Life Technologies, cat. AM1914).  
Briefly, tubes containing cells in RNALater were thawed at room temperature 
and cell suspensions were transferred into 1.5 ml RNase free tubes. Cells were 
centrifuged for 5 min at 12000 rpm, then the supernatant was removed and 350 µl of 
Lysis Buffer provided with the kit was added. Cells were vortexed for around a minute 
until they were completely lysed, then 350 µl of 64 % ethanol was added and tube was 
mixed by inverting several times. From this step manufacturer’s protocol with optional 
DNase I treatment was followed exactly, samples were eluted in 60 µl of elution 
solution heated to 80 °C. After RNA quantification and quality assessment samples 
were stored at - 80 °C. 
2.6.2.2. miRNA analysis 
RNA from human T-lymphocytes and mouse tissues for miRNA analysis was 
extracted by using miRNeasy Mini Kit (Qiagen, cat. 217004).  
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Briefly, cell samples in RNALater were thawed at room temperature. Cell 
suspensions were transferred into 1.5 ml tubes and centrifuged for 5 min at 14000 
rpm, then all traces of RNALater were removed. 700 µl of QIAzol Lysis reagent was 
added to each tube and samples were vortexed until complete lysis. From this step 
manufacturer’s protocol with on-column DNase I treatment was followed exactly, 
samples were eluted in 50 µl of RNase free water applied on the filter.   
For the RNA extraction kit comparison, mirVana™ miRNA Isolation Kit 
(Ambion/Life Technologies, cat. AM1560) was used additionally with the 
manufacturer’s protocol for extraction total RNA with DNase I treatment being 
followed exactly; samples were eluted in 50 µl. 
2.7. RNA concentration and quality assessment 
RNA concentrations were measured by using NanoDrop 1000 
spectrophotometer (Thermo Scientific). 
2.7.1. Agarose gel 
The quality of all RNA samples except for those extracted with miRNeasy Mini 
kit was assessed using 1.3 % agarose gel. Briefly, 0.65 g of Certified Molecular Biology 
Grade Agarose (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK, cat. 161-3101) was 
added to 50 ml of 1 x Tris-Borate-EDTA buffer (TBE, Sigma-Aldrich, cat. T4415-10L) and 
heated in a microwave until the agarose dissolved. The agarose was cooled down 
under running water and 5 µl of GelRed Nucleic Acid Gel Stain, 10,000X in water 
(Cambridge Bioscience Ltd., Cambridge, UK, cat. 41003) was added and mixed 
thoroughly. The gel was poured into electrophoresis tray (Bio-Rad) and left at room 
temperature for an hour to solidify. The solidified gel was placed in Mini-Sub® Cell GT 
electrophoresis system (Bio-Rad) containing 1 x TBE buffer. 
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3 µl of a sample and 1 µl of loading buffer consisting of 40 % sucrose and 0.25 % 
of bromophenol blue (both from Sigma-Aldrich, cat. S7903 and B0126 respectively) in 
water, were mixed on a piece of parafilm and loaded into a gel well. 0.3 ng of 1 Kb Plus 
DNA Ladder (Life Technologies, cat. 10787-018) in loading buffer was run with every 
gel. Samples were separated for 45 min at 80 V and visualised by using U:Genius3 gel 
documentation system (Syngene Europe, Cambridge, UK). Good quality RNA was 
characterised by absence of genomic DNA above the 12 kb band and sharp 28 S and 18 
S ribosomal RNA bands, where the upper band was approximately twice as intense as 
the lower band in fluorescence. 
2.7.2. 2200 TapeStation instrument 
The quality of RNA samples extracted by using miRNeasy kit was assessed using 
2200 TapeStation instrument (Agilent Technologies UK Ltd., Wokingham, UK) 
according to manufacturer’s protocol. Briefly, R6K ScreenTape and Reagents (Agilent, 
cat. 5067-5576 and 5067-5577 respectively) were warmed to room temperature. 4 µl 
of R6K reagent and 1 µl of RNA sample were mixed in 8 well strips (ABgene/Thermo 
Scientific, cat. AB-0264). Strips were vortexed at 2500 rpm for 15 s in MixMate 
(Eppendorf UK Ltd., Stevenage, UK) and centrifuged at room temperature for one 
minute at 3000 rpm on SIGMA 2-16P Centrifuge (Sciquip Ltd. Newtown, UK). Next the 
samples were incubated for 3 min at 72 °C in a Thriller® thermoshaker-incubator 
(Peqlab Ltd., Sarisbury Green, UK) to denature RNA and then cooled down on ice for 
two minutes. The strip was centrifuged at room temperature for one minute at 3000 
rpm on SIGMA 2-16P Centrifuge (Sciquip) and samples were loaded into TapeStation. 
The TapeStation analysis software produced RNA Integrity Number equivalent (RINe) 
number which indicated level of RNA integrity. 
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2.8. Microarray experiment 
Microarray experiments and data analysis were performed by Dr Alan Mackay 
(Breakthrough Breast Cancer Research Centre, the Institute of Cancer Research, 
London, UK).  
Briefly, 1 μg of total RNA was T7 amplified by in vitro transcription using the 
MessageAmp™ kit (Ambion/Life Technologies, cat. 4385821) according to 
manufacturer’s instruction. 1 mg of amplified RNA was coupled to either Cy3 or Cy5 
dye and hybridised to Breakthrough 20K cDNA microarrays in replicate dye swap 
hybridisations. Overnight hybridisation was performed at 42 °C in a hybridisation 
buffer (GE Healthcare, Amersham, UK, cat. RPN3006), then the arrays were washed at 
65 °C in a wash buffer 1 comprised of 2 × SSC and 0.1 % SDS and wash buffer 2 
comprised of 0.1 × SSC and 0.1 % SDS. After washing, the arrays were scanned on an 
Axon 4000B microarray scanner and GenePix 5.1 software (Axon 
Instruments/Molecular Devices Corporation Sunnyvcale, CA, USA) was used for TIFF 
images analysis.  
Expression values from spots with extremely low intensities were converted to 
missing values and probes with missing values in more than 80% of hybridisations 
within each cell type were removed from subsequent analysis. The raw intensity values 
were converted to log2 ratios of sample to reference and log2 average spot intensity. 
Data from blood samples and lymphocyte samples were analysed separately. The dye 
biases were removed by using LOESS local regression function and then log2 ratios 
were subjected to quantile normalisation. The final data sets contained 10736 and 
9698 probes for the analysis of lymphocytes and blood samples respectively. 
Significance analysis of microarrays (SAM) was used to identify differential gene 
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expression by comparing irradiated samples with respective controls in each tissue, at 
each time point with 5% false discovery rate used as a cut-off. 
2.9. RT reaction 
2.9.1. mRNA and lncRNA 
Reverse transcription (RT) reactions for mRNA and lncRNA expression analysis 
were performed in iQ5 thermocyclers (Bio-Rad), using High Capacity cDNA Reverse 
Transcription Kit (Life Technologies, cat. 4368814) according to manufacturer’s 
protocol with 700ng of total RNA in 50 µl reaction volume. “-RT” reactions were 
performed on representative samples to control for genomic DNA (gDNA) 
contamination by adding water instead of RT enzyme. The cycling conditions were 10 
min at 25 °C, 2 h at 37 °C and 5 min at 85 °C. The cDNA samples were stored at – 20 °C. 
2.9.2. miRNA 
RT reactions for miRNA expression analysis were performed using qScript™ 
microRNA cDNA Synthesis Kit (Quanta BioSciences, Gaithersburg, USA, cat. 95107-025) 
according to manufacturer’s protocol. Briefly, total RNA containing small RNA species 
was normalised to concentration 100 ng in 7 µl of RNase free water (Ambion/ Life 
Technoogies, cat. AM9937). Polyadenylation reactions were set up on ice as follows: 7 
µl of normalised RNA was mixed in 0.2 ml tube stips (ABgene/Thermo Scientific) with 2 
µl of Poly(A) Tailing Buffer and 1 µl of Poly(A) Polymerase. The reactions were gently 
vortexed, centrifuged briefly to collect all liquid on the bottom of the tube and placed 
in Veriti® 96-Well Thermal Cycler (Life Technologies). Cycling conditions were 20 min at 
37 °C and 5 min at 70 °C. Samples were then briefly centrifuged and placed on ice.  
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The first strand cDNA synthesis reaction was performed as follows: 9 µl of cDNA 
Reaction Mix and 1 µl of qScript Reverse Transcriptase were added to Poly(A) Tailing 
Reactions from the step above. Samples were mixed by gentle vortexing, then briefly 
centrifuged to collect contents and incubated for 20 min at 42 °C followed by 5 min at 
85 °C. Several controls were prepared: (1) “-RT” reactions to control for genomic DNA 
contamination and (2) “-poly(A)” reactions to control for non-specific binding of 
universal primers were performed on representative samples by adding water instead 
of enzyme. Prepared cDNA was diluted 50 x before performing qPCR analysis. 
2.10. Quantitative Real-Time PCR (qPCR) 
2.10.1. TaqMan assays design 
For each assay a set of primers, a fluorescent probe and a set of covering 
primers spanning the amplification region were designed. All TaqMan assays for mRNA 
detection were designed and validated in silico by Dr François Paillier (bioMérieux Ltd, 
Rhône-Alpes, France). All lncRNA assays were designed by using PrimerQuest software 
(Integrated DNA Technologies, Leuven, Belgium).  
2.10.2. Standard curve preparation 
For each qPCR assay a set of covering primers flanking the amplicon was 
designed. The covering primers were used to obtain PCR products for standard curve 
preparation. Briefly, for each assay a 100 µl PCR reaction containing 10 µl of 10 x PCR 
Buffer, 2.5 units of Taq DNA Polymerase (both from Qiagen, cat. 201205), 200 µM of 
each dNTP (Invitrogen/Life Technologies, cat. 10297-018), covering primers at 300 nM 
each and 10 µl of representative cDNA was set up in 0.2 ml strip tubes 
(ABgene/Thermo Scientific). The cycling conditions were 3 min at 94 °C, then 35 cycles 
of 30 s at 94 °C, 30 s at 60 °C and 30 s at 72 °C and final extension for 10 min at 72 °C. 
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The resulting PCR product was loaded in 3 wells of a 1.3 % agarose gel and run 
for 45 min at 100 V. After electrophoresis the gel was placed on a UVT 400-M 
ultraviolet transilluminator (International Biotechnologies Inc., New Haven, 
Connecticut, US) to visualise the PCR product. The band of appropriate size was 
excised with sterile scalpel blade and placed in 1.5 ml tube and the PCR product was 
purified by using MinElute Gel Extraction Kit (Qiagen, cat. 28604). The manufacturer’s 
protocol was followed exactly and samples were eluted with 15 µl of Elution Buffer. 
The DNA quantity was assessed using Nanodrop 1000 (Thermo Fisher) and molar mass 
of the PCR product was calculated using online software Mongo Oligo Mass Calculator 
v2.06 (http://mods.rna.albany.edu/masspec/Mongo-Oligo).  
Approximate number of PCR product copies per µl was calculated by using 
following formula: 
                   
             
 
  
 
where M is molar mass of PCR product and NA is Avogadro’s constant.  
 Standard curve stock was prepared by mixing 1.5625 x 109 molecules of each 
PCR product in 50 µl of TE buffer (Sigma, cat. 93283-100ML). The standard curve stock 
was diluted 1600 times by serial dilutions to obtain the first concentration used for 
standard curve. The standard curve was prepared by eight 5-fold dilutions and 
spanned concentrations from 25 to 9765625 copies of each PCR product per µl. To 
avoid repeated freeze-thaw cycles, 5 µl of each concentration was aliquoted into 12-
wells strips (ABgene/Thermo Scientific) and stored at -20 °C. 
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2.10.3. TaqMan assay qPCR experiment 
TaqMan assay qPCR experiments were performed using PerfeCTa® MultiPlex 
qPCR SuperMix (Quanta Biosciences, cat. 95063-200). Reactions were performed in 30 
µl volumes on an iQ5 real time platform (Bio-Rad) or in 10 µl volumes in a Rotor-Gene 
Q (Qiagen). Reagent concentrations were as follows: 1 x PerfeCTa® MultiPlex qPCR 
SuperMix, 300 nM of each primer, 300 nM of each probe and 10 % of a template. All 
reactions were run in triplicate, standard curve reactions and no template control 
(NTC) were run in each plate. 3’ 6-Carboxyfluorescein (FAM)/Black Hole Quencher 1 
(BHQ1), 6-Hexachlorofluorescein (HEX)/BHQ1, Texas Red/BHQ2, CY5/BHQ3, 
ATTO390/Deep Dark Quencher 1 (DDQ1) and ATTO680/BHQ3 were used as 
fluorochrome/quencher pairs for the hydrolysis probes analysed in multiplexed 
reactions. Cycling parameters were 2 min at 95 °C, then 45 cycles of 10 s at 95 °C and 
60 s at 60 °C.  
Cycle threshold (Ct) is defined as cycle where amplification curve crosses 
predefined threshold and it is inversely proportional to starting template amount. Ct 
values were converted to copy numbers using standard curve and then normalised to 
hypoxanthine phosphoribosyltransferase 1 (HPRT1) reference gene for human samples 
or hypoxanthine guanine phosphoribosyl transferase (Hprt) for mouse samples. 
Relative gene expression levels after irradiation were obtained comparison with sham 
irradiated controls. 
2.10.4. TaqMan assays validation protocol 
Sequences of all designed assays were first checked by using the Ensembl 
database (http://www.ensembl.org/index.html) for transcript coverage and single 
nucleotide polymorphism (SNP) presence. The aim was to design an assay with 
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maximum alternative transcript coverage and no SNPs in the sequence as the SNP 
present in the primer or probe annealing site would significantly affect the 
oligonucleotide specificity and binding efficiency. 
The specificity of the designed assay primers and covering primers was 
validated by a SYBR Green assay. Validation qPCR experiments were performed using 
an iQ5 thermocycler (Bio-Rad). 25 µl reactions were set up as follows: 12.5 µl of 
PerfeCTa® SYBR® Green SuperMix for iQ™ (Quanta Biosciences, cat. 95053-500), 300 
nM concentrations of each forward and reverse primers and 1 µl of template were 
mixed in 0.2 ml strip tubes (ABgene/Thermo Scientific). All reactions were run in 
triplicate with a separate NTC reaction for every assay. The cycling conditions were 2 
min at 95 °C then 45 cycles of 10 s at 95 °C and 60 s at 60 °C followed by melt curve. 
Data were collected and analysed by iQ5 Detection System software. Primers were 
considered as specific if only one peak was present on the melt curve graph and the 
PCR product was of expected size on an 1.3 % agarose gel. 
The performance of the probes was assessed in TaqMan qPCR experiments 
with a standard curve. The assay was considered as validated only if PCR efficiency was 
between 93 and 105 % and R2 value for the standard curve linear regression fit was 
greater than 0.998. 
2.10.5. miRNA detection 
miRNA expression analysis experiments were performed on Rotor-Gene Q 
(Qiagen). 10 µl qPCR reactions were set up as follows: 5 µl of PerfeCTa®SYBR®Green 
SuperMix, 10 µM concentration of each PerfeCTa microRNA Assay Primer and 
PerfeCTa Universal PCR Primer (all from Quanta Biosciences, cat. 95054-500) and 1 µl 
of miRNA cDNA were mixed. All reactions were run in triplicate and a NTC reaction was 
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run for each assay with a calibrator sample included in each plate. One cDNA sample 
was used as a calibrator for all runs in order to normalise for inter-run variation. The 
cycling conditions were 2 min at 95 °C then 45 cycles of 10 s at 95 °C and 30 s at 60 °C 
followed by a melt curve. Data was collected and analysed by Rotor-Gene Q analysis 
software. 
The NormFinder algorithm (Andersen CL, 2004) was used to find the most 
stable control genes combination. Irradiated samples were normalised to the non-
irradiated controls and presented as fold change in expression. 
2.11. Statistical methods 
The statistical analysis was performed in Minitab software (Minitab Ltd., 
Coventry, UK).  
Anderson-Darling test was performed in Minitab in order to assess normality of 
the data. It generates probability plot and performs a hypothesis test whether or not 
the observations follow a normal distribution and provides associated p values 
(Minitab help). 
General Linear Model (GLM) was used to perform univariate analysis of 
variance. It allows estimation of the relative statistical significance of each parameter, 
taking into account the errors associated with them (Minitab help). 
Linear regression analysis was used for curve fitting and dose estimation. The 
best fit was determined by the highest R2 value. 
2.11.1. Uncertainty measurement 
The measurement error was calculated as follows. Standard deviation (SD) of 
copy number was calculated from triplicate qPCR reactions for HPRT1 and FDXR genes 
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in each sample. Next, for each sample the SDs for both genes were combined by taking 
the square root of the sum of SD squares, then, the error was normalised by dividing it 
by average of HPRT1 copy number. 
The intra-individual variation was calculated as follows. The mean and SD of 
endogenous level for FDXR gene from three independent experiments was calculated 
for each one of 32 healthy blood donors, then coefficient of variation (COV) was 
calculated by dividing SD by the mean. Finally, the intra-individual variation was 
calculated by averaging COV from control and irradiated samples. 
In order to calculate the inter-individual variation the average and SD of 32 
healthy blood donors in endogenous level for FDXR gene was calculated for each of 
three independent experiment. Then, COV was calculated by dividing SD by the mean. 
Finally, the inter-individual variation was calculated by averaging COV from three 
independent repeats for control and irradiated samples. 
The uncertainty of dose estimation was calculated as follows. The 
measurement error and intra- or inter-individual variability were combined by 
calculations square root of the sum of squares and then outcome was multiplied by 
the dose estimation given by equation.  
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3.1. qPCR protocol optimisation 
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3.1.1. Introduction 
qPCR is a ‘gold standard’ method for measuring gene expression. The principle 
of the technique is relatively simple, however, in order to obtain meaningful results 
many aspects of the workflow have to be tightly controlled, which is very often ignored 
(Derveaux et al., 2010). Many factors can influence the outcome of a qPCR experiment; 
for example: assay design, sample collection and stabilisation, RNA extraction method, 
RNA quality, cDNA synthesis strategy, cycling conditions or normalisation choice 
(extensively reviewed in (Bustin, 2004)). All these factors contribute to technical 
variation and may mask real biological responses or contribute to false positive results. 
In response to a lack of consensus on how best to perform and interpret qPCR 
experiments, Bustin et al published in 2009 a set of MIQE guidance (Bustin et al., 
2009). The paper stressed the need for standardisation and transparency of qPCR 
experiments. Being aware of this report, we performed extensive optimisation of our 
workflow as qPCR is the main technique used in this project. 
In this chapter, we present results of optimisation of several aspects of the 
qPCR protocol: assay design and validation, sample collection, RNA extraction, cDNA 
synthesis and multiplexing. 
3.1.2. Assay design validation protocol 
Designing a robust and specific assay is the first and essential step to obtain 
meaningful and reliable qPCR results. In order to ensure a successful approach we 
have developed a design validation protocol involving several quality control steps. All 
mRNA assays were designed by Dr Francois Paillier (bioMérieux) using RT_qPCR_SLv8 
software developed by Dr Paillier according to the protocol described in Figure 6. The  
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Figure 6.  Individual design workflow using RT_qPCR_SLv8 software.  
Entries corresponding to transcribed sequences from a single gene were downloaded 
from Ensembl and/or Refseq Genbank division automatically (both databases can 
provide non overlapping data). Conflict bases and/or SNPs were masked in each of the 
corresponding sequences (base replaced by a -N). The masked sequences populations 
were aligned (multiple alignment using ClustalX 2.0) and a consensus was built after 5' 
and 3' UTR masking using a dedicated script. The consensus sequence was used for the 
assay design (3 oligonucleotides in blue) and for the covering PCR primers (2 
oligonucleotides in red) necessary to amplify the DNA fragment used for the standard 
curve (figure produced in collaboration with Dr Francois Pallier, bioMérieux, France). 
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lncRNA assays were designed by us using PrimerQuest software from Integrated DNA 
Technologies (https://eu.idtdna.com/PrimerQuest/Home/Index).  
The oligonucleotide sequences of all designed assays were examined on the 
Ensembl (http://www.ensembl.org/index.html) database against transcript coverage 
and SNP presence. A SNP present in the primer or probe annealing site would change 
the oligonucleotide binding efficiency and negatively impact the assay performance. 
The ideal assay would target all alternatively spliced transcripts, have no SNPs in the 
primers and probe sequences and overlap two exons to avoid amplification of gDNA. 
Unfortunately, quite often there was no common sequence present in all the 
alternatively spliced transcripts, therefore it was not always possible to design an assay 
which would cover all of them; in this situation the assay was designed in a region 
present in most of the transcripts. The presence of one or more SNPs in the sequence 
of any oligonucleotides led to the exclusion of this particular assay from further 
investigation and a new assay was designed.  
When an assay passed in silico quality control, the assay primers were 
synthesised and tested by qPCR as described in chapter 2.10.4. A specific primer set 
should produce a single, sharp peak on melt curve profile (Figure 7B) and single band 
of expected size on a 1.3 % agarose gel. Any primers producing multiple peaks on melt 
curve profile (Figure 7A) or multiple bands on a gel were discarded as nonspecific and 
new assay was designed. 
When assay primers specificity was confirmed, the covering primers were 
synthesised and tested in the same way as above. If covering primers produced 
unspecific products, a new set of covering primers was designed. After passing quality 
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Figure 7. Melt curve analysis of gene specific primers product by SYBRGreen assay.  
A. An example of unspecific primer set for the mouse gene Cenpe – two peaks (red 
circles) are visible confirming that there are two PCR products with melting 
temperature of respectively 83 °C and 86 °C. B. Re-designed primers for the mouse 
Cenpe gene – only one PCR product (green circle) is now present with a melting 
temperature of 79 °C.    
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control, a PCR template was prepared as described in chapter 2.10.2 using covering 
primers. In order to test PCR template quality a SYBRGreen experiment was performed 
using assay primers and 1000 x diluted PCR template; amplification and melt curve 
shapes were assessed as described above. 
When specificity of covering primers was confirmed, a double-dye, fluorescent 
probe was ordered. Probe performance was tested by running a TaqMan assay as 
described in chapter 2.10.3 using a standard curve prepared as described in chapter 
2.10.2. Design was considered as validated only if PCR efficiency in multiplex reaction 
was between 93 % and 105 % and linear regression analysis gave R2 > 0.998 (Figure 8). 
We performed a microarray experiment (described in the next chapter) and 
literature search in order to find radiation-responsive genes and we designed assays 
for 16 human and nine murine genes listed in Table 3 and Table 4 respectively. In total 
27 assays were designed, including two assays for human (HPRT1) and mouse (Hprt) 
reference genes. Four sets of primers and probes for human and two for mouse had to 
be re-designed because they did not pass the quality control. Primer and probe 
sequences for each assay can be found in Appendix A. 
3.1.3. Blood collection 
A part of our project involved using blood samples which requires use of an 
anticoagulant like heparin or EDTA in collection tubes. We investigated if the choice of 
anticoagulant for blood sample collection influenced the gene expression results in our 
experimental system, as it has been previously reported that heparin is a potent PCR 
reaction inhibitor (Holodniy et al., 1991).  
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Figure 8. Four-colour multiplex TaqMan assay.  
Serial dilution of PCR-amplified DNA fragments for the following four mouse genes: 
Hprt, Phpt1, Fdxr and Cenpe. They were co-amplified in order to check PCR efficiency 
of primers and probe sets, and multiplexing compatibility. All four designs passed the 
quality control. 
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Table 3. Human radiation responsive genes identified by microarray experiment and 
literature search for which qPCR assays were designed. 
Gene name Description 
ATF3M activating transcription factor 3 
BBC3(PUMA) 
BCL2 binding component 3 (Badie et al., 2008) up-regulated 2 
h post 2 Gy X-ray exposure 
CCNB1 
cyclin B1 (Badie et al., 2008) down-regulated 2 h post 2 Gy X-
ray exposure 
CCNG1M cyclin G1 
CDKN1A(p21)M cyclin-dependent kinase inhibitor 1A 
DDB2 
damage-specific DNA binding protein 2, 48kDa (Paul and 
Amundson, 2008) up-regulated 6 h and 24 h post exposure to 
0.5, 2, 5 and 8 Gy of γ-ray 
FAS-AS1* FAS antisense RNA 1 (Yan et al., 2005) 
FDXR 
ferredoxin reductase (Paul and Amundson, 2008) up-regulated 
6 h and 24 h post exposure to 0.5, 2, 5 and 8 Gy of γ-ray 
GADD45AM growth arrest and DNA-damage-inducible, alpha 
MDM2 
Mdm2 TP53 binding protein homolog (mouse) (Paul and 
Amundson, 2008) up-regulated 6 h and 24 h post exposure to 
0.5, 2, 5 and 8 Gy of γ-ray 
PANDAR* 
promoter of CDKN1A antisense DNA damage activated RNA 
(Hung et al., 2011) up-regulated after doxorubicin treatment 
PHPT1 
phosphohistidine phosphatase 1 (Paul and Amundson, 2008) 
up-regulated 6 h and 24 h post exposure to 0.5, 2, 5 and 8 Gy 
of γ-ray 
PLK3 
polo-like kinase 3 (Paul and Amundson, 2008) up-regulated 6 h 
and 24 h post exposure to 0.5, 2, 5 and 8 Gy of γ-ray 
PRC1M protein regulator of cytokinesis 1 
SESN1M sestrin 1 
TP53TG1* 
TTP53 target 1 (non-protein coding) (Takei et al., 1998) up-
regulated after exposure to bleomycin 
*long non coding RNA 
M
 genes identified by microarray experiment  
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Table 4. Mouse radiation responsive genes identified by literature search. 
Gene name Description 
Atf3 activating transcription factor 3 
Bbc3(Puma) BCL2 binding component 3 
CcnB1 cyclin B1 
Cdkn1a(p21) cyclin-dependent kinase inhibitor 1A  
Cenpe centromere protein E 
Fdxr ferredoxin reductase 
Phpt1 phosphohistidine phosphatase 1 
Sesn1 sestrin 1 
Sesn2 sestrin 2 
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Human blood samples were collected into either potassium-EDTA or lithium-
heparin blood collection tubes (Becton-Dickinson). Two 100 µl aliquots were taken 
from each blood sample and irradiated with a sham dose or exposed to 4 Gy of X-ray. 
Blood samples were incubated at 37 °C for 24 h followed by RNA stabilisation by 
adding 1 ml of RNALater (Invitrogen) and then samples were frozen at – 80 °C. RNA 
was extracted as described in chapter 2.6.1.2 and reverse transcribed as described in 
chapter 2.9.1. Expression of four genes: HPRT1, CCNB1, BBC3 and CDKN1A was 
evaluated by qPCR as described in chapter 2.10.3. There was no difference in the yield 
or purity of RNA obtained from samples collected into two types of collection tubes 
(Table 5), however the Ct values for the samples collected into heparin tubes are at 
least 2 Cts higher than for samples collected into EDTA tubes, indicating that indeed 
significant inhibition takes place in samples collected into heparin tubes (Table 6). 
3.1.4. RNA extraction optimisation 
Historically in our lab, RNAqueous®-4PCR kit (4PCR, Ambion/Life Technologies) 
was used for RNA extractions. However, despite the fact that the kit allowed extraction 
of good quality RNA from broad range of samples, it did not quantitatively preserve 
small RNA species (notably those below 200 bp as stated in the RNAqueous®-4PCR kit 
manual). When we started working with miRNAs it was obvious that we had to find 
another kit for RNA extraction. We decided to test mirVana™ miRNA Isolation Kit 
(mirVana) from Ambion/Life Technologies and miRNeasy mini kit (miRNeasy) from 
Qiagen. Both kits allowed extraction of total RNA including small RNA species from 
broad ranges of samples.  
In order to compare the kits, we performed a pilot experiment using two 
human T-lymphocyte samples (control and irradiated with 4 Gy X-ray, collected 4 h  
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Table 5. Nanodrop 1000 spectrophotometer readings on RNA samples collected into 
EDTA or heparin blood collection tubes. 
  
Sample 
ID ng/uL A260 260/280 260/230 
EDTA 
0Gy 24h 27.59 0.69 1.97 1.47 
4Gy 24h 31.38 0.785 1.93 1.36 
Heparin 
0Gy 24h 30.26 0.756 1.96 1.35 
4Gy 24h 30.88 0.772 1.91 1.35 
 
Table 6. Ct values of samples collected into EDTA or heparin blood collection tubes. 
  
  Sample 
Ct mean 
HPRT1 CCNB1 BBC3 CDKN1A 
EDTA 
0Gy 24h 27.54 28.08 24.18 25.53 
4Gy 24h 27.69 28.65 24.08 24.61 
Heparin 
0Gy 24h 30.13 30.57 28.89 27.47 
4Gy 24h 30.83 31.11 28.43 27.39 
Ct 
difference 
0Gy 24h 2.59 2.49 4.72 1.94 
4Gy 24h 3.14 2.46 4.35 2.79 
 
  
94 
 
post exposure) frozen in RNALater (Ambion/Life Technologies). Each sample contained 
6 x 106 cells, samples were split into three aliqots containing equal numbers of cells 
and RNA was extracted with three different kits: 4PCR, mirVana and miRNeasy 
according to manufacturer’s protocols and eluted in 50 µl of corresponding elution 
buffer. 
RNA extracted with all three kits was of good quality as represented on an 
electrophoresis gel (Figure 9) with well-defined 28S and 18S ribosomal bands; all 
samples had RINe values above 9. Nanodrop 1000 spectrophotometer readings 
obtained from RNA samples are presented in Table 7. All three kits produced RNA free 
from protein contamination as indicated by A260/A280 ratios around 2, as well as free 
from organic contaminants, like phenol or ethanol, as indicated by ratio A260/A230 
higher than 1.8 (except for sample mirVana 0 Gy 4 h). The mirVana kit gave the highest 
RNA yield, however the large band below 200 bp visible on the gel (lines 3 and 4 on 
Figure 9) contributed significantly to the total RNA concentration. Both Ambion’s kits 
use DNase I digestion at the last step of RNA extraction protocol where DNA digestion 
fragments are still present in the eluted solution; Qiagen’s kit uses on column digestion 
with subsequent washes to purify RNA from any DNA contamination. We assumed that 
the band below 100 bp consists of DNA digestion products and small RNA species. 
Next, we wanted to check if there is any difference in qPCR results between 
samples extracted with three different kits. We prepared cDNA from mRNA as 
described in chapter 2.9.1 using 700 ng of total RNA per 50 µl reaction and from 
miRNA as described in chapter 2.9.2 using 200 ng of total RNA per 20 µl reaction. We 
measured the expression level of six genes by TaqMan assay qPCR as described in 
chapter 2.10.3. We observed quite large differences in Ct values between samples  
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Figure 9. Gel electrophoresis produced by TapeStation 2200 instrument 
Six RNA samples were analysed using TapeStation 2200, lines represent: M – RNA size 
marker (bp), 1 – 0 Gy 4 h miRNeasy kit, 2 – 4 Gy 4 h miRNeasy kit, 3 – 0 Gy 4 h miRVana 
kit, 4 – 4 Gy 4 h miRVana kit, 5 – 0 Gy 4 h 4PCR kit, 6 – 4 Gy 4 h 4PCR kit . The green 
band at 50 bp represents lower marker used by instrument for lines alignment.   
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Table 7. Nanodrop 1000 spectrophotometer readings on RNA samples extracted with 
three different kits. 
 
Sample ID ng/ul A260 A280 260/280 260/230 
mirVana 
0Gy 4h 153.52 3.838 1.973 1.94 1.47 
4Gy 4h 213.74 5.344 2.757 1.94 1.96 
4PCR 
0Gy 4h 85.02 2.126 1.069 1.99 1.94 
4Gy 4h 114.81 2.87 1.423 2.02 2.01 
miRNeasy 
0Gy 4h 50 1.25 0.592 2.11 1.85 
4Gy 4h 61.42 1.535 0.736 2.09 1.89 
 
Table 8. mRNA Ct values obtained for samples extracted with three different RNA 
extraction kits 
 
 
Sample 
Ct mean 
HPRT GADD45A FDXR DDB2 ATF3 SESN1 
mirVana 
 
0Gy 4h 22.77 24.05 21.80 21.01 25.61 23.73 
4Gy 4h 22.78 21.53 19.37 19.32 23.08 21.95 
4PCR 
 
0Gy 4h 21.85 23.93 21.65 20.23 24.85 23.35 
4Gy 4h 21.93 21.50 19.34 18.90 22.51 21.19 
miRNeasy 
 
0Gy 4h 21.10 22.84 21.27 19.76 24.11 22.09 
4Gy 4h 21.13 20.58 18.93 18.12 21.74 20.31 
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extracted with different kits (Table 8) despite using the same amount of RNA for cDNA 
synthesis, and the same amount of cDNA per qPCR reaction. The samples extracted 
with the miRNeasy kit gave lowest Cts, then samples extracted with 4PCR kit and 
samples extracted with mirVana gave the highest Ct values meaning that there were 
more mRNA templates per reaction in samples prepared with miRNeasy than in other 
kits. By contrast, there was no major difference in the fold change results between 
samples extracted with different kits (Figure 10A). The most probable explanation for 
this observation is that DNA degradation products seen in samples extracted with 
Ambion kits overestimated total RNA yield given by Nanodrop reading. However, there 
was still possibility that samples extracted with the mirVana kit contained more small 
RNA species than samples extracted with the miRNeasy kit and simply diluted the 
mRNA. To test this possibility we looked at expression of two miRNAs and one small 
nuclear RNA (snRNA) in the same samples.   
The expression of these two miRNAs and one snRNA does not seem to be 
influenced by IR exposure in our system, we also could not see any obvious difference 
in the fold change after radiation exposure between samples extracted with different 
kits (Figure 10B). However, the samples extracted with miRNeasy again gave lowest Ct 
values for two out of three small RNA assays (Table 9). Our pilot experiment results 
suggest, that most of the small fragments on the gel are in fact DNA degradation 
products, because the mirVana kit does not seem to extract small RNA species more 
efficiently than the miRNeasy kit. As expected, samples extracted with 4PCR kit gave 
the highest Ct values, because kit is not optimised for extraction of small RNA species.  
Finally, we looked at melt profiles to assess if we detected the correct products 
(Figure 11). RNA, U6 small nuclear 1 (RNU6-1) had the same melting temperature for  
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Figure 10. Gene and miRNA expression results from RNA samples extracted with 
three different kits.  
A. Comparison of fold changes in expression of six genes analysed in 6-plex qPCR 
reaction between samples extracted with three different RNA extraction kits. All 
samples were normalised to HPRT1 internal control and then irradiated samples were 
normalised to the controls. B. Comparison of fold changes in expression of two 
miRNAs analysed by SybrGREEN reaction between samples extracted with three 
different RNA extraction kits. All samples were normalised to RNU6-1 internal control 
and then irradiated samples were normalised to the controls. Both graphs represent 
results of a single experiment 
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Table 9. miRNA Ct values obtained for samples extracted with three different RNA 
extraction kits 
  
  Sample 
Ct mean 
RNU6-1 miR-195 miR-34c 
mirVana 
  
0Gy 4h 13.48 19.15 25.43 
4Gy 4h 13.42 18.69 25.43 
4PCR 
  
0Gy 4h 15.82 27.26 29.58 
4Gy 4h 16.10 27.39 29.36 
miRNeasy 
  
0Gy 4h 12.61 17.61 26.06 
4Gy 4h 12.24 17.46 25.93 
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Figure 11. Melt profiles of samples extracted with three different kits 
Melt profiles of samples extracted with miRNeasy (red), mirVana (blue) and 4PCR 
(green) kits were assessed by SYBRGreen for RNU6-1 (A), miR-195 (B) and miR-34c (C).  
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all samples, however samples extracted with the 4PCR kit have a one degree higher 
melting temperature for miR-195 and produce multiple unspecific products for miR-
34c. These differences in melt profiles are probably caused by the fact 4PCR kit is not 
suitable for extraction of short RNA species, however, human RNU6-1 is 106 
nucleotides long in contrast to miRNAs which are around 20 nucleotides and it may be 
just long enough for efficient extraction with the 4PCR kit. 
3.1.5. RT reaction optimisation 
The High Capacity cDNA Reverse Transcription Kit (Life Technologies) utilising 
random hexamers has been historically used in our lab. From the literature it is known 
that the RT step introduces the highest level of variability into qPCR experiments 
(Stahlberg et al., 2004). It has been also shown that using random hexamers results in 
different transcription efficiencies between targets and non-linear reverse 
transcription (Nolan et al., 2006). We, therefore, wanted to assess the performance of 
our cDNA synthesis kit.  
In order to test the kit performance, different volumes of mouse blood from 5 
µl up to 100 µl were prepared and RNA was extracted. The experiment was repeated 
twice and a linear correlation between blood volume used and amount of total RNA 
extracted was observed with a linear regression R2 value of 0.9981 thus confirming 
that in the range we have tested, there is a linear relationship between the amount of 
blood used and the amount of extracted RNA (Figure 12). 
Next, we investigated if the amount of total RNA used for reverse transcription 
reaction influences the performance of our RT kit. It has been previously reported that 
RT efficiency depends on total RNA concentration and is different for different genes 
(Stahlberg et al., 2004). In order to investigate this issue, an RT reaction was set up  
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Figure 12. Correlation between volume of blood used and amount of total RNA 
extracted.  
RNA was extracted from different volumes of mouse blood; error bars represent 
standard deviation between two independent experiments. 
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using equal volumes but different concentrations of total RNA extracted from aliquots 
of mouse blood. A qPCR reaction was performed and Ct values for seven mouse genes: 
Hprt, Ccnb1, Bbc3, Cdkn1a, Sesn1, Sesn2 and Atf3 were converted into mRNA copy 
numbers using a standard curve. The results of this experiment are presented in Figure 
13. The reproducibility of RT reaction was good for all genes except for Bbc3 and 
Ccnb1, as indicated by error bars representing SD. There was a linear dependence 
between the amount of RNA used in cDNA synthesis and the gene copy number 
measured by qPCR suggesting that the amount of total RNA used does not affect the 
RT reaction efficiency in the range tested (from 60 ng up to 1.2 µg of total RNA per 
reaction) for all seven genes. However, the linear regression R2 value for Bbc3 was 
slightly lower suggesting that there might be some other factors influencing the cDNA 
synthesis step for this particular gene. 
 It has been reported that using random hexamers can overestimate transcript 
copy number by up to 19 fold (Zhang and Byrne, 1999), and consequently we wanted 
to investigate if it was true for our RT kit. We assumed that when a transcript is reverse 
transcribed with 100 % efficiency, doubling of RNA input should result in doubling of 
transcript copy number measured by qPCR. Using the mouse blood samples from the 
previous experiment, we calculated theoretical mRNA copy numbers which should be 
measured if RT reaction efficiency was 100 %, by multiplying the gene copy number for 
the lowest RNA concentration by fold increase in RNA input. For example, if the 
measured mRNA copy number for gene X was 10 in the sample with the lowest RNA 
concentration and the next sample contained twice as much RNA as the first one, then 
if the RT reaction efficiency was 100 %, the measured copy number in the second 
sample should be 20. We have performed two independent repeats of this exercise for  
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Figure 13. Correlation between volume of blood used and gene copy number for 
seven mouse genes.  
RNA was extracted from different volumes of mouse blood and equal volumes of total 
RNA have been used for cDNA synthesis, prepared cDNA was used in 4-plex qPCR 
reactions; error bars represent standard deviations for two independent experiments.  
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all seven genes and our results show that the RT reaction efficiency indeed seems to 
be gene dependant confirming previous findings (Stahlberg et al., 2004) (Figure 14), 
however, we did not observe a massive overestimation of gene copy number reported 
by Zhang et al. Gene copy numbers for some genes (Hprt, Sesn1 and Atf3) seem to be 
slightly overestimated (maximum of 1.8 fold for Atf3 in the sample with the highest 
RNA concentration). Three genes (Ccnb1, Bbc3 and Cdkn1a) were faithfully reverse 
transcribed whereas copy number of Sesn2 transcript was slightly underestimated (1.3 
fold for the sample with the highest RNA concentration). 
3.1.1. 6-plex protocol development 
A 4-plex qPCR protocol had been developed in our laboratory by Ms Claudine 
Raffy. More recently, a new qPCR platform become available – the Rotor-Gene Q 6-
plex (Qiagen) – which replaced the four channel iQ5 system. The Rotor-Gene Q was 
capable of measuring fluorescence in six different channels in 10 µl reaction volumes. 
To take advantage of this extra capacity, other dyes compatible with the new system 
were required. The new machine had two extra channels: crimson (laser source 680 ±5 
nm and detection at 710 high pass) and blue (laser source 365 nm ±20 and detection at 
460 nm ±20).  
We started our optimisation with crimson channel as there was already a 
report of successful 5-plex qPCR reaction with Quasar® 705 dye fluorescing in far red 
spectrum of visible light (Bio-Rad, private communication). We ordered four probes for 
the human ATF3 gene with different dyes emitting fluorescence in crimson channel: 
Quasar® 705, AlexaFluor® 680, ATTO 680 and CY® 5.5. In order to test which dye 
performed the best, we set up four independent single-plex reactions with a standard 
curve in 30 µl reaction volumes.  
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Figure 14. Comparison of theoretical and measured transcript copy number  
Theoretical gene copy number (black diamonds) was calculated from RNA input and 
compared to measured gene copy number (blue diamonds); error bars represent 
standard deviations for two independent experiments.  
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First, we looked at raw fluorescence data (Figure 15) and it was clear that Alexa Fluor® 
680 probe had very high background fluorescence and therefore was unsuitable for 
our multiplex setup. The other probes had acceptable background fluorescence level 
with CY® 5.5 labelled probe having the lowest but it also had the shortest exponential 
phase which is a disadvantage in qPCR experiments. Next, we looked at four probes 
PCR efficiency in single-plex reaction (Figure 16) and all four probes showed good PCR 
efficiencies and linear regression R2 values except for the Quasar® 705 probe which 
showed a lower than acceptable R2 value but this could have been caused by pipetting 
error.  We excluded Alexa Fluor® 680 and CY® 5.5 labelled probes as unsuitable for 
multiplexing based on raw fluorescence data, and although Quasar® 705 had the 
longest exponential phase, it was significantly more expensive than ATTO 680 dye, 
therefore we decided to focus our interest on the ATTO 680.  
Finally, we wanted to investigate ATTO 680 probe performance in 5-plex 
reaction. We set up 5-plex reaction with a standard curve in a 30 µl reaction volume. 
All five genes in 5-plex reaction showed PCR efficiency above 93 % and linear 
regression R2 values above 0.999 (Figure 17) confirming that ATTO 680 probe is 
compatible with our multiplex setup.  
We also wanted to investigate if we could reduce the reaction volume without 
compromising assay performance as this would lower the cost of running the qPCR 
assays. In order to test this possibility we performed 5-plex reaction with the same 
genes as above but in a 10 µl reaction volume where the concentrations of all reagents 
were kept the same. As illustrated in Figure 18, the PCR efficiencies for all five assays 
were between 93 and 104 % and the linear regression R2 values were above 0.998, 
confirming that reducing reaction volume does not compromise assay performance. 
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Figure 15. Raw fluorescence data for crimson channel. 
Raw fluorescence data was collected for Quasar® 705 (red), Alexa Fluor® 680 (blue), 
ATTO 680 (green) and CY® 5.5 (purple) dyes. 
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Figure 16. Standard curve in single-plex reaction. 
Standard curves for ATF3 gene with four different dyes: Quasar® 705 (A), Alexa Fluor® 
680 (B), ATTO 680 (C) and CY® 5.5 (D) were run in single-plex reaction.  
110 
 
 
Figure 17. Standard curve in 5-plex 30 µl reaction with ATTO 680 probe. 
Standard curve with five human genes: HPRT1 (A), GADD45A (B), FDXR (C) MDM2 (D) 
and ATF3 (E) was run in 5-plex 30 µl reaction. 
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Figure 18. Standard curve in 5-plex 10 µl reaction with ATTO 680 probe. 
Standard curve for five human genes: HPRT1 (A), GADD45A (B), FDXR (C) MDM2 (D) 
and ATF3 (E) was run in 5-plex 10 µl reaction. 
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After the successful development of 5-plex qPCR assay, we proceeded to 6-plex 
assay optimisation. We identified four dyes compatible with the blue channel of 
theRotor-Gene Q: ATTO 390, ATTO 425, Marina Blue® and Alexa Fluor® 390. We 
ordered four probes for human SESN1 gene labelled with these dyes and DDQ1 
quencher.  
First, we tested the probes on a standard curve in a single-plex reaction. As 
presented on the raw fluorescence plot (Figure 19) all four probes have very short 
exponential phase. ATTO425 showed the lowest background but also the shortest 
exponential phase; alternatively ATTO390 presented the best combination of 
background level and length of exponential phase. Then we looked at PCR efficiency of 
these probes (Figure 20) and all probes except for ATTO 425 showed good PCR 
efficiency, although linear regression R2 values for Marina Blue and Alexa Fluor 390 
were slightly lower than acceptable. Considering raw fluorescence data and probes 
performance we decided to focus on ATTO 390 dye in further optimisation.  
To validate the two new dyes in 6-plex reaction, we prepared a standard curve 
consisting of eleven 5-fold dilutions containing from 1 up to 9765625 copies of each 
gene per 10 µl reaction, the standard curve was run in triplicate. All six genes 
presented very good PCR efficiency and high R2 values in the 6-plex assay (Figure 21). 
Finally, we wanted to be sure that the same gene run in 6-plex and single-plex 
reaction performs similarly. In order to do so, we assessed the expression of six genes 
in one sample run in quadruplicate and a standard curve, assayed both in 6-plex and 
single-plex reactions. The standard curve results are presented in Figure 22. Five out of 
six genes shown no differences between standard curves assayed in 6-plex or single- 
plex reaction, however MDM2 gene detected in red channel demonstrated a shift in Ct  
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Figure 19. Raw fluorescence data for blue channel. 
Raw fluorescence data was collected for SESN1 probe with ATTO 390 (red), Marina 
Blue® (blue), ATTO 425 (green) and Alexa Fluor 390 (purple) dyes. 
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Figure 20. Standard curve in single-plex reaction. 
Standard curve for SESN1 gene with four different probes: ATTO 390 (A), Marina Blue 
(B), ATTO 425 (C) and Alexa Fluor 390 (D) were run in single-plex reaction. 
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Figure 21. Standard curve in 6-plex reaction. 
Standard curve for 6 genes: HPRT1 (A), GADD45A (B), FDXR (C), MDM2 (D), ATF3 (E) 
and SESN1 (F) was run in triplicates. Error bars represent standard deviation.  
116 
 
 
Figure 22. Comparison of 6-plex vs single-plex reaction. 
Standard curve for 6 genes: HPRT1 (A), GADD45A (B), FDXR (C), MDM2 (D), ATF3 (E) 
and SESN11 (F) was run in 6-plex and single-plex reaction. On each graph there are 
points from 6-plex and single-plex reaction.  
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values. This is probably caused by Texas Red (orange) dye bleeding into red detection 
channel as shown on Figure 23A. We have also noticed that FAM (green dye) is 
bleeding slightly into yellow channel although it does not change the GADD45A gene 
Ct values (Figure 23B).  
The Ct values for the test sample assessed in 6-plex and single-plex reaction are 
presented in Table 10. The Ct means for samples assayed in single-plex and 6-plex 
reactions are within 0.5 Ct from each other, which is perfectly acceptable threshold for 
technical replicates (Nolan et al., 2006); however samples run in 6-plex reactions have 
slightly lower replicate reproducibility as indicated by higher standard deviation. 
3.1.2. Discussion 
Quantitative PCR is considered to be the “gold standard” for accurate and 
sensitive measurement of gene expression. Nevertheless, because of its simplicity it is 
easy to forget that in order to obtain biologically meaningful and statistically significant 
results, strict quality control must be applied to all steps of the workflow (Derveaux et 
al., 2010). The major part of our project was investigation of gene expression changes 
by qPCR, therefore, in order to obtain sound data, it was decided to spend 
considerable time and effort to demonstrate that we controlled every step of the 
qPCR. 
One of the first issues that must be addressed when setting up a new qPCR 
experiment is the quality of primers and probe design. This step is crucial as 
poor/unspecific primers or probe result in poor PCR efficiency and unreliable results 
(Bustin, 2004). We decided to use TaqMan probe based chemistry because of its 
specifity and because it allows multiplexing. High efficiency multiplexing is a real 
challenge and we needed to be sure that all designs were specific, showing high PCR  
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Figure 23. Raw fluorescence data for channels red (A), yellow (B) and orange (C). 
High magnification of raw fluorescence plot. A. Texas Red® probe (green) bleeds 
through red channel and amplification can be detected in background level of CY5® 
probe (red). B. FAM probe (pink) bleeds through yellow channel and amplification can 
be detected in the background of HEX probe (blue).C. No amplification of HEX probe 
(blue) can be detected in the background level of Texas Red® probe (green)  
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Table 10. Comparison of Ct values between sample assayed in 6-plex and single-plex 
reaction. 
  
6-plex Single-plex 
Ct mean SD Ct mean SD 
HPRT1 20.45 0.17 20.38 0.14 
GADD45A 20.38 0.18 20.64 0.08 
FDXR 20.53 0.12 20.89 0.10 
MDM2 18.83 0.24 19.24 0.09 
ATF3 22.49 0.17 22.94 0.06 
SESN11 23.64 0.07 23.81 0.19 
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efficiency and low background fluorescence. All designs were in silico and 
experimentally validated for specificity, SNPs presence, alternative transcript coverage 
and PCR efficiency. The obvious advantages of multiplex qPCR experiments are cost 
reduction, conservation of limited or precious samples and decreased technical 
variability due to the detection of reference gene and genes of interest in a single 
reaction. 
  A part of our project involved processing blood samples. Blood contains 
considerable amount of heme – a powerful inhibitor of PCR reaction (Akane et al., 
1994) but also the sampling procedure can introduce additional inhibitors like heparin 
(Holodniy et al., 1991). Our data showed that heparin used as an anti-coagulant in 
blood sampling can somehow survive phenol-chloroform extraction and substantially 
inhibit qPCR reactions (Table 6). As a result of this pilot, we decided to use EDTA blood 
collection tubes for our experiments, except for the NATO exercise described further in 
chapter 3.4, where collaborative nature of the study required using heparin as an 
anticoagulant. 
RNA extraction is another critical step in performing qPCR experiments as it is 
widely accepted that RNA quality is significantly negatively correlated with Ct values 
(Fleige et al., 2006) and reference genes vary in their sensitivity to degradation (Perez-
Novo et al., 2005). We investigated the performance of three extraction kits and 
observed that although there was no difference in RNA quality or fold change gene 
expression results, the miRNeasy kit consistently produced lower Ct values for both 
mRNA and miRNA despite using the same amount of RNA for cDNA synthesis step. The 
most probable explanation for this phenomenon is dilution of transcripts with 
products of DNase treatment as the DNase treatment is performed at the end of the 
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extraction in the 4PCR and mirVana kits as opposite to the miRNeasy kit and we did 
not observe higher yields of small RNA species in samples produced by other kits 
(Table 9). Although, we did not observe any differences in fold change results between 
samples extracted with different kits, the lower Ct values produced by the miRNeasy 
kit are advantageous especially when investigating genes expressed at low level. As a 
result of this study we decided to use the miRNeasy kit for all future RNA extractions. 
We also studied performance of our cDNA synthesis kit, as it is generally 
considered to be the most variable step in qPCR workflow (Stahlberg et al., 2004). Our 
kit utilises random hexamers as a priming strategy and it has been reported that using 
random hexamers is the least reliable method of priming RT reaction as it results in (i) 
overestimation of mRNA copies when compared to gene specific primers (Zhang and 
Byrne, 1999), (ii) gene-dependant transcription efficiencies and (iii) non-linear 
amplification of mRNA depending on RNA concentration (Nolan et al., 2006).  
Our results show that in contrast to Nolan et al report (Nolan et al., 2006) the 
performance of our RT kit does not seem to be influenced by total RNA concentration 
in the range tested as our kit enables linear reverse transcription over a broad range of 
RNA input for all seven genes (Figure 13), however the linear regression R2 value for 
Bbc3 is slightly lower implying that other factors, such as complicated secondary RNA 
structure, may play a role as well.  
Zhang et al reported that using random hexamers can overestimate transcript 
copy number by as much as 19 fold (Zhang and Byrne, 1999). In contrast to this report, 
we did not observe massive overestimation of gene copy number of seven tested 
genes (maximum of 1.8 fold in case of Atf3 gene when using 1.2 µg of RNA per RT 
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reaction) (Figure 14); however, we cannot exclude the possibility that other genes are 
reverse transcribed more efficiently.  
The efficiency of RT reactions seems to be gene dependant as previously 
reported (Stahlberg et al., 2004), with copy number for some transcripts being slightly 
overestimated, others underestimated or faithfully transcribed. One very important 
conclusion emerges from our results – the same amount of total RNA should always be 
used for cDNA synthesis, because different genes are reverse transcribed with 
different efficiencies and the gene of interest/reference gene ratio changes with 
different RNA concentrations. Overall, we concluded that our RT kit allows 
reproducible and relatively faithful cDNA synthesis as long as we use the same RNA 
concentration for all samples.  
A strict quality control and robust assay design allowed us to multiplex six 
genes in 10 µl reaction without compromising assay performance (Figure 21,Figure 22 
and Table 10) this is an achievement in itself as not many labs can accomplish such 
deep multiplexing. The only gene which showed discrepancy in Ct values between 
samples assayed in 6-plex and single-plex is MDM2 (red channel). We believe this is 
caused by the TexasRed® probe signal bleeding into red channel (Figure 23A). The 
discrepancy is observed only in standard curve samples (Figure 22D) but not in the 
unknown sample (Table 10). The most probable explanation for this phenomenon is 
the fact that in the standard curve, the PCR products for all six genes are in equimolar 
concentration; therefore, the Texas Red® probe signal is stronger and bleeds into the 
red channel more significantly. In the unknown samples FDXR gene has lower 
expression than MDM2, consequently it affects the red channel to lesser extent. We 
concluded that as long the gene measured by the orange channel had lower 
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expression than the gene measured in red channel, the multiplexing does not affect 
relative gene expression results.  
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3.2. Identification of biomarkers for IR dose 
estimation 
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3.2.1. Introduction 
The dicentric chromosome assay is considered to be the gold standard for 
biodosimetric estimation of IR exposures, however it is not well suited to cases 
requiring mass screening in a triage scenario due to limited capacity, as it is labour 
intense, time consuming and requires experienced staff for scoring (Wojcik et al., 
2010). There is clearly a need for new, minimally invasive and rapid biodosimetry 
techniques.  
It is well known that expression of a number of genes are modified after IR 
exposure, and depends on tissue type (Pawlik et al., 2009), dose of radiation and time 
between the exposure and analysis (Franco et al., 2005, Meadows et al., 2008, 
Manning et al., 2013), features that potentially make gene expression very useful for 
biodosimetry purposes. Gene expression assays are much quicker than dicentric 
chromosome assays, as they can provide dose estimation within 8 h following samples 
receipt as demonstrated in Badie et al (Badie et al., 2013) and it is suitable for high 
throughput application. 
The aim of this project was to establish a panel of robust and highly responsive 
genes for biodosimetry purposes and to study inter- and intra-individual variation in 
transcriptional response to IR exposure. We were also interested in comparing gene 
expression signatures in blood and stimulated T-lymphocytes obtained from the same 
donor in order to assess the role of cell cycle in transcriptional response to IR 
exposure. The gene expression signatures in T-lymphocytes can be also informative in 
terms of individual sensitivity to IR, as we had demonstrated previously that aberrant 
transcriptional response of CDKN1A to IR was associated with abnormal normal tissue 
reaction to therapeutic radiation treatment for breast cancer (Badie C, 2008).  
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3.2.2. Identification of IR-responsive genes 
In order to identify genes responsive to IR, we first performed a microarray 
experiment. To obtain information about the impact of the dose of radiation and time 
post-exposure on gene expression profiles, blood samples and corresponding 
stimulated T-lymphocytes obtained from three donors were irradiated with a sham 
dose or exposed to 2 or 4 Gy of X-ray and collected 2 h and 24 h following exposure. 
Total RNA was extracted and half was sent to Dr Alan Mackay (Breakthrough Breast 
Cancer Research Centre, the Institute of Cancer Research, London, UK) for microarray 
analysis, the other half was kept for later qPCR validation experiments. Three 
independent experiments were carried out and the results presented in this chapter 
have been already published (Kabacik et al., 2011a).  
The microarray experiment identified genes, the expression of which was 
significantly modified by IR exposure in blood leukocytes and/or in stimulated T-
lymphocytes. Altogether, 570 up-regulated and 31 down-regulated genes were 
detected in non-cycling blood leukocytes compared to 232 up-regulated and 1357 
down-regulated genes in stimulated T-lymphocytes when using false discovery rate of 
< 5 % (Table 11). The heatmap representing the top twenty genes the expression of 
which is up- or down-regulated in response to IR in blood leukocytes and in stimulated 
T-lymphocytes is presented in Figure 24. The corresponding tables with the ranking of 
genes based on fold change in expression after radiation are shown in Table 12A, B, C 
and D. More genes were up-regulated in blood leukocytes than in T-lymphocytes 
following IR exposure, whereas many more down-regulated genes are observed in 
cycling lymphocytes, i.e. there were very few genes significantly down-regulated in 
blood at the 2 h time-point (Table 11 and Table 12D). The stimulated T-lymphocytes,  
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Table 11. Radiation responsive genes in blood leukocytes and stimulated T-
lymphocytes 
 
Blood Lymphocytes 
2h 24h 2h 24h 
2Gy 4Gy 2Gy 4Gy 2Gy 4Gy 2Gy 4Gy 
up 296 234 13 247 31 100 107 116 
down 0 1 7 29 29 267 113 1109 
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Figure 24. Heatmaps of microarray data. 
Twenty of the most radiation responsive genes are shown in stimulated lymphocytes 
(left panels) and blood (right panels). A colour bar showing the level of expression is 
shown in the bottom right of the figure. Figure was prepared by Dr Alan Mackay. 
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Table 12A. Most significantly up-regulated genes in irradiated stimulated T- 
lymphocytes 
Symbol Description 
Unigene 
entry 
2h 2Gy 2h 4Gy 24h 2Gy 24h 4Gy 
GADD45A Growth arrest and 
DNA-damage-
inducible, alpha 
Hs.80409 1* 1 1 1 
SESN1 Sestrin 1 Hs.591336 3 5 3 3 
CDKN1A Cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) 
Hs.370771 2 3 7 5 
ATF3 Activating 
transcription factor 3 
Hs.460 5 6 13 4 
FAS Fas (TNF receptor 
superfamily, member 
6) 
Hs.244139 6 8 4 11 
FBXW2 F-box and WD repeat 
domain containing 2 
Hs.494985 7 14 6 6 
RBM15 RNA binding motif 
protein 15 
Hs.435947 4 4 42 8 
ANKRA2 Ankyrin repeat, family 
A (RFXANK-like), 2 
Hs.239154 23 33 31 9 
PPM1D Protein phosphatase 
1D magnesium-
dependent, delta 
isoform 
Hs.591184 11 20 60 35 
C12orf5 Chromosome 12 open 
reading frame 5 
Hs.504545 12 32 48 43 
RRM2B Ribonucleotide 
reductase M2 B 
(TTP53 inducible) 
Hs.512592 22 54 45 16 
C11orf24 Chromosome 11 open 
reading frame 24 
Hs.303025 19 47 85 29 
IFNG Interferon, gamma Hs.856 NS 9 2 2 
FBXO22 F-box protein 22 Hs.591115 28 69 94 80 
CCNG1 Cyclin G1 Hs.79101 10 23 10 NS 
BLOC1S2 Biogenesis of 
lysosome-related 
organelles complex-1, 
subunit 2 
Hs.576605 NS 15 12 18 
PRDM1 PR domain containing 
1, with ZNF domain 
Hs.436023 NS 19 21 15 
TncRNA Trophoblast-derived 
noncoding RNA 
Hs.523789 14 39 NS 7 
RPS27L Ribosomal protein 
S27-like 
Hs.108957 NS 44 5 20 
LRRC58 Leucine rich repeat 
containing 58 
Hs.518084 NS 36 23 14 
 
NS: Not Significant (false discovery rate higher than 5%) 
* The numbers indicate the ranking of genes based on fold change (1 being the most 
responsive gene at a particular dose and time-point); prepared by Dr Alan Mackay. 
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Table 12B. Most significantly down-regulated genes in irradiated stimulated T-
lymphocytes 
Symbol Description 
Unigene 
entry 
2h 2Gy 2h 4Gy 24h 2Gy 24h 4Gy 
BUB1 
BUB1 budding 
uninhibited by 
benzimidazoles 1 
homolog (yeast) 
Hs.469649 8* 19 NS 242 
CCNA2 Cyclin A2 Hs.58974 22 22 NS 474 
KIF23 
Kinesin family member 
23 
Hs.270845 6 3 NS 686 
NCAPG 
Non-SMC condensin I 
complex, subunit G 
Hs.567567 20 79 NS 720 
PPP1R3D 
Protein phosphatase 1, 
regulatory (inhibitor) 
subunit 3D 
Hs.42215 26 34 NS 771 
PRC1 
Protein regulator of 
cytokinesis 1 
Hs.567385 17 26 NS 826 
CENPE 
Centromere protein E, 
312kDa 
Hs.75573 5 11 NS 913 
LDHA 
Lactate dehydrogenase 
A 
Hs.2795 NS NS 1 1 
HMMR 
Hyaluronan-mediated 
motility receptor 
(RHAMM) 
Hs.72550 1 2 NS NS 
DKFZp76 
2E1312 
Hypothetical protein 
DKFZp762E1312 
Hs.532968 2 1 NS NS 
DLG7 
Discs, large homolog 7 
(Drosophila) 
Hs.77695 3 5 NS NS 
CBLN2 Cerebellin 2 precursor Hs.569851 NS NS 8 2 
PTGES3 
Prostaglandin E 
synthase 3 (cytosolic) 
Hs.50425 NS NS 6 5 
INSIG1 Insulin induced gene 1 Hs.520819 NS NS 3 8 
BNIP3 
BCL2/adenovirus E1B 
19kDa interacting 
protein 3 
Hs.144873 NS NS 2 9 
PIF1 
PIF1 5'-to-3' DNA 
helicase homolog (S. 
cerevisiae) 
Hs.112160 4 7 NS NS 
PTMA 
Prothymosin, alpha 
(gene sequence 28) 
Hs.459927 NS NS 13 4 
PSRC1 
Proline/serine-rich 
coiled-coil 1 
Hs.405925 9 8 NS NS 
RRM2 
Ribonucleotide 
reductase M2 
polypeptide 
Hs.226390 NS NS 7 11 
KIF14 
Kinesin family member 
14 
Hs.3104 7 18 NS NS 
 
 
NS: Not Significant (false discovery rate higher than 5%) 
*The numbers indicate the ranking of genes based on fold change (1 being the most 
responsive gene at a particular dose and time-point); prepared by Dr Alan Mackay. 
 
131 
 
Table 12C. Most significantly up-regulated genes in irradiated whole blood 
Symbol Description 
Unigene 
entry 
2h 2Gy 2h 4Gy 24h 2Gy 24h 4Gy 
PCNA Proliferating cell 
nuclear antigen 
Hs.147433         1* 1 1 1 
DUSP21 Dual specificity 
phosphatase 21 
Hs.534478 5 6 11 7 
SESN1 Sestrin 1 Hs.591336 6 5 22 11 
GADD45A Growth arrest and 
DNA-damage-
inducible, alpha 
Hs.80409 2 3 38 15 
TMEM30A Transmembrane 
protein 30A 
Hs.108530 4 4 40 18 
CCNG1 Cyclin G1 Hs.79101 3 2 62 26 
RBM15 RNA binding motif 
protein 15 
Hs.435947 108 13 13 10 
RPS27L Ribosomal protein 
S27-like 
Hs.108957 7 NS 3 4 
CDKN1A Cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) 
Hs.370771 39 NS 6 3 
IER5 Immediate early 
response 5 
Hs.15725 50 NS 12 14 
FAS Fas (TNF receptor 
superfamily, member 
6) 
Hs.244139 32 NS 23 24 
HSP90AA1 Heat shock protein 
90kDa alpha 
(cytosolic), class A 
member 1 
Hs.525600 73 NS 17 12 
FBXW2 F-box and WD repeat 
domain containing 2 
Hs.494985 90 NS 49 30 
ARL6IP1 ADP-ribosylation 
factor-like 6 
interacting protein 1 
Hs.634882 104 NS 64 105 
PERP PERP, TTP53 apoptosis 
effector 
Hs.520421 56 NS 105 119 
UBC Ubiquitin C Hs.520348 86 NS 134 99 
BLOC1S2 Biogenesis of 
lysosome-related 
organelles complex-1, 
subunit 2 
Hs.576605 64 NS 169 90 
ZFR Zinc finger RNA 
binding protein 
Hs.435231 40 NS 179 156 
PPM1D Protein phosphatase 
1D magnesium-
dependent, delta 
isoform 
Hs.591184 48 NS 185 153 
STX11 Syntaxin 11 Hs.118958 215 NS 72 150 
 
NS: Not Significant (false discovery rate higher than 5%) 
*The numbers indicate the ranking of genes based on fold change (1 being the most 
responsive gene at a particular dose and time-point); prepared by Dr Alan Mackay. 
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Table 12D. Most significantly down-regulated genes in irradiated whole blood 
Symbol Description 
Unigene 
entry 
2h 2Gy 2h 4Gy 24h 2Gy 24h 4Gy 
BANK1 B-cell scaffold protein 
with ankyrin repeats 1 
Hs.480400 NS NS 1* 2 
IGJ Immunoglobulin J 
polypeptide 
Hs.651109 NS NS 2 4 
IL2RB Interleukin 2 receptor, 
beta 
Hs.474787 NS NS 3 3 
EDG1 Endothelial 
differentiation, 
sphingolipid G-protein-
coupled receptor, 1 
Hs.154210 NS NS 5 13 
GLCCI1 Glucocorticoid induced 
transcript 1 
Hs.131673 NS NS 7 24 
CD8A CD8a molecule Hs.85258 NS NS 6 26 
KLRF1 Killer cell lectin-like 
receptor subfamily F, 
member 1 
Hs.183125 NS NS NS 1 
TCL1A T-cell 
leukemia/lymphoma 1A 
Hs.2484 NS 1 NS NS 
GZMK Granzyme K (granzyme 
3; tryptase II) 
Hs.277937 NS NS 4 NS 
SLC2A3 Solute carrier family 2, 
member 3 
Hs.419240 NS NS NS 5 
TRA@ T cell receptor alpha 
locus 
Hs.74647 NS NS NS 6 
IGHG1 Immunoglobulin heavy 
constant gamma 1 
(G1m marker) 
Hs.510635 NS NS NS 7 
GFRA3 GDNF family receptor 
alpha 3 
Hs.58042 NS NS NS 8 
FGFBP2 Fibroblast growth 
factor binding protein 2 
Hs.98785 NS NS NS 9 
FOXRED1 FAD-dependent 
oxidoreductase domain 
containing 1 
Hs.317190 NS NS NS 10 
INSIG1 Insulin induced gene 1 Hs.520819 NS NS NS 11 
SH3BP5 SH3-domain binding 
protein 5 (BTK-
associated) 
Hs.654642 NS NS NS 12 
PBEF1 Pre-B-cell colony 
enhancing factor 1 
Hs.489615 NS NS NS 14 
ZNF182 Zinc finger protein 182 Hs.189690 NS NS NS 15 
FOLH1 Folate hydrolase 
(prostate-specific 
membrane antigen) 1 
Hs.654487 NS NS NS 16 
 
NS: Not Significant (false discovery rate higher than 5%) 
*The numbers indicate the ranking of genes based on fold change (1 being the most 
responsive gene at a particular dose and time-point); prepared by Dr Alan Mackay. 
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unlike the blood leukocytes, are actively cycling and dividing, and seven out of the 
twenty highest ranked down-regulated genes in T-lymphocytes after IR exposure have 
cell division associated functions (e.g. BUB1, CCNA1, KIF23, NCAPG, PRC1, CENPE, 
KIF14, Table 12B).  
Among the IR-responsive genes identified by the microarray experiment, there 
are some in which the response is specific to blood leukocytes (e.g. PCNA, Table 12C) 
or T-lymphocytes (e.g ATF3, PRC1 Table 12A and B), however ten genes are 
consistently up-regulated in at least one dose or time-point in blood and lymphocytes, 
in all donors and in three independent experiments: GADD45A, CDKN1A, SESN1, 
CCNG1, FAS, FBXW2, RBM15, PPM1D, RPS27L and BLOC1S2 (Table 12A and C) 
suggesting that these genes play a role in general, cellular response to IR exposure. The 
highlighted genes play a role in cell cycle progression (GADD45A, CDKN1A, CCNG1, 
PPM1D, RPS27L), apoptosis (FAS), oxidative stress response (SESN1), proteolysis 
(FBXW2), proliferation (BLOC1S2) and regulation of haematopoiesis (RBM15). 
There are genes which seem to be particularly good IR exposure biomarkers in 
stimulated T-lymphocytes (ATF3) or in blood (PCNA). ATF3 is a stress response gene 
and a direct target of TP53, it plays a role in proliferation, oncogenesis, DNA damage 
response and apoptosis (Taketani et al., 2012). PCNA is involved in DNA replication, 
repair, chromosome segregation chromatin structure maintenance and cell cycle 
progression (Stoimenov and Helleday, 2009). Crucially for biological dosimetry 
purposes, both genes are significantly up-regulated in all donors at all doses and time-
points (Figure 24).  
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3.2.3. Validation of IR-responsive genes identified by microarray by 
qPCR 
We performed qPCR experiments on the same samples to validate microarray 
results for four genes (GADD45A, CDKN1A, PRC1 and SESN1). All four genes were 
confirmed to be IR-responsive and displayed similar alteration in expression pattern 
following IR exposure when tested by both techniques (Figure 25). However, it should 
be mentioned that several promising genes identified in other studies like BBC3, 
MDM2, DDB2 or CCNB1 were not identified by the present microarray experiment. 
Nonetheless, we confirmed by qPCR that BBC3 and MDM2 genes were significantly up-
regulated in blood and T-lymphocytes, for all donors used in this study and at all doses 
and time-points (Figure 26A and B respectively). Moreover, BBC3 gene showed dose-
dependent up-regulation in T-lymphocytes assessed 2 h post exposure. The probe for 
another candidate gene, FDXR, which was previously identified as radiation responsive 
(Paul and Amundson, 2008), was not present on the array and therefore could not be 
detected. The qPCR analysis revealed that this gene was highly up-regulated in a dose-
dependent manner in blood at 24 h post exposure (Figure 26C), making it particularly 
promising for biodosimetry purposes.  
Independently, we were also interested in the individual response to IR 
exposure.  In order to investigate the significance of the differences in transcriptional 
response between the three donors we performed statistical analysis using the 
General Linear Model (GLM) as described in chapter 2.11. GLM analysis of variance 
allows estimation of the relative statistical significance of each parameter (in this case: 
sample type, donor, repeat, dose or time), taking into account the errors associated 
with them.  
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Figure 25. Validation of microarray data by qPCR for four selected genes.  
Comparison of microarray (left panel) and qPCR (right panel) gene expression data in 
T-lymphocytes (top panel) and blood (bottom panel) for four genes: GADD45A (A), 
CDKN1A (B), PRC1 (C) and SESN1 (D) and three donors (1, 2 and 3). For microarray log2 
ratios of each gene are plotted for each donor after 2 h and 24 h in response to either 
2 Gy or 4 Gy of X-ray. Data are presented for one of the three replicate experiments. 
For qPCR the fold change relative to non-irradiated control and normalised to the 
HPRT1 reference gene are presented. The mean of three independent experiments 
with triplicate reactions is presented. Data for donor 1 are presented in blue, in green 
for donor 2 and in red for donor 3. Error bars indicate the standard error of the mean 
for three independent experiments. 
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Figure 26. Up-regulation in stimulated lymphocytes and blood of three genes BBC3 
(A), MDM2 (B) and FDXR (C) not identified by microarray.  
Fold changes in expression assessed by qPCR compared to non-irradiated controls and 
normalised to the HPRT1 reference gene of each gene are plotted for each donor after 
2 h and 24 h in response to either 2 Gy or 4 Gy irradiations. The mean of three 
independent experiments with triplicate reactions are presented, error bars represent 
the standard error of the mean for three independent experiments 
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Gene expression data are not normally distributed (Bengtsson et al., 2005), 
(Figure 27A), therefore in order to obtain normally distributed data to perform GLM 
analysis we log-transformed the fold change values (Figure 27B). We used the log-
transformed fold change values for nine genes the expression of which was measured 
by qPCR (PLK3, PRC1, CDKN1A, GADD45A, SESN1, ATF3, PUMA, FDXR and MDM2) for 
GLM analysis.  The p-values associated with every parameter are presented in Table 
13. The gene expression pattern was significantly different in blood and T-lymphocytes 
for all genes except for PRC1 (p<0.001). The transcriptional response of five genes 
(PCR1, CDKN1A, ATF3, BBC3 and FDXR) measured 2 h post irradiation was significantly 
different than when measured 24 h post exposure suggesting time-dependant 
expression changes after IR exposure. There were significant differences in CDKN1A 
expression between three independent experiments (p=0.031). Interestingly, only one 
gene – FDXR showed significant differences in expression post IR exposure between 
three donors (p=0.007) which might be due to genetic influence. We also observed a 
trend of donor dependence in gene expression response to IR – i.e. when a donor 
displayed the highest transcriptional response to IR in T-lymphocytes it usually also 
showed the highest response in blood (Figure 28), again suggesting the influence of 
genetic factors. 
3.2.4. Discussion 
RNA microarray experiments are very useful for identification of responsive 
transcripts and have been successfully used for the discovery of radiation exposure 
biomarkers (Amundson SA, 2004, Gruel et al., 2008, Meadows et al., 2008, Paul et al., 
2011). Here, we used microarray profiling to identify genes, the expression of which is 
modified by IR in human blood leukocytes and stimulated T-lymphocytes. We found a  
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Figure 27. Normal probability plot for GADD45A gene.  
Normal probability plot was created in Minitab, the software also performs Anderson-
Darling normality test and provides associated p-value. A. Fold changes for GADD45A 
gene obtained in qPCR analysis were used, data shows significant deviation from 
normal distribution (p<0.005). B. Log-transformed fold change values for the same 
gene show normal distribution (p=0.856) 
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Table 13. p-values associated with GLM 
 
PLK3 PRC1 CDKN1A GADD45A SESN1 ATF3 BBC3 FDXR MDM2 
Sample type 
(blood, T-
lymphocytes) 
<0.001 0.157 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Experiment  
(1, 2, 3) 
0.159 0.260 0.031 0.464 0.649 0.168 0.954 0.618 0.902 
Donor  
(1, 2, 3) 
0.399 0.691 0.407 0.362 0.347 0.470 0.113 0.007 0.265 
Dose  
(2 Gy, 4 Gy) 
0.499 0.303 0.456 0.476 0.983 0.069 0.170 0.101 0.445 
Time 
 ( 2 h, 24 h) 
0.200 0.024 0.003 0.153 0.630 <0.001 <0.001 0.001 0.711 
Significant differences are shown in bold 
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Figure 28. Individual transcriptional responses to radiation exposure. 
Gene expression changes 24 h after 4 Gy of X-ray in three donors for four radiation 
responsive genes: GADD45A (A), ATF3 (B), BBC3 (C) and PLK3 (D) were measured by 
qPCR; error bars indicate standard error of the mean for three independent 
experiments. 
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number of transcripts which expression was either up- or down-regulated in response 
to IR exposure in vitro. While some of the identified genes were specific to blood  
(PCNA) or T-lymphocytes (ATF3) (Table 12), ten genes (GADD45A, CDKN1A, SESN1, 
CCNG1, FAS, FBXW2, RBM15, PPM1D, RPS27L and BLOC1S2) were consistently up-
regulated by at least one dose in blood and lymphocytes and in all donors, indicating 
that these genes may play a role in general response to IR (Figure 24).  
Interestingly, several promising candidates identified by others, like BBC3, 
DDB2, MDM2 or CCNB1 were not detected by the microarray experiment, either 
because no significant difference was found or because they were not represented on 
the array (e.g. FDXR). Three such transcripts (BBC3, MDM2 and FDXR) were confirmed 
by qPCR assays to be highly responsive to IR (Figure 26). Microarrays are a powerful 
technique to provide an overview of expression of thousands of transcripts at the 
same time, however, at least in our hands, it lacks the sensitivity of qPCR. Moreover, 
microarray results have been reported to be affected by the statistical methods used 
for analysis (Albanese et al., 2007); this would therefore influence the level of 
significance for the gene expression changes characterised as radiation responsive. 
This is, to our knowledge, the first time that a comparison of the transcriptional 
response to IR in cell subpopulations obtained from the same donor has been made 
using resting blood leukocytes and stimulated cycling T-lymphocytes. Blood leukocytes 
are composed of different cell types such as lymphocytes, monocytes and neutrophils 
each of which have specific gene expression patterns and differ in response to IR 
exposure (Mori et al., 2005, Gruel et al., 2008). Undoubtedly, some of the genes 
differentially expressed between blood and lymphocytes can be attributed to the cell 
type specific response to IR; however, a large proportion of the twenty most down-
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regulated genes in cycling T-lymphocytes are associated with cell division (BUB1, 
CCNA1, KIF23, NCAPG, PRC1, CENPE, KIF14, Table 12B) which is the main reason for 
the differences in the responsive genes observed between both cell populations. These 
genes are poor candidates for biodosimetry purposes as they are not responsive in 
blood; however, the down-regulation of these genes by IR exposure is still very 
interesting and can have important consequences. For example, Carter et al have 
reported gene expression profile signatures of chromosomal instability which predicts 
clinical outcome in multiple human cancers (Carter et al., 2006) and remarkably, 
eleven out of the 25 genes from their classifier are significantly down-regulated after 
IR-exposure in our stimulated T-lymphocyte samples. The modification of expression of 
these genes can therefore provide information which could not be obtained using 
blood as source of material. 
Also, it is worth noting, that gene expression can also be useful for 
identification of individuals sensitive to IR or those predisposed to severe normal 
tissue reactions after radiotherapy. For example, we have reported that in breast 
cancer radiotherapy patients expression of CDKN1A in stimulated T-lymphocytes after 
IR exposure was significantly lower in patients with severe acute skin reactions than in 
patients with minimal skin reaction (Badie C, 2008). We have also shown that an 
individual with AT disorder, characterised by extreme sensitivity to IR exposure, has 
significantly lower post irradiation induction of direct TP53 target genes like BBC3 
(Kabacik et al., 2011b). 
A good candidate gene for biodosimetry purposes should show relatively little 
intra- and inter-individual variation. We adopted GLM analysis to investigate this issue. 
The sample type (blood leucocytes or stimulated T-lymphocytes) most significantly 
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influenced gene expression results as eight out of nine investigated genes showed p-
values of less than 0.001 (Table 13). Five genes (PRC1, CDKN1A, ATF3, BBC3 and FDXR) 
showed significantly different transcriptional responses to IR exposure when assessed 
at the early time-point (2 h post irradiation) than when assessed at 24 h post exposure 
indicating that some genes may be better for dose assessment at early time-points 
whereas others may be more suitable for later dosimetry, what is in agreement with 
previous reports (Manning et al., 2013, Paul et al., 2013). We did not observe any 
significant differences between the two doses of radiation used which is surprising, 
however this can be at least partially explained by the shape of dose response curve in 
blood irradiated ex-vivo. We have shown previously that for the majority of the 
investigated genes, the dose-response in blood collected 24 h post exposure was best 
fitted by the quadratic function and reached a plateau around 2 Gy, making 
distinguishing between higher doses very difficult (Manning et al., 2013).  
Only the CDKN1A gene showed significant differences in expression in three 
independent experiments suggesting high intra-individual variability, that suggest that 
CDKN1A transcriptional response to IR exposure may be influenced by other factors 
and makes it a poor candidate for biological dosimetry purposes. In contrast, the FDXR 
gene, showed significant differences in expression between three donors indicating 
high inter-individual variation, although taking into account the small number of 
individuals a bigger experiment is needed to confirm this finding. Overall, we have 
shown that gene expression responses to IR can be a valuable source of information 
for many aspects of radiation biology including individual radiosensitivity and biological 
dosimetry. 
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3.3. Investigation of transcriptome response to 
IR exposure 
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3.3.1. Introduction 
There have been many attempts to use gene expression endpoints as 
biomarkers of IR exposure (Amundson SA, 2004, Gruel et al., 2006, Gruel et al., 2008, 
Templin et al., 2011a, Kabacik et al., 2011a, Manning et al., 2013) or sensitivity (Badie 
C, 2008, Kabacik et al., 2011b). Although gene expression assays offer significant 
advantages in terms of speed and throughput they have so far been less precise in 
dose estimation than classical cytogenetics assays (Badie et al., 2013, Rothkamm et al., 
2013). In order to improve dose prediction accuracy it is essential to learn more about 
transcriptional changes occurring following radiation. The detailed temporal and dose 
response characteristics of candidate transcripts have to be known. As we have shown 
recently, for some genes, there is significant variability in the transcriptional response 
to IR within the healthy population (Manning et al., 2013). There are also individuals in 
the population who show abnormal radiosensitivity like Ataxia-Telangiectasia (AT) or 
Nijmegen breakage syndrome patients. AT is an autosomal, recessive disorder and 
while cases are very rare the estimated frequency of heterozygous carriers is around 
0.5 % in the UK (Taylor and Byrd, 2005). It has been reported that AT heterozygous 
carriers have increased cancer risk and cellular experiments have revealed increased 
sensitivity to IR (Watts et al., 2002).  
A growing body of evidence suggests that the majority of the mammalian 
genome is actively transcribed but only about 2% of the transcriptome encodes for 
proteins (Okazaki et al., 2002, Carninci et al., 2005, Djebali et al., 2012). The “dark 
matter” of the genome consists of non-coding RNAs. There are several groups of non-
coding RNAs: well-known tRNAs and rRNAs, small nucleolar and nuclear RNAs 
implicated in various steps of RNA processing, miRNAs which are posttranscriptional 
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regulators of gene expression, piRNA involved in the epigenetic silencing of 
transposons in germ lines and finally a large group of long non-coding RNA (lncRNA) 
the function of which is just starting to be uncovered. Gene expression changes after 
exposure to IR are well documented (Kabacik et al., 2011a, Manning et al., 2013) and 
also numerous miRNAs the expression of which is altered following IR exposure have 
been reported (Templin et al., 2011a, Templin et al., 2012), (Sokolov et al., 2012). By 
contrast, there are only about two dozen lncRNAs for which it is reported that 
expression is modified after treatment with radiomimetic drugs. Examples of such 
responsive lncRNAs include TP53TG1 (Takei et al., 1998), Trp53cor1 (Huarte et al., 
2010), PANDAR (Hung et al., 2011). So far only four IR-responsive lncRNAs have been 
reported: lncRNA-CCND1 (Wang et al., 2008, Ozgur et al., 2013), CDKN2B-AS1 (Ozgur et 
al., 2013), GAS5 (Ozgur et al., 2013) and SOX2-OT (Chaudhry, 2013). 
In this part of the project, we investigated temporal and dose-dependent 
changes in the expression of several radiation responsive protein coding genes 
identified in the previous chapter and by literature search. This was done in stimulated 
human T-lymphocytes derived from two healthy donors and one AT patient. We also 
studied the possibility of employing lncRNAs and miRNAs as biomarkers of IR exposure. 
The majority of the results presented in this chapter have been published (Kabacik et 
al., 2015). 
3.3.2. Temporal transcriptome response to IR in human T-
lymphocytes 
The temporal, transcriptiome response to ionising radiation was assessed in 
stimulated T-lymphocytes obtained from two healthy donors (C1 and C2) and from one 
AT patient (AT). The cells were exposed to a sham dose or 2 Gy of X-ray and collected 
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at various time-points ranging from 15 min up to 24 h post exposure. From 13 assays 
designed for human protein coding genes (Table 3) we selected ten, which gave the 
greatest response to IR in the stimulated T-lymphocytes – CDKN1A, SESN1, ATF3, 
MDM2, CCNB1, DDB2, FDXR, CCNG1, BBC3 and GADD45A. The results for mRNA 
expression are presented in Figure 29.  
The majority of genes investigated responded rapidly with the peak of 
expression around 2-3 h post exposure (CDKN1A, SESN1, ATF3, MDM2, BBC3 and 
GADD45A). Three genes: DDB2, FDXR and CCNG1 responded with slower kinetics 
reaching the peak of expression between 5 and 24 h in the time range tested. 
Expression of CCNB1 decreased rapidly following IR exposure but increased 24 h post 
irradiation. For all the genes studied here, AT lymphocytes showed a lower and 
delayed response to IR than healthy donors at the early time-points, however 
differences disappeared at the 24 h time-point. 
We also investigated the lncRNA response to IR, however there was very 
limited literature published on lncRNA and IR; we therefore selected two lncRNAs the 
expression of which was reported to be altered by radiomimetic drugs treatment: 
TP53TG1 (Takei et al., 1998) and PANDAR (Hung et al., 2011) as well as FAS antisense 
RNA 1 (FAS-AS1) which is transcribed in anti-sense orientation to FAS gene (Yan et al., 
2005) - a well-known, IR-responsive transcript (Manning et al., 2013).  
The lncRNA temporal response data is presented in Figure 30. While PANDAR 
showed no alteration of expression after IR exposure in the range of time points 
studied, TP53TG1 demonstrated a radiation-responsive expression profile similar to 
CCNG1 with a time dependant increase in expression, however, the up-regulation 
stayed relatively low (maximum of 1.5 times at 24 h). In contrast, FAS-AS1 was  
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Figure 29. Temporal expression pattern of protein coding genes after exposure to IR 
T-lymphocytes from two healthy donors (C1 – black diamonds and C2 – black squares) and one AT 
patient (AT – empty circles) were exposed to a sham dose or 2Gy of X-ray and collected at various time-
points ranging from 15 min up to 24 h. The expression level of genes of interest CDKN1A (A), SESN1 (B), 
ATF3 (C), MDM2 (D), CCNB1 (E), DDB2 (F), FDXR (G), CCNG1 (H), BBC3 (I) and GADD45A (J) was 
normalised to the HPRT1 reference gene first, then the radiation-induced fold change in expression was 
calculated relative to non-irradiated control. Error bars represent ± one standard deviation from three 
independent experiments.  
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Figure 30. Temporal expression pattern of three lncRNAs after exposure to IR 
T-lymphocytes from two healthy donors (C1 – black diamonds and C2 – black squares) and one AT 
patient (AT – empty circles) were exposed to a sham dose or 2Gy of X-ray and collected at various 
time-points ranging from 15 min up to 24 h. Expression levels of three lncRNAs: PANDAR (A), 
TP53TG1 (B) and FAS-AS1 (C) were normalised to the HPRT1 reference gene first, then fold change 
was calculated relative to non-irradiated control. Error bars represent ± one standard deviation 
from three independent experiments.  
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up-regulated by up to 5 fold by IR and showed two peaks of expression: one early peak 
at 1.5 h and a later one around 6 h post exposure. Similarly to expression of protein 
coding genes, the FAS-AS1 up-regulation in AT lymphocytes, was delayed compared to 
healthy controls, however the differences disappeared as early as 3 h following 
irradiation. 
Next, we studied miRNA response to IR exposure. We investigated the 
expression of 19 miRNAs which had been highlighted in the literature as radiation 
responsive or were reported to be involved in the DDR network: let-7a-5p, let-7b-5p, 
let-7g-5p, miR-15a-5p, miR-16-5p, miR-19b-3p, miR-21-5p, miR-27a-3p, miR-32-5p, 
miR-34a-5p, miR-106b-5p, miR-107, miR-125b-5p, miR-150-5p, miR-182-5p, miR-185-
5p, miR-192-5p, miR-195-5p and miR-215-5p (Figure 31). In our experimental setup, 
only miR-34a-5p and miR-182-5p showed a significant modification of expression after 
IR exposure (Figure 32A and B respectively). The up-regulation occurred at late time-
points reaching a few fold at 24 h but no difference in response to IR between controls 
and AT lymphocytes could be detected. Interestingly, we noticed that the endogenous 
level of let-7b-5p in non-irradiated samples was very different for each donor (Figure 
33A) with the AT lymphocytes showing the lowest let-7b-5p expression; differences 
between donors are highly significant as measured by two-tailed t-test (Figure 33B). 
let-7b-5p was the only miRNA in our panel which showed such differences in 
endogenous level. 
3.3.3. Transcriptome dose-response to ionising radiation 
The dose-response in three donors was investigated for three genes presenting 
different temporal profiles: CDKN1A, FDXR and CCNB1. The cells were exposed to a 
series of doses ranging from 0.1 Gy up to 5 Gy and collected 2 h and 24 h post 
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Figure 31. Temporal expression pattern of two miRNAs after exposure to IR in 
stimulated T-lymphocytes 
Heatmap representing time course expression profiles from 19 miRNAs in averaged C1 
and C2 samples after 2 Gy irradiation treatment in vitro: let-7a-5p, let-7b-5p, let-7g-5p, 
miR-15a-5p, miR-16-5p, miR-19b-3p, miR-21-5p, miR-27a-3p, miR-32-5p, miR-34a-5p, 
miR-106b-5p, miR-107, miR-125b-5p, miR-150-5p, miR-182-5p, miR-185-5p, miR-192-
5p, miR-195-5p and miR-215-5p. Expression level of miRNAs was normalised to 
SNORD44 and SNORA73A small RNA expression first, then fold change was calculated 
relative to non-irradiated control. The arbitrary scale is used to show up-regulated 
miRNAs (red) and down-regulated (blue) relative to untreated control.  
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Figure 32. Temporal expression pattern of two IR-responsive miRNAs  
Expression level of two miRNAs: miR-34a-5p (A) and miR-182-5p (B) was normalised to 
SNORD44 and SNORA73A small RNA expression first, then the radiation-induced fold 
change in expression was calculated relative to non-irradiated control. Error bars 
represent ± one standard deviation from two independent experiments.  
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Figure 33. Endogenous level of let-7b-5p in the control samples. 
A. Endogenous level of let-7b-5p in the non-irradiated samples normalised to 
SNORD44 and SNORA73A small RNA expression; Error bars represent ± one standard 
deviation from two independent experiments. B. Mean of let-7b-5p expression level in 
the ten non-irradiated samples for three donors, error bars represent ± one standard 
deviation; three stars represent p<0.001 calculated by two-tailed t-test. 
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irradiation. The results of dose response experiment are presented in Figure 34. The 
shape of dose response curves was very different for samples collected at 2 h and 24 h. 
After 2 hours, the data points for C1 and C2 were best fitted by a logarithmic function 
with strong transcriptional response for low doses and up to 1 Gy then reaching a 
plateau phase at higher doses (2-5 Gy). The transcriptional response to IR was much 
weaker in AT than in C1 and C2 and interestingly, the data points for CDKN1A and 
FDXR were best fitted by the linear regression curve, not the logarithmic one as for C1 
and C2. The dose response for CCNB1 gene in the AT has similar shape as in controls, 
however, the magnification of the repression is much lower (Figure 34E). 
The dose responses for CDKN1A and FDXR obtained for samples collected 24 h 
post irradiation was linear and AT could not be distinguished from C1 and C2 at this 
time-point (Figure 34B and D respectively). The data points for CCNB1 gene better fit a 
quadratic function with a peak of up-regulation at approximately 3 Gy.  Again, the AT 
patient responded in the same way as healthy donors at 24 h (Figure 34F).  
We also investigated the dose response of two lncRNAs which showed 
modification of expression after IR exposure: TP53TG1 and FAS-AS1 (Figure 35). 
TP53TG1 lncRNA, as expected from temporal response data, showed no response to IR 
at 2 h time-point (Figure 35A); on the contrary the dose dependent fold of change at 
24 h time-point was linear and reached 3-fold after 5 Gy. Although expression in AT 
was slightly lower, no real differences between AT and controls could be seen (Figure 
35B). The FAS-AS1 transcript was radiation-responsive already at 2 hours post 
exposure and the data points for C1 and C2 were best fitted by power function 
whereas for AT it was obtained using the quadratic function. AT showed lower 
response than healthy donors which was especially evident at lower doses  
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Figure 34. Dose response of three protein coding genes. 
T-lymphocytes from two healthy donors (C1 – black diamonds and C2 – black squares) 
and one AT patient (AT – empty circles) were exposed to a series of X-ray doses 
ranging from 0.1 Gy up to 5 Gy. The expression levels of three genes CDKN1A, FDXR, 
CCNB1 were analysed 2 h (A, C and E respectively) and 24 h (B, D and F respectively) 
post irradiation. Expression levels for three genes were normalised to the HPRT1 
reference gene first, then the radiation induced fold change in expression was 
calculated relative to non-irradiated control. R2 values ale listed in the following order 
top –C1, middle – C2, bottom – AT.  Error bars represent ± one standard deviation 
from two   independent experiments. 
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Figure 35. Dose responses of two lncRNAs 
Expression level of two lncRNAs: TP53TG1 and FAS-AS1 after exposure to doses ranging from 
0.1 to 5 Gy of X-ray were analysed 2 h (A, C respectively) and 24 h (B, D respectively) post 
irradiation. Copy numbers were normalised to the HPRT1 reference gene first, then radiation-
induced fold change in expression was calculated relative to non-irradiated control. R2 values 
ale listed in the following order top –C1, middle – C2, bottom – AT. Error bars represent ± one 
standard deviation from two independent experiments.  
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(Figure 35C).At the 24 h time-point, similarly as for CCNB1 gene, data-points for all 
donors seemed to fit the best quadratic function regression with the maximum of up-
regulation for the highest dose tested (i.e. 5 Gy). 
We then studied the dose responses for the two miRNAs which showed 
alteration in their expression following IR exposure: miR-34a-5p and miR-182-5p; 
however, as the up-regulation was minor after 2 Gy and observed only at a late time-
point, with no differences between AT and controls, we limited the experiment to C1 
and C2 at the 24 h post exposure (Figure 36). Five doses ranging from 1 up to 5 Gy 
were studied and results showed a dose-dependent up-regulation for both miRNAs 
with differences between C1 and C2 becoming apparent for the higher doses. This was 
already clear at 2 Gy for miR-182-5p. Interestingly, the higher up-regulation 
(approximately 3 fold for both miRNA) with C2 cells reached a plateau-phase around 5 
Gy, while for C1, the up-regulation was at maximum around 3 Gy and then decreased 
in response to higher doses, hence showing clear differences in response between cells 
from different donors. Data were best fitted with the quadratic function linear 
regression 
Additionally, we have investigated transcriptional response of ten protein 
coding genes and two lncRNAs to low doses of IR. T-lymphocytes from C1 were 
exposed to a series of doses ranging from 5 mGy up to 100 mGy and collected 2 h and 
24 h post irradiation. From twelve transcripts tested, only 3 genes: MDM2, CDKN1A 
and SESN1 showed linear response to IR exposure (Figure 37). Expression levels for 
samples collected 2 h post irradiation were higher than samples collected 24 h. 
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Figure 36. Dose response of two miRNAs 
T-lymphocytes from two healthy donors (C1 – black diamonds and C2 – black squares) 
were exposed to five doses ranging from 1 Gy up to 5 Gy and collected 24 h post 
exposure. Expression levels of miR-34a-5p (A) and miR-182-5p (B) were normalised to 
SNORD44 and SNORA73A small RNA expression first, then radiation-induced fold 
change in expression was calculated relative to non-irradiated control. R2 values ale 
listed in the following order top – C1, bottom – C2.  Error bars represent ± one 
standard deviation from two independent experiments. 
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Figure 37. Low dose response of three protein coding genes. 
T-lymphocytes from healthy donors C1 were exposed to a series of doses ranging from 
5 mGy up to 100 mGy. Expression level of three genes MDM2 (A), CDKN1A (B), and 
SESN1 (C) was analysed 2 h (black diamonds) and 24 h (empty diamonds) post 
irradiation. Expression level for three genes was normalised to HPRT1 reference gene 
first, then radiation-induced fold change in expression was calculated relative to non-
irradiated control. R2 values obtained from linear regression fits are listed in the 
following order top – 2 h, bottom – 24 h.  Error bars represent ± one standard 
deviation from four independent experiments. 
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3.3.4. Discussion  
Gene expression signatures have proved to be useful for estimating the dose of 
radiation in vitro (Badie et al., 2013) and in vivo (Paul et al., 2011). Despite the fact that 
gene expression dose estimation is still less accurate and precise than the “gold 
standard” dicentric assay, it holds great potential due to the speed and high 
capacity(Rothkamm et al., 2013). Better understanding the transcriptional response to 
IR is essential in order to identify specific and sensitive transcriptional biomarkers of IR 
exposure and improve the accuracy of gene expression based biodosimetry. Here, we 
investigated transcriptional temporal and dose-response of stimulated T-lymphocytes 
from two healthy donors and one A-T patient in order to better understand how cells 
respond to IR insult. 
We have decided to use stimulated T-lymphocytes because obtaining blood 
samples, particularly from AT patients was impossible for us as the disease is very rare. 
By using stimulated T-lymphocytes we were able to culture the cells to obtain 
sufficient material for all our experiments. Due to the large number of cells from the 
same donors required for dose-responses as well as time course experiments, we 
believe the use of stimulated lymphocytes was the only realistic choice. 
Moreover, in the previous chapter we have shown that, although there are 
differences between blood and simulated T-lymphocytes obtained from the same 
individual in terms of genes, the expression of which is modified in response to 
radiation, they mostly relate to cell cycle such as cyclins A and B, PRC1, BUB1, CDC25C, 
MAD2L1 or CENPE. On the contrary most genes up-regulated following IR exposure 
(e.g. SESN1, GADD45A, CCNG1, RBM15, CDKN1A, FAS, PPM1D, BLOC1S2) were up-
regulated in all donors in both blood and T-lymphocytes indicating that those genes 
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represent universal response to IR (Kabacik et al., 2011a). Our previous results suggest 
that stimulated human T-lymphocytes can be used as a model for studying IR 
responsive genes for biodosimetry purposes. 
In order to study the temporal response to IR, human T-lymphocytes were 
collected at various time-points ranging from 15 min to 24 h post exposure. The 
majority of protein coding genes responded to IR very rapidly, with detectable 
modulation of expression as early as 30 min post exposure for GADD45A, CDKN1A and 
ATF3 genes (Figure 29). The rapidly responding genes play a role in cell cycle 
progression (CDKN1A, CCNB1, CCNG1, GADD45A, SESN1), apoptosis (PUMA, FDXR, 
GADD45A, CDKN1A), oxidative stress response (SESN1, FDXR) and TP53 stabilisation 
(ATF3, MDM2, CCNG1). It is not surprising that these genes are early responders, as 
many participate in processes essential for maintaining genome stability after DNA 
damage. 
Recently, Melanson et al have reported that an overwhelming majority of 
transcripts involved in DDR and regulated by TP53 including CDKN1A, SESN1, ATF3 and 
MDM2 are unstable with a half-life shorter than 2h, and that their short half-life is due 
to presence of destabilising sequences in their 3’ UTR (Melanson et al., 2011). The 
rapid turnover of TP53 regulated genes ensures plasticity of the DDR system and has 
one important implication for our results – the fluctuations in short lived mRNA level 
we observed in the time-course experiment, are caused by mRNA synthesis activity as 
the mRNA degradation rate seems to be fast and constant. This emphasises the 
importance of performing gene expression biodosimetry at a precise time-point post IR 
exposure, when the dose response shape for a particular transcript is known. 
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It is worth noting that Melanson et al placed FDXR mRNA in a stable transcript 
cluster with a half-life of 4-6 h, which explains the constant increase of the FDXR mRNA 
we observed – the mRNA is synthesised but not degraded rapidly. One could speculate 
that the FDXR transcript number should be less sensitive to variation with time after 
irradiation than the fast degraded genes.  
We were also interested in transcriptional alterations in non-coding RNA 
expression caused by IR exposure. Non-coding RNAs significantly outnumber protein 
coding genes, their expression is very often tissue specific and they are just emerging 
as potential biomarkers (Sorensen et al., 2013, Pescador et al., 2013). We looked at the 
expression of three lncRNAs and 19 miRNAs selected from literature. One lncRNA – 
PANDAR, showed no changes in expression after IR exposure (Figure 30A) despite the 
fact that it has been previously reported as being up-regulated after DNA damage. 
Interestingly, recently Özgür et al reported no change in PANDAR expression in HeLa 
and MCF-7 cells following IR or bleomycin treatment (Ozgur et al., 2013). PANDAR is a 
direct TP53 target and in parallel with CDKN1A it promotes cell cycle arrest by 
repressing pro-apoptosis genes after DNA damage through the NF-YA transcription 
factor (Hung et al., 2011). The up-regulation of PANDAR following doxorubicin 
treatment was reported in human primary foreskin fibroblasts which enter cell cycle 
arrest after DNA damage but not apoptosis and PANDAR has been implicated in 
supporting this response. In contrast, DNA damage induces a strong apoptotic 
response in human T-lymphocytes, so it may be an evolutionary conserved, tissue 
specific pattern of expression.  
The second lncRNA investigated – TP53TG1 showed a slight up-regulation 
following IR exposure at the late time-point (Figure 30A) which is dose dependant at 
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24 h following irradiation (Figure 35B). TP53TG1 is also a direct target of TP53 and it 
has been reported to be responsive to DNA damage in the human SW480 colon cancer 
cell line and normal human dermal fibroblasts (Takei et al., 1998); again the very 
modest response to IR in human T-lymphocytes can be attributed to tissue specific 
differences.  
The third lncRNA investigated – FAS-AS1 was rapidly up-regulated by IR 
exposure in T-lymphocytes derived from two healthy donors reaching first peak of 
expression 1.5 h and second between 5 and 6 h post exposure. FAS-AS1 has been 
identified by Yan et al (Yan et al., 2005)  as an antisense transcript of the FAS gene and 
the authors proposed that it might protect T-lymphocytes from FAS-mediated 
apoptosis. It is very interesting to see pro- and anti-apoptotic genes being up-regulated 
at the same time in a very similar manner. To our knowledge, this is the first report of 
FAS-AS1 being up-regulated by IR, but we believe that there are other radiation-
responsive lncRNAs awaiting discovery.  
For both protein coding genes and responsive lncRNAs, AT lymphocytes 
consistently showed a lower and delayed response to IR than lymphocytes obtained 
from healthy donors at the early time-points; however, the difference disappeared at 
24 h time-point. We observed that activation of ATM downstream targets has been 
delayed and impaired but not abrogated (Figure 29 andFigure 34) and this observation 
is in agreement with previous reports e.g. (Canman et al., 1994), but it also suggests 
that in the absence of ATM, some other kinases can activate ATM downstream targets 
but they seem to be less efficient. Over 14 year ago, Tibbetts et al suggested that 
another kinase – ATR can be responsible for this action (Tibbetts et al., 1999) and 
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subsequent reports seem to support this hypothesis (Jazayeri et al., 2006, Myers and 
Cortez, 2006).  
From the 19 radiation-responsive miRNAs identified from the literature only 
two demonstrated modulation of expression after IR exposure in our experimental 
setup: miR-34a-5p and miR-182-5p. The most probable explanation for this 
discrepancy is the fact that every study seems to employ a different experimental 
model and that there are considerable differences in miRNA expression between 
tissues and miRNA response to IR seems to be tissue dependent (Table 1). Moreover, 
the majority of the miRNA research is performed using microarrays, however, at least 
in our hands, it is not the most reliable technique for miRNA detection (own 
unpublished observation).  
The IR-responsive miR-34a-5p is a direct target of TP53 and it exhibits strong 
pro-apoptotic and anti-proliferating properties (He et al., 2007). miR-182-5p is 
considered to have dual properties as an oncogene and tumour suppressor depending 
on the cellular context. It targets many genes positively regulating DDR but also cyclin-
dependent kinase 6 (CDK6) which can phosphorylate retinoblastoma 1 protein and 
consequently promote cell cycle progression (Krishnan et al., 2013). Both miRNAs were 
up-regulated at the late time-point and we could not detect any differences between 
healthy controls and the AT. Interestingly, when we looked at miRNA level in the non-
irradiated samples, we noticed that the endogenous level of let-7b-5p is significantly 
higher in healthy controls that in the AT. The let-7 miRNA family is considered to act as 
tumour suppressors because they target genes positively regulating cell proliferation 
such as Kirsten rat sarcoma viral oncogene homolog (KRAS), cyclin D1 (CCND1), v-myc 
avian myelocytomatosis viral oncogene homolog (MYC) or CDC25A, their deletion is 
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associated with cancer and their overexpression inhibits cancer cell proliferation and 
sensitises them to radiation (Johnson et al., 2007). miRNAs belonging to let-7 family 
were reported to be down-regulated after IR exposure in primary fibroblasts and 
human colon cancer cell line HCT116 (Saleh et al., 2011). Mi et al showed that let7b 
expression is lower in acute lymphoblastic leukaemia (ALL) patients than in acute 
myeloid leukaemia (AML) and healthy controls (Mi et al., 2007). Interestingly, ALL is 
the most common cancer in AT patients and it is usually of T-cell origin in contrast to 
ALL in the general population (Reiman et al., 2011). Unfortunately, we have no 
information related to the AT patient from whom the lymphocytes were obtained and 
it is unknown if this person was diagnosed with ALL, therefore we could not conclude if 
lower let-7b level was an underlying cause of ALL or a marker of existing cancer, 
nonetheless, it seems to be an exciting possibility. 
The transcriptional response of CDKN1A and FDXR to IR at the 2 h time-point in 
healthy donors reached a plateau at around 2 Gy. The AT showed a constant and linear 
up-regulation of the transcripts which was still lower than in controls even after a dose 
of 5 Gy (Figure 34A and C). However, at 24 h post exposure, the dose-response is linear 
and AT cannot be distinguished from healthy donors (Figure 34B and D). CCNB1 
expression in the C1/C2 controls is significantly repressed by doses as low as 0.4 Gy 2 h 
following exposure and the repression reaches a plateau around a dose of 3 Gy 
whereas the AT sample does not significantly repress CCNB1 for exposures as high as 2 
Gy (Figure 34E). At the 24 h time-point all donors present the same dose response 
shape which is best described by quadratic function, indicating that the higher the 
dose of radiation used, the longer time the cells require to recover and resume cell 
cycle (Figure 34F). CCNB1 is a main cyclin active during G2/M phase of the cell cycle 
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and together with cyclin-dependent kinase 1 (CDK1) form maturation-promoting factor 
which is necessary for entry into mitosis, therefore CCNB1 expression is under tight 
control as entering mitosis with unrepaired DNA damage can have significant 
consequences for cells (Yu et al., 2002).  
From the two lncRNAs for which the dose-response was assessed, only 
TP53TG1 seems to be suitable for biodosimetry purposes as, although its expression 
was not modified by IR 2 h post irradiation, a linear dose-response to IR 24 h post 
exposure was seen for all three donor cells (Figure 35). FAS-AS1 transcriptional up-
regulation reached a plateau at around 1 Gy 2 h post irradiation, but after 24 h the 
dose-response was not linear but best described by quadratic function.  
The dose response for the two IR-responsive miRNAs was also not linear but 
described by quadratic function, similar to the CCNB1 gene (Figure 36). However, the 
overall miRNA expression pattern in blood is probably different. Recently there has 
been much interest in exosomes, which are nanosize vesicles secreted by all cells into 
extracellular space and body fluids. It is believed that exosomes serve as a form of 
communication between distant cells in the body and they can contain proteins, lipids, 
miRNAs and some regulatory mRNAs (reviewed in (Zhang and Grizzle, 2014). It is very 
likely that after in vivo irradiation the blood will contain other IR-responsive miRNAs 
secreted in a form of exosomes coming from different types of cells, and some of these 
miRNAs may be better suited for biodosimetry purposes. Very recently, Jacob and 
colleagues identified miR-150 as a sensitive biomarker of in vivo exposure in mouse 
serum (Jacob et al., 2013).  
Low doses of radiation are increasingly being used in diagnostics, however, 
there is still a lot of uncertainty regarding health effects of low dose exposure 
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(extensively reviewed in (Morgan and Bair, 2013)). We were interested in the 
transcriptional response of human T-lymphocytes to low doses of radiation. T-
lymphocytes obtained from one healthy donor were exposed to a range of doses from 
5 mGy to 100 mGy and the cells were collected 2 and 24 h following exposure. Three 
out of twelve tested transcripts (MDM2, CDKN1A and SESN1) showed linear response 
to IR at both time-points (Figure 37). Our data show that at the transcriptional level, 
cells can detect very low doses of radiation (20 mGy after 2 h for CDKN1A) and the 
three genes could be potentially used as biomarkers of low dose exposure.  
In summary, our data indicates that gene expression profiles at early time-
points can highlight individuals with AT deficiency and associated radiation sensitivity 
to IR. It would be very interesting to see gene expression profiles in T-lymphocytes 
obtained from AT carriers, as Watts et al showed that lymphoblastoid cells from AT 
carriers have an "expression phenotype” which was different than in lymphoblastoid 
cells obtained from healthy donors (Watts et al., 2002)we have previously 
demonstrated that monitoring expression of IR–responsive TP53 downstream targets 
can be used as a surrogate assay for assessing ATM/CHK2/TP53 pathway activity, in 
order to assess individual cancer risk when analysed at an early time point (i.e. 2 h) 
(Kabacik et al., 2011b). Our results also suggest that it is best to use 24 h time-point for 
biodosimetry purposes, as the dose responses tend to be linear and inter-individual 
differences in radiation sensitivity do not in general confound the response, since the 
expression profiles obtained from the AT patient characterised by extreme 
radiosesitivity cannot be distinguished from healthy donors.  
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3.4. Gene expression as a biomarker for 
radiation exposure 
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3.4.1. Introduction 
Gene expression biomarkers of radiation exposure hold great potential in terms 
of speed and throughput in the case of a mass screening scenario but assays utilising 
gene expression are still less accurate than the “gold standard” dicentric chromosome 
assay. In 2011 North Atlantic Treaty Organization (NATO) ran a biodosimetry exercise 
organised by Prof Michael Abend from Bundeswehr Institute of Radiobiology, (Munich, 
Germany), which aimed to compare established (dicentric chromosome and CBMN) 
and emerging (γ-H2AX foci and gene expression) biodosimetry assays for radiation 
injury assessment in a triage scenario (Rothkamm et al., 2013, Badie et al., 2013). We 
were one of the eight laboratories which participated in a gene expression assay 
comparison. The results of our work are presented in this chapter. 
It is vital to validate the potential gene expression biomarkers in vivo, however 
it is very difficult to obtain suitable samples. There are several publications 
investigating gene expression changes in humans undergoing radiotherapy (Amundson 
SA, 2004, Dressman et al., 2007, Meadows et al., 2008, Filiano et al., 2011), however, 
to our knowledge, there were only two reports published utilising gene expression 
changes to estimate the dose of radiation received by radiotherapy patients (Paul et 
al., 2011, Templin et al., 2011b). In both papers blood samples from patients 
undergoing total body irradiation before bone marrow transplant were used and all 
patients had previous radiotherapy and chemotherapy treatments which could 
potentially affect the transcriptional response to IR and confound the results. The 
results provided proof-of-principle that the dose can be predicted following in vivo 
exposure. However in the case of a mass casualty scenario, the majority of exposed 
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individuals would most likely be partially exposed and part body exposures present a 
particular challenge for all biodosimetry methods. 
In this chapter we selected the most suitable gene for dose estimation and we 
validated it in vitro as well as in vivo, additionally we measured intra- and inter-
individual variation in its expression before and after irradiation in blood samples 
obtained from 32 healthy donors. It should be noted that for in vitro dose estimation 
collaborative nature of this project required using slightly different protocol that the 
one described in chapter 3.1, namely, blood was collected into heparin tubes and RNA 
was extracted by using Qiamp RNA Blood Mini kit. Additionally, in order to save time 
expression of only two genes was measured by qPCR. Part of the work presented in 
this chapter has been already published (Badie et al., 2013). 
3.4.2. Identification of the best gene for biodosimetry purposes 
The blood collection, irradiation and preparation of white blood cell pellets 
were performed in Prof Michael Abend’s laboratory as described in chapters 2.2.1.2, 
2.5.1.1 and 2.6.1.3. In the first part of the NATO study the blood sample was taken 
from one individual and was irradiated with known doses of radiation which was sent 
to all participating laboratories in order to prepare a calibration curve. We selected 
eight genes (GADD45A, CCNG1, BBC3, FDXR, CDKN1A, DDB2, PCNA and SESN1) 
identified in chapter 3.2 or in the literature (Manning et al., 2013), the expression of 
which was modified 24 h post IR exposure in blood. The expression of these genes was 
investigated for the samples used to prepare calibration curve provided by Prof 
Abend’s laboratory (Figure 38). 
The expression level among all eight genes was very diverse with 57 fold 
difference between the lowest expressed FDXR and the highest CCNG1 (0.05 and 3.04  
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Figure 38. Blood calibration curve expression of eight radiation-responsive genes. 
The expression of eight radiation-responsive genes was investigated in human blood 
samples irradiated ex-vivo with known doses of X-ray to produce a calibration curve. 
Endogenous levels for each gene were normalised to HPRT1 expression; black lines 
represent quadratic polynomial regression fits, red lines represent linear regression fits 
with corresponding R2 values.  
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relative to HPRT1 in the control sample respectively). The dose response curve for all 
tested genes was best fitted by a quadratic function, the linear regression fit being the 
second best. Amongst tested genes, FDXR expression demonstrated the highest R2 
value of all eight genes (R2=0.9933 with respect to the quadratic function fit), it also 
had the most linear response with R2=0.9769 (Figure 38). 
3.4.3. Assessment on inter- and intra-individual variability in 
transcriptional response to IR in blood samples 
A good biomarker should ideally display low inter- and intra-individual 
variability to allow precise dose estimation in different exposed individuals. In order to 
assess these parameters for our candidate gene, we took blood samples from 32 
healthy donors on three independent occasions. The blood samples were split in half 
and irradiated with either a sham dose or exposed to 2 Gy X-ray and collected 2 h post 
irradiation. We investigated the expression of FDXR and two other genes, CCNG1 and 
CDKN1A, which have been reported previously as displaying respectively low and high 
inter-individual variability (Manning et al., 2013), in control and irradiated samples.  
The intra-individual variation is presented as COV, (SD expressed as percentage 
of the mean) for three independent measurements for each donor (Table 14). In both, 
control and irradiated samples expression of the CCNG1 gene showed the smallest 
variation between three independent repeats, CDKN1A the highest variation and FDXR 
variation was intermediate. Donors displaying lower variability in CDKN1A expression 
in control samples tend to show lower variability in irradiated samples (Pearson 
product moment correlation coefficient r= 0.441, p=0.011); this may indicate influence 
of genetic factors. The inter-individual variation in expression of CCNG1, CDKN1A and 
FDXR is presented in Table 15. Expression of CCNG1 again showed the smallest  
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Table 14. Coefficient of variation in transcriptional response to IR exposure 
measured in three independent repeats 
 
Control Irradiated 
Donor CCNG1 CDKN1A FDXR CCNG1 CDKN1A FDXR 
H2 18 18 11 21 18 37 
H7 7 17 24 15 5 28 
H8 18 9 17 16 29 27 
H9 12 25 34 7 14 5 
H12 22 20 7 26 16 24 
H14 22 6 22 17 13 25 
H17 6 18 40 16 7 25 
H19 26 12 35 21 15 23 
H20 20 11 12 25 10 24 
H29 26 16 25 28 10 20 
H30 15 31 26 14 12 31 
H31 30 19 16 15 26 31 
H33 8 15 6 19 22 18 
H34 6 34 14 26 20 36 
H43 25 29 17 14 27 4 
H48 10 35 11 13 33 29 
H50 10 22 38 11 35 8 
H53 12 28 28 13 23 12 
H54 12 29 7 15 46 19 
H56 25 15 6 7 49 3 
H57 17 26 23 16 39 26 
H58 7 13 23 11 45 24 
H59 23 28 5 18 44 24 
H60 6 66 21 19 55 33 
H61 31 27 13 11 39 19 
H62 28 42 10 10 36 39 
H63 17 44 19 8 37 55 
H64 29 7 6 17 47 13 
H65 14 72 23 10 58 33 
H66 27 20 31 21 24 30 
H67 25 26 16 32 12 28 
H68 10 40 8 26 8 25 
Mean 17.64 25.61 18.54 16.83 27.35 24.31 
SD 8.05 14.99 10.03 6.39 15.32 10.88 
SD – standard deviation  
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Table 15. Inter-individual variation in transcriptional response to IR exposure 
represented and coefficient of variation measured in 32 healthy donors 
  Control Irradiated 
  Repeat 1 Repeat 2 Repeat 3 Repeat 1 Repeat 2 Repeat 3 
CCNG1 16.71 19.11 15.39 15.09 16.96 17.97 
CDKN1A 39.43 35.06 28.19 41.62 22.18 18.64 
FDXR 15.51 23.29 23.89 29.82 32.02 37.79 
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differences between 32 donors both before and after IR exposure as represented by 
low coefficients of variation. The inter-individual variation in CDKN1A expression was 
very variable with coefficients of variation ranging from 18.64 to 41.62 in the irradiated 
samples, which can be at least partially explained by high intra-individual variation 
(Table 14). Expression of the FDXR gene showed quite low inter-individual variation in 
the control samples (COV between 15.51 and 23.89), however it was much higher in 
irradiated samples (COV between 29.82 and 37.79) suggesting that there was more 
variability in the response to IR exposure between the donors than intrinsic variation. 
3.4.4. In vitro dose estimation 
In the second part of the NATO study, a blood sample was taken from the same 
donor used for preparation of calibration curve, irradiated with ten unknown doses 
and sent out to participants. The aim of this exercise was to (i) assess accuracy of dose 
prediction by gene expression, (ii) measure inter-laboratory variation in dose 
estimation, (iii) assess the time necessary to provide dose estimation. In order to save 
time during the reaction setup and data acquisition we focused on the most promising 
gene, FDXR.   
Unknown samples were received early morning and we performed RNA 
extraction, RT reaction and duplex qPCR with HPRT1 and FDXR only as described in 
chapters 2.6.1.3, 2.9.1 and 2.10.3 respectively. The calibration curve samples were 
measured by qPCR together with unknown samples in order to avoid run-to-run 
variation. Each sample had prepared a “-RT” control which did not contain reverse 
transcriptase enzyme in order to control for gDNA contamination. Three samples 
showed minor gDNA contamination, however the signal for gDNA was detected above 
35 Ct and at least 10 Cts away from the highest Ct in the samples, therefore it did not 
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influence the results. The whole procedure from receiving the samples until providing 
dose estimates took just below 8 h. We were the first, along with a group utilising non-
enzymatic Chemical Ligation Dependent Probe Amplification methodology, to deliver 
the results amongst all participating laboratories (Table 1 extended in (Badie et al., 
2013)). The time needed for reporting the results was comparable to that for the γ-
H2AX assay, but 6.75 times quicker than dicentric chromosome assay and 12 times 
quicker than CBMN assay (Rothkamm et al., 2013). 
The results for the unknown samples and calibration curve samples measured 
together are presented in Figure 39. It is clear that four unknown samples had a higher 
expression level of FDXR than the highest calibration sample. The standard curve 
obtained from calibration samples measured together with unknown samples was best 
fitted by linear quadratic function, the linear fit being the second best; the 
corresponding equations used for dose estimations are presented in Figure 40. It has 
to be noted that the quadratic function cannot provide a dose estimate for values 
higher than the maximum of the function (dotted line on Figure 39).  
We noticed that the endogenous levels for calibration samples measured by 
qPCR the second time gave higher values than in the first measurement (Figure 41A); 
we believe the differences in the expression level are due to the use of a different 
batch of standard curve in two independent qPCR experiments. When a standard 
curve is prepared, a highly concentrated template for each gene is added, leading to 
variability in the amount of the added template due to unavoidable technical error. 
Thus, the ratio between gene of interest and reference gene is going to be different in 
each batch of the standard curve. That will influence the calculated endogenous levels 
for each gene. If we normalise FDXR endogenous levels obtained in two runs to the  
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Figure 39. Endogenous expression level of FDXR obtained from blood calibration 
curve and unknown samples. 
Endogenous expression levels of the FDXR gene are plotted for calibration curve 
samples (black) and unknown samples (red), the dotted line represents maximum 
value for calibration curve samples. 
  
181 
 
 
Figure 40. Endogenous level of FDXR obtained from blood calibration curve run 
together with unknown samples. 
Two regression fits were employed in order to estimate the dose of unknown samples: 
polynomial (red line) and linear (black line). The trendlines were projected forward in 
order to estimate for doses higher than in calibration curves. 
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Figure 41. Comparison of FDXR expression measurement in two separate qPCR 
experiments in calibration curve samples. 
A. Endogenous levels of FDXR in calibrator curve samples were measured in two qPCR 
experiments. The expression values for the second run (pink) are higher than for first 
run (black). B. Endogenous level values for two qPCR experiments were normalised to 
non-irradiated control. 
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non-irradiated control, the differences disappear (Figure 41B) supporting this theory. 
As the unknown samples and calibrator curve samples were measured in one qPCR 
experiment, using different batches of standard curve does not influence our results. 
In order to estimate the doses of radiation the unknown samples were exposed 
to, we used both linear and quadratic equations obtained from fitting the calibrator 
samples (Figure 40). The dose estimates together with real doses to which the 
unknown samples were exposed to are presented in Table 16. As expected, the 
polynomial fit failed to estimate doses of radiation for four samples, which had 
measured FDXR endogenous levels higher than the maximum of the quadratic 
function. However, for the remaining six samples, the dose estimates were more 
accurate than provided by linear fit, with only one estimate being further than 0.5 Gy 
from the real dose. The dose estimates provided by the linear fit were slightly less 
accurate with 3 samples out of 10 outside of the 0.5 Gy threshold, however, in contrast 
to linear quadratic function, the linear fit provided dose estimation for all ten samples 
and seven out of ten acceptable dose estimates. The graphical representation of dose 
estimates is provided in the Figure 42. 
Finally, we wanted to assess the uncertainty associated with our dose 
estimates. We calculated the measurement error as described in chapter 2.11.1, and 
we assumed that uncertainties coming from the curve fits are negligible as the R2 
values for both regression fits were above 0.95. Since the blood samples for calibration 
curve and the unknown samples were taken from the same individual on two separate 
occasions we used the average of COV in control and irradiated samples for FDXR gene 
obtained from 32 blood donors described in previous chapter as an approximation of  
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Table 16. Dose estimation for unknown samples using polynomial or linear fit 
Unknown 
samples 
Dose 
used 
Dose estimation 
polynomial Difference (Gy) linear Difference (Gy) 
1 0 0.07 0.1 -0.21 0.2 
2 3  x  x 3.99 1.0 
3 2.2 2.85 0.7 3.12 0.9 
4 6.4  x  x 6.02 0.4 
5 2  x  x 3.63 1.6 
6 0.1 0.17 0.1 -0.03 0.1 
7 1.4 1.35 0.1 1.72 0.3 
8 0.7 0.72 0.0 0.85 0.1 
9 4.2  x  x 3.80 0.4 
10 2.6 2.86 0.3 3.13 0.5 
Values in red represent dose estimation different for more than 0.5 Gy from a real dose 
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Figure 42. Graphical representation of dose estimates provided by polynomial and 
linear fits. 
The doses delivered to unknown samples were estimated by linear (black) and 
polynomial (blue) fits. For seven out of ten samples the dose estimates were very close 
to the doses delivered (red). The three remaining samples had the doses 
overestimated by more than 0.5 Gy. 
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intra-individual variability. The estimated uncertainties associated with dose 
estimation are presented in Table 17.   
3.4.5. In vivo dose estimation 
To confirm usefulness of our candidate gene for biodosimetry purposes, we 
wanted to validate it in vivo. Unfortunately, we did not have an access to uniformly 
exposed donors, however Dr Ales Tichy from University of Defence in Czech Republic, 
kindly provided us with blood samples from two endometrium cancer patients 
undergoing radiotherapy. None of the patients had previous chemo- or radiotherapy; 
the blood samples were taken just before the first fraction of radiotherapy and then 24 
h after the first fraction of 1.9 Gy of X-ray. We measured expression level of the FDXR 
gene in these samples and in the calibration curve from chapter 3.4.4 in order to 
estimate the dose received by the white blood cells (Figure 43). We could clearly 
distinguish between blood samples taken before and after radiotherapy, also the FDXR 
expression level was very similar in both patients in control and exposed samples. We 
attempted to estimate the dose that both radiotherapy patients received to the blood 
cells by using the quadratic equation obtained from calibration curve (Figure 44), we 
also assessed uncertainty associated with dose estimation as in previous chapter, using 
data from blood samples obtained from 32 donors as approximation of inter-individual 
variability. The results are presented in Table 18. The dose estimates for blood samples 
taken 24 h after first fraction of radiotherapy were 0.64 (dose range 0.57 – 1.14 Gy) 
and 0.74 (dose range 0.66 – 1.25 Gy) for patient A and B respectively. 
3.4.6. Discussion 
In a large-scale radiological incident it will be important to quickly separate 
individuals requiring urgent medical attention from the “worried-well” who are not 
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Table 17. Dose estimation for unknown samples with associated uncertainty values 
Unkn
own 
sampl
es 
Dose 
used 
Measur
ement 
error 
Intra-
individual 
variability 
Dose 
estimation 
uncertainty 
Dose estimation 
Polyn
omial 
Dose 
range linear Dose range 
1 0 39% 21% 44% 0.07 0.04 - 0.10 -0.21 -0.31 - (-0.12) 
2 3 3% 21% 22% - - 3.99 3.12 - 4.85 
3 2.2 19% 21% 29% 2.85 2.03 - 3.67 3.12 2.22 - 4.02 
4 6.4 14% 21% 26% - - 6.02 4.47 - 7.58 
5 2 11% 21% 24% - - 3.63 2.75 - 4.50 
6 0.1 25% 21% 33% 0.17 0.12 - 0.23 -0.03 -0.04 - (-0.02) 
7 1.4 8% 21% 23% 1.35 1.04 - 1.66 1.72 1.33 - 2.11 
8 0.7 7% 21% 23% 0.72 0.55 - 0.88 0.85 0.66 - 1.04 
9 4.2 5% 21% 22% - - 3.80 2.97 - 4.64 
10 2.6 7% 21% 22% 2.86 2.21 - 3.50 3.13 2.42 - 3.83 
Values in red represent doses which were not in a range of dose estimation uncertainty. 
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Figure 43. FDXR expression in radiotherapy patients samples. 
FDXR expression level was measured in blood samples obtained from two 
endometrium cancer patients (A and B) undergoing radiotherapy (red diamonds) and 
in calibration curve samples from chapter 3.4.4 (black diamonds) 
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Figure 44.  Endogenous level of FDXR obtained from blood calibration curve run 
together with radiotherapy patients samples. 
Quadratic regression fit was employed in order to estimate the dose of radiotherapy 
patients samples. 
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Table 18. Dose estimation with associated uncertainty for radiotherapy patients 
samples using polynomial regression fit. 
Unknown 
samples 
Dose 
used 
Measurement 
error 
Inter-
individual 
variability 
Dose 
estimation 
uncertainty 
Dose estimation 
Polynomial Dose range 
A 0Gy 0 38% 27% 47% 0.170867 0.09 - 0.25 
A 1.9Gy 24h 1.9 20% 27% 33% 0.855016 0.57 - 1.14 
B 0Gy 0 44% 27% 52% 0.176686 0.09 - 0.27 
B 1.9Gy 24h 1.9 15% 27% 31% 0.956233 0.66 - 1.25 
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expected to require early medical attention. Gene expression assays have the potential 
to screen large numbers of individuals and, as demonstrated here, dose estimation can 
be provided within 8 h from receiving the samples (Badie et al., 2013). The reporting 
time can potentially be decreased by using fast cDNA synthesis protocols and faster 
thermal cycling conditions, although these modifications would have to be validated. 
Here we attempted to validate the candidate genes identified and 
characterised in chapters 3.2 and 3.3 for use in radiological biodosimetry. In the in 
vitro part of the work, a calibration curve was constructed with blood sample taken 
from one individual and irradiated with doses ranging from 0 to 4 Gy. We measured 
expression of eight radiation responsive genes the expression of which was modified in 
blood 24 h post exposure selected from chapter 3.2 and the literature (Manning et al., 
2013) in calibration curve samples. All tested genes showed similar shaped dose-
response curves and these fitted best quadratic functions (Figure 38) which is in 
agreement with published reports (Paul and Amundson, 2008, Manning et al., 2013). 
The quadratic function shape of the dose-response curve has two important 
implications for biodosimetry – first, it implies that there is a maximum dose of 
radiation to which the expression of the particular gene will increase but at higher 
doses due to various mechanisms as cell killing or pathway saturation, a relative 
decrease in the expression of the gene would be observed. In other words, two 
distinctive doses in theory can induce the expression of candidate gene to the same 
level, as observed for miRNAs (Figure 36), however it will have to be experimentally 
validated. Second, it cannot provide dose estimation for expression level higher than 
the maximum of the function. It is possible that the polynomial shape of the dose-
response curve in blood irradiated ex-vivo is an artefact of the 24 h incubation at 37 °C, 
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however, Filliano et al measured expression of five genes in mice exposed in vivo to 
different doses of radiation 23 h post exposure and three genes showed quadratic 
dose response (Filiano et al., 2011). Interestingly, Ccng1 expression increased linearly 
with dose of radiation (Filiano et al., 2011) indicating that there may be gene, organism 
or type of exposure differences in the shape of dose response curve. 
In the second part of the in vitro experiment we received ten blood samples 
from the same individual which were exposed to unknown doses and we provided the 
dose estimates using the calibration curve prepared before. One of the aims of this 
exercise was to measure the time necessary to report the dose estimation, therefore 
we focused our interest on the FDXR gene only as it demonstrated the highest R2 value 
for polynomial regression fit and the most linear response of all tested genes (Figure 
38). FDXR expression in four unknown samples was higher than the maximum of the 
quadratic function and for those samples, we were unable to extrapolate the dose 
from the quadratic equation. For that reason, we also used linear regression fit to 
estimate the doses to which the unknown samples were exposed to. In six unknown 
samples, for which we obtained dose estimates using the quadratic function, the 
estimations were more accurate than those obtained with linear regression fit (Table 
16). In order to obtain more accurate dose estimations it would be beneficial to have a 
calibration curve spanning wider range of doses. It would be also worth investigating 
possibility of using two or three genes for biodosimetry instead of one as it has been 
reported that using two genes produced better dose estimates than any single gene in 
blood exposed in vitro to IR (Manning et al., 2013).   
We noticed that two ‘unknown’ samples exposed to doses 2 and 3 Gy had 
higher FDXR expression level than the calibration sample exposed to 4 Gy. This 
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unexpected result could be caused by technical error or high intra-individual variation 
in expression of FDXR gene, as high intra- or inter-individual variation would negatively 
impact dose estimation in real case scenario. In order to address this issue, FDXR 
expression was measured in blood samples taken on three independent occasions 
from 32 healthy individuals and irradiated in vitro with a sham dose or exposed to 2 Gy 
of X-ray. We also measured expression of CDKN1A and CCNG1 which were reported to 
have respectively high and low inter-individual variation in response to IR exposure 
(Manning et al., 2013).  
CCNG1 shoved very low intra- and inter-individual variability that would be  
very beneficial for biodosimetry purposes, however our data indicates that CCNG1 
expression reaches a plateau at doses of 3 Gy and above (Figure 38) in agreement with 
previous findings (Manning et al., 2013). Alternatively, CDKN1A expression showed 
high intra- and inter-individual variation both in control and in irradiated samples. The 
variability in CDKN1A expression may reflect individual sensitivity to radiation. We 
have shown previously that CDKN1A expression can identify individuals with acute skin 
reaction to radiotherapy (Badie C, 2008). We have also demonstrated that induction of 
Cdkn1a after IR exposure depends on Atm/Chk2/TP53 pathway activity and it is 
correlated with cancer incidence in mice (Kabacik et al., 2011b). These features make 
CDKN1A poor candidate for biodosimetry purposes but it would be informative to 
investigate further its potential as biomarker of radiation sensitivity or cancer 
susceptibility.  
The observed intra-individual variation in FDXR expression in control samples 
was low, very similar to variation in CCNG1 expression, however it increased in 
irradiated samples (Table 14). It is possible that some environmental factors can 
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influence FDXR induction upon IR exposure. For example, it has been reported that 
FDXR can also be induced by lipopolysaccharide (Budworth et al., 2012) and although it 
is unlikely that an infection caused the different response to IR exposure in our 
experiment as the control level showed good reproducibility between three 
independent repeats, we cannot exclude the possibility that there are other factors 
modifying response to IR which have not been identified yet. The inter-individual 
variation in FDXR expression was relatively low in control samples however it increased 
after irradiation, which could cause problems in dose estimation in a real scenario. This 
potential issue could be resolved by creating a calibration curve with several donors 
representing real inter-individual variability. We showed that, when a calibration curve 
was constructed with blood samples obtained from ten donors, we could predict a 2 
Gy dose received by 25 donors with a mean estimate of 1.6 Gy (range 0.78 - 2.8 Gy) 
and 1 Gy dose with a mean estimate of 0.8 Gy (range 0.35 – 1.15 Gy) using expression 
of the FDXR gene (Manning et al., 2013). The dose estimations for some donors are 
outside the recommended 0.5 Gy threshold for accurate dosimetry, however it should 
be kept in mind that, whereas from a biodosimetry point of view, it is crucial to get the 
dose estimates as accurate as possible, from a clinical perspective the prospect of 
quick separation of individuals who received a dose in the range needing immediate 
medical attention from those who do not would be extremely beneficial. 
Gene expression changes have been successfully used to predict dose in mice 
irradiated in vivo (Dressman et al., 2007, Meadows et al., 2008, Filiano et al., 2011). 
There are also two reports utilising gene expression (Paul et al., 2011) and miRNA 
expression (Templin et al., 2011b) changes for dose assessment in cancer patients 
undergoing total body irradiation prior bone marrow transplant, both of them 
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presenting impressive accuracy. However, in a real scenario, the majority of individuals 
will probably receive non-uniform exposures due to partial body shielding. Therefore 
we decided to investigate if gene expression changes could be detected in patients 
partially exposed to IR. We measured FDXR expression in two endometrium cancer 
patients undergoing radiotherapy. Unfortunately, we did not have access to patients 
treatment plans and we were not able to assess how accurate our dose estimates 
were. However, the standard treatment for endometrium cancer is a surgery, whereas 
inoperable or unsuitable cases are treated with aggressive radiotherapy which covers 
large volume of abdomen where a high concentration of lymph nodes is 
(www.nhs.gov.uk). It is estimated that only about 2 % of lymphocytes are circulating in 
the blood stream, the remaining 98 % are located in tissues and particularly high 
concentrations are found in lymph nodes, tonsils, thymus, spleen and bone marrow 
(IAEA, 2011). It is known that inflammation is associated with cancer and white blood 
cells infiltrate the tumour to various extents (Hanahan and Weinberg, 2011), meaning 
that the population of blood cells in the radiotherapy beam could be relatively high. 
Any particular lymphocyte cell is present in the peripheral blood for about 30 min, and 
then moves to the extravascular pools. When the radiation exposure is partial, it takes 
about 24 h to establish equilibrium between populations of irradiated and non-
exposed lymphocytes in peripheral blood (IAEA, 2011) therefore sampling blood 24 h 
post exposure should provide a representative population of irradiated cells in the 
blood.  
Taking all this into account, we were surprised to detect an up-regulation in 
FDXR expression in both patients with relatively high and similar dose estimation. To 
our knowledge there is only one report investigating gene expression changes in mice 
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partially exposed to IR; the microarray based approach generated multiple gene 
signatures however, these were specific to irradiated site and poorly discriminated the 
doses (Meadows et al., 2010). Meadows and colleagues also showed that gene 
expression signatures obtained from total body irradiated mice, failed to predict doses 
in partially irradiated mice (Meadows et al., 2010) which additionally complicates the 
use of gene expression for biodosimerty purposes. 
Our in vivo experiment cannot answer the question how accurate the dose 
estimation using gene expression profiling is in this case but it demonstrates that 
partial exposure induces gene expression changes that are different from those in 
unexposed samples and these differences can be detected in peripheral human blood. 
This single gene protocol is much quicker than the microarray approach and does not 
require complicated and time consuming data analysis. Of course it would have to be 
validated with a larger number of patients but single gene analysis is clearly a 
promising complementary approach for traditional biodosimetry in the case of a mass 
casualty scenario.  
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Chapter 4.  General discussion and 
future perspectives 
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In the event of a radiological accident or incident there is a need to quickly 
separate people exposed to high doses of radiation from others including the ‘worried-
well’ in order to provide those exposed with necessary medical treatment. The 
dicentric chromosome assay is the “gold standard” in radiological dosimetry as it is 
specific to radiation and can provide accurate dose estimation even for partial body 
exposures (IAEA, 2011). However, it is not well suited for mass casualty incidents as it 
is time consuming, labour intense and requires highly trained staff to perform the 
scoring (Wojcik et al., 2010). Here we investigated the possibility of using gene 
expression as an alternative assay for radiation dosimetry. qPCR was selected the as a 
quick and sensitive method for assessing changes in expression of IR-responsive genes. 
Extensive technique optimisation was performed, which resulted in creating a 
protocol allowing simultaneous measurement of the expression of six genes, which, by 
itself is an achievement. We believe the optimised qPCR protocol was the main reason 
why we performed so well in the NATO biodosimetry exercise as all participants 
received exactly the same samples and all the differences in dose estimations were 
due to methodology used (Badie et al., 2013). 
Gene expression changes after IR-exposure are well documented and many 
genes show dose- and time-dependent changes in expression following exposure, 
which made them particularly promising candidates as radiation biomarkers 
(Amundson SA, 2004, Gruel et al., 2008, Kabacik et al., 2011a, Manning et al., 2013). 
First, a microarray experiment was performed to identify genes suitable for 
biodosimetry using resting blood leukocytes and stimulated T-lymphocytes from three 
healthy human donors. Some genes showed cell type specific expression but ten genes 
(GADD45A, CDKN1A, SESN1, CCNG1, FAS, FBXW2, RBM15, PPM1D, RPS27L and 
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BLOC1S2) were consistently up-regulated in all three donors for at least one dose in 
blood and lymphocytes, indicating that these genes may play a role in the general 
response to IR. Although in this part of the project, we focused on four genes 
(GADD45A, CDKN1A, SESN1, CCNG1), which showed the greatest modulation of 
expression flowing IR-exposure, and FAS is already well known radiation responsive 
gene (Manning et al., 2013), it would be valuable to further investigate the remaining 
five genes. To our knowledge, none of the remaining five genes was studied in details 
for biodosimetry purposes, although PPM1D and RPS27L were among a 74-gene 
signature published by Paul et al used for dose estimation (Paul and Amundson, 2008). 
PPM1D is a serine/threonine protein phosphatase involved in negative feedback 
control of DDR. It is a direct TP53 target and following DNA damage it takes part in 
silencing the DDR signal by targeting TP53 (Crescenzi et al., 2013) and ATM (Choi et al., 
2013) proteins. RPS27L is another direct p53 target up-regulated following genotoxic 
stress and it positively regulates CDKN1A expression (Li et al., 2007, He and Sun, 2007). 
PPM1D and RPS27L are clearly involved in DDR, however the remaining three genes do 
not seem to have any obvious links with it: FBXW2 is a subunit of ubiquitin protein 
ligase responsible for glial cell missing homolog 1 ubiquitination and degradation 
(Chiang et al., 2008), BLOC1S2 is associated with centromeres, γ-tubulin, lysosome 
formation and it promotes proliferation (Wang et al., 2004) and RBM15 is a repressor 
of myeloid differentiation in hematopoietic cells (Ma et al., 2007). 
Next, the transcriptional responses to IR of ten genes identified by our 
microarray experiment or literature search as high responders in stimulated 
lymphocytes was characterised in more detail. Additionally, the expression of 19 
miRNAs identified in the literature and three lncRNAs following IR exposure was 
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investigated. To our knowledge, this is the first time when expression of protein-coding 
genes, miRNAs and lncRNAs is investigated in the same samples following IR exposure. 
Temporal expression patterns and dose-responses were studied in stimulated human 
T-lymphocytes obtained from two healthy donors and one AT patient. For the majority 
of protein coding genes, their transcriptional response to IR at early time-points 
allowed the AT donor and healthy controls to be distinguished; however, the 
differences disappeared after 24 h.  
Although AT is a rare recessive disease, it is estimated that AT carriers comprise 
0.05 – 1 % of the population (Swift et al., 1991). It has been shown that some genes 
and miRNAs have different endogenous levels and respond differently to IR in AT 
carriers than in healthy donors (Watts et al., 2002, Smirnov and Cheung, 2008). 
Moreover, carriers of another recessive disorder, Nijmegen Breakage Syndrome which 
also manifests itself with hypersensitivity to IR, also have gene expression profiles 
distinct from both healthy donors and AT carriers (Cheung and Ewens, 2006). 
Additionally, we have shown that transcriptional response to IR of Tp53 downstream 
target genes depend on Tp53 copy number in mice (Kabacik et al., 2011b). All these 
factors can influence gene expression and therefore negatively impact gene 
expression-based dosimetry. Our data suggests that it is important to perform gene 
expression-based dose estimation at least 24 h post exposure to avoid impaired DSB 
signalling pathway confounding the results as at this time-point the expression level of 
tested genes is the same in stimulated T-lymphocytes obtained from healthy donors 
and in AT patient even though the later one has severe defect in DSB signalling and 
repair. Of course, it still remains to be established if expression profile of IR-responsive 
genes in blood obtained from AT patients is similar as in stimulated T-lymphocytes.  
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This study also found for the first time that lncRNA FAS-AS1 is IR-responsive in 
human stimulated T-lymphocytes and we presented it’s time-course and dose-
response to IR. FAS-AS1 is transcribed from intron 1 of FAS gene but in the opposite 
direction and it was proposed that it might protect T-lymphocytes from FAS-mediated 
apoptosis and might regulate the alternative FAS splice forms through pre-mRNA 
processing (Yan et al., 2005). These results are very promising, as using lncRNA in 
biodosimetry is a new concept in radiation biology and very few lncRNAs have been 
investigated in terms of IR responsiveness. lncRNAs hold a great potential as  the 
number of lncRNAs greatly exceeds number of protein coding genes in mammalian 
cells (Djebali et al., 2012) and they usually show tissue specific expression (Mercer et 
al., 2008). It would be extremely useful to perform a large scale screen for lncRNA 
biomarkers of radiation exposure and validate the potential candidates for use in 
radiation dosimetry. 
In the last part of the thesis, the usefulness of gene expression assays for 
radiation dosimetry was assessed in vitro and in vivo. First, we investigated the dose-
responses of eight protein coding genes in human blood exposed to IR ex-vivo. Dose 
responses in human blood follows linear quadratic function (Paul and Amundson, 
2008) (Manning et al., 2013) and FDXR gene showed the highest R2 value of all tested 
genes and the most linear response. As a part of a larger biodosimetry comparison 
study, we needed to report dose estimations in the shortest possible time, therefore 
expression of only two genes was measured: FDXR and a reference gene HPRT1. 
However, the protocol developed here allows the measurement of six genes 
simultaneously, it is possible to use a combination of two or more IR-responsive genes 
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which might provide more accurate dose estimation than only one gene (Manning et 
al., 2013).  
Finally, the FDXR gene dose-response was used to estimate a dose of IR in vivo. 
Blood samples from two cancer patients undergoing radiotherapy were obtained 
before the first fraction and 24 h after a 1.9 Gy partial body irradiation (large volume of 
abdomen). Importantly, none of the cancer patients had previous chemo- or 
radiotherapy which could have confounded the gene expression results. To our 
knowledge, this is the first attempt to use gene expression for dose estimation of 
partial exposure in humans, as so far only one similar experiment was performed using 
animals (Meadows et al., 2010).  
The FDXR level in patients control samples and the calibration curve unexposed 
sample were very similar justifying the validity of using an in vitro standard curve for in 
vivo dose estimation. Surprisingly, both patients also showed very similar FDXR 
expression levels after irradiation, suggesting that inter-individual variability in FDXR 
expression may not be as large in vivo as has been observed in in vitro experiments. It 
should be noted that the blood samples for inter- and intra-individual variability 
experiments were prepared differently than the samples for dose estimation, and this 
could explain some of the differences in the results. Conversely, as we used blood 
samples from only two donors, the similar expression level between the samples could 
be just a coincidence. Undoubtedly, more samples are needed to address this issue.  
Also, a larger experiment would be needed to assess the influence of other 
possible confounding factors like infection or smoking, which potentially could affect 
the accuracy of gene expression-based dosimetry. It has been reported that expression 
of three genes often quoted as suitable for IR biodosimetry: CDKN1A, FDXR and PUMA 
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was also modified by lipopolysaccharide (LPS) and their transcriptional response to IR 
was altered by inflammation, which can compromise the usefulness of these genes as 
biomarkers of radiation exposure (Budworth et al., 2012). Additionally, Paul et al 
identified eight genes for which radiation-response was modified by smoking status 
and 14 genes for which radiation response was different depending on gender (Paul 
and Amundson, 2011). 
Moreover, it would be very interesting to investigate lncRNA and miRNA 
expression in cancer patients samples, as it has been shown that miRNAs can be also 
useful for dose estimation (Templin et al., 2011b) (Jacob et al., 2013) and there is no 
data on lncRNAs so far. 
Ideal biomarker of IR exposure should be specific to IR, sensitive and accurate. 
Unfortunately, so far no IR-specific transcript or miRNA have been identified. Gene 
expression is very complex and influenced by many factors, what makes gene 
expression based dosimetry challenging. Our experiments show, that FDXR expression 
was up-regulated in blood following an in vitro dose of 0.1 Gy. Moreover, in human 
stimulated T-lymphocytes three genes (MDM2, CDKN1A and SESN1) showed linear 
response to IR in doses ranging from 5 to 100 mGy, suggesting that gene expression 
changes are sensitive enough to detect very low doses of radiation. The accuracy of 
dose estimations for ten samples exposed to IR in vitro was encouraging, as only one 
out of six and three out of ten estimates were more than 0.5 Gy from the real dose 
when respectively quadratic and linear functions were used. However, time of 
reporting the dose estimates, which is significantly shorter than for dicentric assay is 
the biggest advantage of using the gene expression assay for biodosimetry purposes.  
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In summary, we have developed a sensitive, robust and quick protocol for 
measuring expression of six genes simultaneously. We have identified IR-responsive 
genes, miRNAs and lncRNAs which could be potentially used as biomarkers of IR 
exposure and we characterised their temporal and dose-response. Finally, we 
validated FDXR gene as promising biomarker for dose estimation in vitro and in vivo. 
Our experiments serve as a proof of principle that gene expression can be used in 
radiation biodosimetry to aid classical cytogenetics tools in an event of mass causality. 
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Appendices 
Appendix A 
Primers and probes sequences for human and mouse genes 
 
Gene Name Sequence 5'=>3' 
ATF3 
primer F AGGTTTGCCATCCAGAACAA 
primer R CTGACAGTGACTGATTCC 
covering primer F the same as primer F 
covering primer R CTTCTTGTTTCGGCACTTTGC 
probe CCTCTGCCACCGGATGTCCTCT 
BBC3 
primer F CGGAGACAAGAGGAGCAG 
primer R GGAGTCCCATGATGAGATTG 
covering primer F the same as primer F 
covering primer R the same as primer R 
probe CCCTCACCCTGGAGGGTCCTGT 
CCNB1 
primer F ATAAGGCGAAGATCAACATGGC 
primer R TTTGTTACCAATGTCCCCAAGAG 
covering primer F GAGTCACCAGGAACTCGAAAA 
covering primer R CACTGGCACCAGCATAGGTA 
probe CGCAAAGCGCGTTCCTACGGCC 
CCNG1 
primer F GGAGCTGCAGTCTCTGTCAAG 
primer R TGACATCTAGACTCCTGTTCCAA 
covering primer F the same as primer F 
covering primer R the same as primer R 
probe AACTGCTACACCAGCTGAATGCCC 
CDKN1A 
primer F GCAGACCAGCATGACAG 
primer R TAGGGCTTCCTCTTGGA 
covering primer F GGAAGACCATGTGGACCTGT 
covering primer R AAGATGTAGAGCGGGCCTTT 
probe TTTCTACCACTCCAAACGCCGGCT 
DDB2 
primer F GTCACTTCCAGCACCTCACA 
primer R ACGTCGATCGTCCTCAATTC 
covering primer F CAGAAGAGCGAGATCCGAGT 
covering primer R CATTAAGCGAACTGATGCCA 
probe AGCCTGGCATCCTCGCTACAACC 
FAS-AS1 
primer F CCTCATTTCGCCATCTGTA 
primer R GCATAGCGAGAGAAGTGTT  
covering primer F AGCTCTCTGAACCTCATTTC 
covering primer R GGAGGCTCATTTGAGTACC 
probe ACTACATGGCTCTCGTGAGAATCC 
FDXR 
primer F GTACAACGGGCTTCCTGAGA 
primer R CTCAGGTGGGGTCAGTAGGA 
covering primer F TGGAAATTCCTGGTGAGGAG 
covering primer R TGGAAATTCCTGGTGAGGAG 
probe CGGGCCACGTCCAGAGCCA 
GADD45A primer F CTGCGAGAACGACATCAAC 
230 
 
primer R AGCGTCGGTCTCCAAGAG 
covering primer F ACGAGGACGACGACAGAGAT 
covering primer R TCCCGGCAAAAACAAATAAG 
probe ATCCTGCGCGTCAGCAACCCG 
HPRT1 
primer F TCAGGCAGTATAATCCAAAGATGGT 
primer R AGTCTGGCTTATATCCAACACTTCG 
covering primer F GACCAGTCAACAGGGGACAT 
covering primer R CCTACAACAAACTTGTCTGGAATTT 
probe CGCAAGCTTGCTGGTGAAAAGGACCC 
MDM2 
primer F CCATGATCTACAGGAACTTGGTAGTA 
primer R ACACCTGTTCTCACTCACAGATG 
covering primer F TGCCAAGCTTCTCTGTGAAA 
covering primer R GTGGCGTTTTCTTTGTCGT 
probe CAATCAGCAGGAATCATCGGACTCAG 
PANDAR 
primer F GTCCTGATGCAGACCATAAA 
primer R GATAGCTGGAAAGCTGAGAG 
covering primer F GAGGCCAACTAGCACCA 
covering primer R CACAAGTGCAGGAGAGAATC 
probe CCTTCAGAGGTGGTCCAGATATGT 
PHPT1 
primer F TCGCTCTCATTCCTGATGTG 
primer R TCGTAGATGTCCGCATGGTA 
covering primer F TCGCTCTCATTCCTGATGTG 
covering primer R GCCATGGAATAGCCGTACAC 
probe CTTGTAGCCGCGCACGATCTCCTT 
PLK3 
primer F ATCAGCGCGAGAAGATCCTA 
primer R GATGTTGTCAGCGTCCTCAA 
covering primer F CTGACACAGAGACTGGCAGC 
covering primer R GATCTGCCGCAGGTAGTAGC 
probe CGAGACCTGCAGCACCGCC 
PCR1 
primer F AATCTGATGCTACTTCTGGAATC 
primer R AGCCACAGCTGGTTGACTGA 
covering primer F CCACCTGTTCAGGGAAGAAA 
covering primer R AAGGTTTCAAGCACGCCTAA 
probe CAATTCAACCAACATCCAGTCCTGAGAA 
SESN1 
primer F GCTGTCTTGTGCATTACTTGTG 
primer R CTGCGCAGCAGTCTACAG 
covering primer F GCTCAGCAACAACCATTTTG 
covering primer R AGGCAGAGGCAGAGAGACTG 
probe ACATGTCCCACAACTTTGGTGCTGG 
TP53TG1 
primer F CCAAATGAGCTGTCCTAACT 
primer R AGAGTGCCTTCTAGATCCT 
covering primer F GGTGCCAAATGAGCTGT 
covering primer R GAGGAGCGTGTGGTAAG 
probe CAGCTTCCTGCATGATGCTGG 
Atf3 
primer F ACAGACCCCTGGAGATGT 
primer R CGCCTCCTTTTCCTCTCA 
covering primer F ATAAACACCTCTGCCATCGG 
covering primer R GCAGGCACTCTGTCTTCTCC 
probe GCCGCCTCAGACTTGGTGACTG 
231 
 
Bbc3 
primer F CGGCGGAGACAAGAAGAG 
primer R AGGAGTCCCATGAAGAGATTG 
covering primer F CCCAGCAGCACTTAGAGTC 
covering primer R CCTAGTTGGGCTCCATTTCT 
probe CATCGACACCGACCCTCACCCTGG 
Ccnb1 
primer F GTGCATTTTGCTCCTTCTCA 
primer R CCATTCACCGTTGTCAAGAA 
covering primer F TAAAGTCGGAGAGGTTGACG 
covering primer R AGGGAGTCTTCACTGTAGGA 
probe CAGCGCTAAGCAGAAAGCCCCAGC 
Cdkn1a 
primer F GCAAGAGAAAACCCTGAAGTG 
primer R CACACAGAGTGAGGGCTAAG 
covering primer F TATCACTCCAAGCGCAGATT 
covering primer R CAGGCAGCGTATATACAGGA 
probe ACGGGAGCCCCGCCCTCTT 
Cenpe 
primer F AAAGCTTCTGACTGCAAACC 
primer R CTCGCAATGGAGCTTAACAC 
covering primer F GAACAAAGCTCTCACTTCCG 
covering primer R CTCCTGGCTCAGTTTGATCT 
probe TGTTCCCTGGAGTTCCACAGAGCCC 
Fdxr 
primer F AGCTTCGGGAGATGATTCAG 
primer R ACGGGGGACATCCTTAATTC 
covering primer F AAACAGACATCACAGAGGCT 
covering primer R CTTCCACTCCTGGCTTCTC 
probe AACCCGGCCCATTTTGGATCCTTCG 
Hprt 
primer F GGACAGGACTGAAAGACTTG 
primer R TAATCCAGCAGGTCAGCAAA 
covering primer F AGTGTTTATTCCTCATGGACTGA 
covering primer R CCAATAACTTTTATGTCCCCCG 
probe CCCTTGAGCACACAGAGGGCCACA 
Phpt1 
primer F AAGTCAGGTCTCTGCTCTTG 
primer R CAGATTGGTCTGGCCTCTAA 
covering primer F GGCTACTCTATGGGTTACGG  
covering primer R GGCATATCAATGCTTTTAATTCCT 
probe AGCACAGGGCCAGCCCCTCA 
Sesn1 
primer F CATTATCGGCACTACATTGGAA 
primer R TGCAGATTCACCAGGTAGGA 
covering primer F GCTTTGGGTCGTCTGGATAA 
covering primer R TCTGCAGTTTTTGAGGAGCA 
probe ACTGATGCCTCGCTGCCGCC 
Sesn2 
primer F CGTTTTGAGCTGGAGAAGTCA 
primer R GTGGAGAAGGCTCCAGGATA 
covering primer F ACCCACTGAACAACTCAGGG 
covering primer R TATAATCCTGGGCACGGAAG 
probe AGCCTGCTGGTGACCCCCTCAGC 
 
